Detailed Schedule - Wednesday, April 9

Transcription

14_14AM_Wed_Layout 1 3/11/14 12:44 PM Page 565
WEDNESDAY, APRIL 9
AT-A-GLANCE
All sessions eligible for CME credit
unless otherwise noted.
7:00 a.m.-8:00 a.m.
Meet-the-Expert Sessions
567-569
8:00 a.m.-10:00 a.m.
Plenary Session
570
8:00 a.m.-12:00 p.m.
Poster Sessions
571-603
8:00 a.m.-12:00 p.m.
Late-Breaking Poster Sessions
604
10:00 a.m.-11:00 a.m.
AACR-CRI Award Lecture
605
11:00 a.m.-1:00 p.m.
Current Concepts in Diagnostics
and Therapeutics Research
606
11:00 a.m.-1:00 p.m.
Current Concepts in Epidemiology
and Prevention Research
607-608
11:00 a.m.-1:00 p.m.
Current Concepts in Organ Site Research
609
11:00 a.m.-1:00 p.m.
Major Symposia
610-613
April 5-9, 2014 • San Diego, CA
565
AACR
Science
Education
for The Next Generation
of Cancer Researchers
AACR invites students at all levels to explore educational
and career pathways in cancer research; present their own
research and compete for prizes; network with peers; and
experience lively exchanges with established members of
the cancer research community. Sessions are FREE for
undergraduate or post-baccalaureate students, high school
students and their teachers.
The Science Education Committee is pleased to announce
the following programs will be featured during the AACR
Annual Meeting 2014:
• The Ninth Annual Undergraduate Student Caucus
and Poster Competition
• Special Program for High School Students: The
Conquest of Cancer and The Next Generation of
Cancer Researchers
• Meet the Mentor: Undergraduate Focus
Student Membership
If you have an interest in cancer and related biomedical
science and are enrolled in a program leading to a high
school diploma or bachelor’s degree, AACR Student
Membership is for you! Apply online at
www.AACR.org/Membership.
Mentoring
By strengthening interactions between senior cancer
scientists and promising students, we hope to facilitate
the contributions of young students to scientific research
and the conquest of cancer. We invite AACR members to
join us on this journey. Contact us at
[email protected] to volunteer.
Congratulations to
the 2014 AACR-Thomas J. Bardos
Science Education Awardees
For more information on resources for students and
teachers with an interest in biomedical science and cancer
and the most up-to-date program, please visit the Online
Intinerary Planner or stop by AACRcentral.
www.AACR.org/ScienceEducation [email protected]
MEET THE EXPERT SESSIONS
Room 7, San Diego Convention Center
Chimeric Antigen Receptor-Based
Immunotherapy for Pediatric Cancer:
Progress and Challenges
Crystal L. Mackall, National Cancer Institute,
Bethesda, MD
Advances in our understanding of T cell biology
combined with technological breakthroughs in genetic
engineering are providing unparalleled opportunities for
immune-based targeting of cancer. My laboratory has
focused on developing chimeric antigen-based therapies
for childhood malignancies. This session will describe
exciting progress in this arena for acute lymphoblastic
leukemia and explore the challenges in translating similar
progress with these modalities to solid tumors of
childhood. Issues related to antigen selection, CAR
design, and the role of the solid tumor microenvironment
in limiting the effectiveness of adoptive immunotherapy
for pediatric solid tumors will be discussed.
Room 30A-C, San Diego Convention Center
Inflammation and Cancer Progression:
The Tumor Microenvironment
Raymond N. DuBois, Arizona State University,
Tempe, AZ
Although epidemiologic and experimental observations
support the hypothesis that chronic inflammation and
diet are risk factors for colorectal cancer, the
mechanisms by which chronic inflammation and diet
contribute to the development of cancer are poorly
understood. Evidence for the link between inflammation
and cancer comes from epidemiologic and clinical
studies showing that use of nonsteroidal antiinflammatory drugs (NSAIDs) reduce the relative risk for
developing colorectal cancer (CRC) by 40-50%. NSAIDs
exert some of their anti-inflammatory and antitumor
effects by targeting cyclooxygenase enzymes (COX-1
and COX-2). Metabolism of arachidonic acid, a major
ingredient in animal fats, by cyclooxygenase enzymes
provides one mechanism for the contribution of dietary
fats and chronic inflammation to carcinogenesis. COX-2derived prostaglandin E2 (PGE2) is a proinflammatory
mediator that promotes tumor progression. We have
discovered some novel roles of proinflammatory PGE2 in
regulating DNA methylation and attracting certain
Wednesday, 7:00 a.m.-8:00 a.m.
immune cells to the tumor microenvironment in
colorectal cancer. Our in vitro and in vivo studies
demonstrated that PGE2 treatment silenced certain
tumor suppressors and DNA repair genes such as
CDKN2B (p15), CNR1, MGMT, and MLH1 by enhancing
CpG island methylation of their promoter via inducing
DNMT1 and DNMT3B expression. In more recent work,
we have found that PGE2 also upregulates signaling via
the CXCR2 pathway ultimately attracting myeloidderived suppressor cells (MDSCs) to the tumor
microenvironment. These cells help block the immune
response of killer CD8+ T cells to the tumor. Our findings
uncover a previously unrecognized role for PGE2
promotion of tumor formation and progression.
Integrating “Omic” Approaches to
Identify New Therapeutic Approaches
for Cancer
Kimberly Stegmaier, Dana-Farber Cancer Institute,
Boston, MA
The characterization and functional study of cancer has
been transformed with the development of multiple new
“omic” approaches. This talk will focus on the integration
of chemical and functional genomic, and proteomic,
approaches toward the identification of new protein
targets and drugs for cancer.
567
MEET THE EXPERT SESSIONS
Room 29A-D, San Diego Convention Center
Large-Scale Approaches to Study
Cancer Metabolism
Translating Ideas into Cancer
Therapeutics
David M. Sabatini, MIT Whitehead Institute for
Biomedical Research, Cambridge, MA
Perry D. Nisen, GlaxoSmithKline, King of Prussia, PA
Oncogenic Signaling Pathways,
Targeted Therapies, and Chemotherapy
Resistance in T-Cell Acute
Lymphoblastic Leukemia
Adolfo Ferrando, Columbia University, New York, NY
T-cell acute lymphoblastic leukemia is an aggressive
hematologic tumor that requires aggressive treatment
with intensive chemotherapy. Activation of oncogenic
NOTCH signaling and PI3K -AKT as result of activating
mutations in NOTCH1 and loss of function mutations in
PTEN, respectively, play a major role in the pathogenesis
of this disease. This session will discuss the role of
NOTCH and PI3K-AKT as therapeutic targets and the
role of oncogenic signaling pathways in resistance to
chemotherapy and targeted therapies.
Cancer research generates many exciting ideas, terrific
papers, and grant applications. But how does one go
from an experimental result in the laboratory to a
medicine that benefits patients? It “takes a miracle” to
go from identifying and validating a target to generating
a molecule that can be administered to human beings,
establish benefit/risk, approval by regulators, prescribed
by a physician, and paid for by someone. I’ll review the
key elements of that incredible journey from my
perspective as a physician-scientist, former academic,
and pharma executive.
Tumor Subtyping in Epidemiologic
Studies: Lessons from the AMBER
Consortium
Melissa A. Troester, UNC Lineberger Comprehensive
Cancer Center, Chapel Hill, NC
Molecular biomarkers of breast cancer heterogeneity are
increasingly utilized in epidemiologic studies of breast
cancer. A variety of technical methods can be used for
subtyping tumors, including measurement of protein or
RNA and use of either whole tissue or histologic
sections. Each of these methods has strengths and
limitations and produces quantitative or qualitative data
which then must be collapsed to produce a single
classification for each tumor. The technical and
statistical considerations that affect intrinsic subtyping
will be discussed using examples from the African
American Breast Cancer Epidemiology and Risk
(AMBER) Consortium.
568
AACR ANNUAL MEETING 2014
Using Mouse Tumor Models to
Facilitate Cancer Drug Development
(not eligible for CME credit)
Leisa Johnson, Genentech, Inc., South San Francisco,
CA
Historically, the high failure rate of late-stage human
clinical trials, particularly in oncology, has predicated the
need for improved and translatable preclinical tumor
models that better predict therapeutic response as well
as the evolution of therapeutic resistance. Significant
advances in preclinical modeling have been made over
the past decade and invaluable insight gained from their
diverse application. This session will provide an overview
of the types of mouse tumor models available for
evaluating preclinical efficacy as well as various study
design considerations and the challenges associated
with their implementation, analysis, translatability, and
interpretation. Select examples of how preclinical
findings have uniquely influenced clinical development
programs as well as predicted clinical outcomes and
mechanisms of drug resistance for targeted agents will
also be discussed.
569
PLENARY SESSION
Ballroom 20A-D, San Diego Convention Center
Cellular and Molecular Heterogeneity of Cancer
Chairperson: Suzanne J. Baker, St. Jude Children’s Research Hospital, Memphis, TN
8:00 a.m. Extent of subclonal diversification in primary and metastatic
breast cancer
Peter J. Campbell, Wellcome Trust Sanger Institute, Cambridge,
United Kingdom
8:30 a.m.
The breast epithelial hierarchy and its implications for
tumor heterogeneity
Jane E. Visvader, Walter and Eliza Hall Institute of Medical
Research, Parkville, Australia
9:00 a.m.
9:30 a.m.
570
Clonal heterogeneity in acute myeloid leukemia
Timothy J. Ley, Washington University School of Medicine,
St. Louis, MO
Where lies the heterogeneity in GBM?
Luis F. Parada, UT Southwestern Medical Center, Dallas, TX
POSTER SESSION
Hall A-E, Poster Section 1 • Wednesday, 8:00 a.m.-12:00 p.m.
Tumor Biology 45
Circulating and Disseminated Tumor Cells as Predictors of Tumor Metastasis
Poster Abstract
Board Number
1.
4813
DNA methylation of tumor suppressor and
metastasis suppressor genes in primary tumors,
circulating tumor cells and cell free DNA in the same
breast cancer patients. Maria Chimonidou, Areti Strati,
Nikos Malamos, Vassilis Georgoulias, Evi Lianidou.
2.
4814
Molecular interrogation of the androgen
receptor in circulating tumor cells to identify
therapeutic resistance to androgen targeting therapies.
Lindsay N. Strotman, Jamie Sperger, Benjamin Casavant,
Stephanie Theide, David Beebe, Joshua Lang.
3.
4815
A novel AR splice variant identified in
circulating tumor cells from castration-resistant
prostate cancer patient blood as a potentially
prognostic biomarker. Zhigang Kang, Yunkai Yu, Liang
Cao, Paul S. Meltzer, Yuelin Zhu, Avan Shah, James Gulley,
William Duht, Ravi Madan, Ali Bhagat, Kyra Zhao.
4.
5.
4816
Development of an integrated analysis platform
of circulating melanoma cells for PD-L1 expression as a
predictive biomarker. Benjamin K. Gibbs, Lindsay N.
Strotman, Stephanie M. Thiede, Jamie M. Sperger,
Benjamin P. Casavant, Scott M. Berry, David J. Beebe,
Joshua M. Lang.
4817
Circulating tumor cells enriched by the negative
selection system PowerMag is a useful predictor for
treatment response of metastatic colorectal cancer
patients. Jason Chia-Hsun Hsieh, Hung-Chih Lin, Hung-Chih
Hsu, John Wen-Cheng Chang, Ching-Ping Tseng.
6.
4818
Detection of ROS1 rearrangement in circulating
tumor cells in ROS1-positive non-small-cell lung cancer
patients. Emma Pailler, Benjamin Besse, Olivier Zajac,
Benoît Coudert, Jean-Charles Soria, Françoise Farace.
7.
4819
Evaluation of PTEN status in circulating tumor
cells (CTCs) and matched tumor tissue from castrateresistant prostate cancer (CRPC) patients. Elizabeth
Punnoose, Eric Tucker, Edith Szafer-Glusman, Jin Zhu, Dena
Marrinucci, Jessica Louw, Florence Lee, Mikel Kitchen,
Natalee Bales, Lukas Amler, Hartmut Koeppen, Premal
Patel, Yibing Yan, Ruth Riisnaes, Gerhardt Attard, Johann de
Bono.
Poster Abstract
Board Number
11.
4823
Circulating tumor cell miR-27a overexpression
as a novel mechanism of hepatocellular carcinoma
metastasis. Olorunseun O. Ogunwobi, Chen Liu.
12.
4824
Evaluation of CTCs enriched with a flexible
microspring array device as a prognostic biomarker in
lung adenocarcinoma. Ramdane Harouaka, Xin Liu, Waleed
Khan, Tasleema Khan, Ayeh Asiaii, Christine Christ, Rebecca
Miller, Shawn Rice, Chandra Belani, Siyang Zheng.
13.
4825
Circulating tumor cells in metastatic lung
cancer enriched by EpCAM expression and physical
characteristics. Sanne de Wit, Guus van Dalum, Joost van
Dalum, Aufried Lenferink, Arjan Tibbe, Cees van Rijn, Jeroen
Hiltermann, Harry Groen, Leon Terstappen.
14.
4826
Mobilization of tumor cells into the circulation
during radiation therapy for lung cancer. Michael
MacManus, Robin Anderson, Prudence Russell, Ashley Cox,
Agnieszka Swierczak, Judy P. Doherty, Daphne Jacobs, Jai
Smith, Shankar Siva, Patricia E. Daly, David L. Ball, Roger F.
Martin, Olga A. Martin.
15.
4827
Investigation of the survival of circulating
breast tumor cells using biomimetic microfluidic
circulation system. Yang Wang.
16.
4828
Circulating tumor cells (CTCs) isolated from
patients with metastatic breast cancer utilizing a
sensitive microfluidic graphene oxide (GO) nanosheet
device express markers of cancer stem cells. Shamileh
Fouladdel, Hyeun Joong Yoon, Tae Hyun Kim, An Shi, Tahra
Luther, Jill Hayden, Shawn G. Clouthier, Yadwinder S. Deol,
Monika L. Burness, Daniel F. Hayes, Sunitha Nagrath,
Ebrahim Azizi, Max S. Wicha.
17.
4829
Evaluation prognostic significance of circulating
tumor cells (CTCs) using multiplexed gold nanoparticles
in patients with head and neck cancer. Xu Wang, Ximei
Qian, Jonathan J. Beitler, Jun Zhang, Hyunseok Kang, Zhuo
(. Chen, Kelly R. Magliocca, Xiaojing Wang, Zhengjia Chen,
Shuming Nie, Dong M. Shin.
18.
4830
Prognostic value of circulating tumor cells with
podoplanin expression in locally advanced and
metastatic head and neck squamous cell carcinoma.
Ching-Ping Tseng, Hung-Chih Lin, Chia-Hsun Hsieh, HungMing Wang, Ju-Chien Cheng.
8.
4820
Exploring metastatic capacity and targets on
circulating epithelial cells (CEC) in early and late breast
cancer. Leo Habets, Bettina Frenken, Ilham El Ghali,
Mahmoud Danaei, Manfred Kusche, Uwe Peisker, Katharina
Pachmann.
19.
9.
4821
Circulating tumor cells: a key deliverable in
oncology clinical trials. Chengsen Xue, Kasia E. Cortes,
Dorina Hura, Melissa L. Baptiste, Paradiso Renato, Joanne
Cuomo, Thomas W. Mc Closkey.
4831
Breast cancer cells metastasize to bone
through E-selectinⴙ vascular gateways. Trevor Price,
Monika Burness, Ayelet Sivan, Renee Cheng, John L.
Magnani, Dorothy A. Sipkins.
20.
10.
4822
Immunophenotyping circulating tumor cells in
patients with unknown primary. Elizabeth M. Matthew,
Lanlan Zhou, Bora Lim, Nicholas E. Lamparella, David T.
Dicker, Jean-Nicolas Gallant, Monika Joshi, Sheldon L.
Holder, Ramdane Harouaka, Siyang Zheng, Joseph J.
Drabick, Cristina I. Truica, Zhaohai Yang, Wafik S. El-Deiry.
4832
Isolation and molecular characterization of
circulating melanoma cells. Xi Luo, Devarati Mitra, Ryan
J. Sullivan, Ben S. Wittner, Anya M. Kimura, Shiwei Pan,
Mai P. Hoang, Brian W. Brannigan, Donald P. Lawrence,
Keith T. Flaherty, Lecia V. Sequist, Shannon L. Stott, David
T. Ting, Sridhar Ramaswamy, Mehmet Toner, David E.
Fisher, Shyamala Maheswaran, Daniel A. Haber.
April 5–9, 2014 • San Diego, CA
Poster
Section
1
1
571
POSTER SESSION
Tumor Biology 46
Poster
Section
2
2
Diversity of Microenvironmental Signaling
Poster Abstract
Board Number
1.
2.
4.
5.
7.
8.
9.
10.
11.
12.
14.
15.
572
4833
The eicosanoid 20-HETE triggers Ras activation,
pancreatic cancer growth and metastasis through
inflammatory macrophage signaling. Yael Gus-Brautbar,
Jessica Casper, Diane R. Bielenberg, Jennifer Cheng,
Birgitta Schmidt, Bruce D. Hammock, Darryl C. Zeldin, Mark
W. Kieran, Dipak Panigrahy.
4834
Microbiome in Oral Epithelial Dysplasia and
Squamous Cell Carcinoma. Deepak Saxena, Smruti
Pushalkar, Arun Devotta, Yihong Li, Bhuvanesh Singh, Zoya
Kurago Kurago, Alexander Kerr, Wenbo Yan, Peter Sacks,
Xin Li.
4836
Immune-tolerance due to aberrant expression
of Natural Killer-Cell Immunoglobulin-like Receptors
(KIRs) on cancer cells and enhanced cancer-platelet
interactions. Daniel C. Chan, Zhiyong Zhang, Di Zheng,
Tiffany Chan, Mary Berg, Kathryn Horwitz, Natalie Ahn,
Lewis Lanier, Paul Bunn.
4837
Extracellular proteolytic cleavage of peptidelinked antibody-drug conjugates promotes bystander
killing of cancer cells. My-Hanh Lam, Judy Lucas,
Andreas Maderna, Hallie Wald, Megan Wojciechowicz,
Russell Dushin, Bryan Peano, Fang Wang, Jeremy Myers,
Xingzhi Tan, Sylvia Musto, Manoj Charati, Hans-Peter
Gerber, Frank Loganzo.
4839
TGF-␤ signaling in osteoclasts promotes, but in
osteoblasts inhibits prostate cancer induced bone
lesions. Xiangqi Meng, Priscilla Lee, Xiaohong Li.
4840
DNA methyltransferase 3B as a mediator in
cancer associated inflammation and progression. Nicolas
G. Skrypek, Achyut B.R, Christine Hollander, Li Yang.
4841
Oxidized macrophage migration inhibitory factor
(oxMIF) expressed by tumor stroma and tumor cells,
contributes to tumor growth. Thorsten Hagemann,
Alexander Schinagl, Patrice Douillard, Michael Thiele, Dirk
Voelkel, Michael Freissmuth, Friedrich Scheiflinger, Randolf
J. Kerschbaumer.
4842
The stem cell niche detoxifies chemotherapy
and protects malignant hematopoietic cells via
expression of cytochrome P450 enzymes. Salvador
Alonso, Meng Su, Richard Jones, Gabriel Ghiaur.
4843
Neutrophil elastase enhances adaptive
immunity via increase of peptide presentation and
downregulation of T cell inhibitory molecules. Akhil
Chawla, Anne V. Philips, Na Qiao, Pariya Sukhumalchandra,
Celine Kerros, Gheath Alatrash, Jeffrey J. Molldrem,
Elizabeth A. Mittendorf.
4844
Extracellular hyaluronan accumulation by
hyaluronan synthase 3 promotes pancreatic cancer
growth and modulates tumor microenvironment via
epithelial-mesenchymal transition. Anne Kultti, Chunmei
Zhao, Susan Zimmerman, Ryan J. Osgood, Yanling Chen,
Rebecca Symons, Ping Jiang, Curtis B. Thompson, David A.
Tuveson, Gregory I. Frost, H M. Shepard, Zhongdong Huang.
4846
Histamine in myeloid cell maturation and
malignant glioma development. Brian Ahn, Gary
Kohanbash, Akemi Kosaka, Takayuki Ohkuri, Hideho Okada.
4847
Alcoholic chronic pancreatitis increases tissue
transformed macrophages (M2) which promote
pancreatic cancer lesions in a Kras mouse model.
Mouad Edderkaoui, Paul Grippo, Hajar Benhaddou, Yassine
Ouhaddi, Hidekazu Tsukamoto, Steven Swartwood, Beatrice
Knudsen, Helen S. Goodridge, Aida Habtezion, Vay-Liang Go,
Stephen J. Pandol.
Poster Abstract
Board Number
17.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
4849
Implications of cancer induced blood
coagulation in cancer diagnosis and therapy. Yohei
Hisada, Masahiro Yasunaga, Shingo Hanaoka, Shinji Saijou,
Takashi Sugino, Atsushi Tsuji, Tsuneo Saga, Kouhei
Tsumoto, Shino Manabe, Jun-ichiro Kuroda, Jun-ichi
Kuratsu.
4851
Kinase domain activation of FGFR2 yields highgrade lung adenocarcinoma sensitive to a pan-FGFR
inhibitor in a mouse model of NSCLC. Esra A. Akbay,
Jeremy H. Tchaicha, Abigail Altabef, Oliver R. Mikse, Eiki
Kikuchi, Kevin Rhee, Rachel Liao, Roderick T. Bronson,
Lynette M. Sholl, Matthew Meyerson, Peter S. Hammerman,
Kwok-Kin Wong.
4852
Collagen degradation products measured in
serum can separate ovarian and breast cancer patients
from healthy controls. Cecilie L. Bager, Nicholas
Willumsen, Diana J. Leeming, Victoria Smith, Morten
Karsdal, Anne-Christine B. Jensen.
4853
Omental milky-spots serve as a niche for
ovarian cancer metastatic colonization. Venkatesh
Krishnan, Robert Clark, Carrie Rinker-Schaeffer.
4854
Fibulin5 as a novel therapeutic target for
pancreatic cancer. Miao Wang, Mary Topalovski, Jaya
Matharage, Jason Toombs, Christopher Wright, Gomika
Udugamasooriya, Rolf A. Brekken.
4855
Proteomic characterization of the extracellular
matrix in multiple myeloma. Siobhan V. Glavey, Alexandra
Naba, Manuela Gambella, Alberto Rocci, Antonio Sacco,
John Asara, Antonio Palumbo, Richard O. Hynes, Aldo M.
Roccaro, Irene M. Ghobrial.
4856
Survivin packaging into exosomes is lipid raftdependent. Malyn May Asuncion Valenzuela, Heather R.
Ferguson Bennit, Carlos Joel Diaz Osterman, Salma Khan,
Carlos Casiano, Nathan R. Wall.
4857
Clonal expansion of Lkb1-deficient stromal cells
underlies polyp development in mouse models of PeutzJeghers syndrome. Saara Ollila, Kaisa Laajanen, Iris Wong,
Kari Vaahtomeri, Tomi P. Mäkelä.
4858
A novel strategy for the selective and tissue
specific inhibition of MMPs in active breast cancer to
bone metastases. Marilena Tauro, Antonio Laghezza, Paolo
Tortorella, Conor C. Lynch.
4859
Hepatocyte growth factor activator inhibitor
type 1 suppresses invasion of pancreatic
adenocarcinoma cells through inhibition of matriptase/
protease-activated receptor-2 axis. Yukihiro Haruyama,
Jing-Jia Ye, Makiko Kawaguchi, Ai Kanemaru, Tsuyoshi
Fukushima, Hiroaki Kataoka.
4860
Insulin receptor substrate-1 regulates immune
cell content in lung adenocarcinoma. Heather E. Metz,
Stephanie E. Busch, Mark L. Hanke, Julia Kargl, KyoungHee Kim, A M. Houghton.
4861
Pharmacological reversal of caffeine-mediated
phagocytic suppression. Ryan Steck, Spencer Hill, Richard
A. Robison, Kim L. O’Neill.
4862
Reversal of NK cell exhaustion in advanced
melanoma patients by Tim-3 blockade. Anne Gallois, Ines
Pires Da Silva, Sonia Jimenez, Iman Osman, Nina Bhardwaj.
POSTER SESSION
Tumor Biology 47
Microenvironmental Cues
Poster
Section
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
4863 Quantification of cell fusion events between breast
cancer cells and breast epithelial cells. Marieke Mohr, Kurt
Zänker, Thomas Dittmar, Frank Edenhofer.
4864 Tumor promoting role of NF-kappa B in the glioma
environment. Aneta Kwiatkowska, Mohan Sobana Nandhu,
Mariano S. Viapiano.
4865 Differential survival and self-renewal of LSC and
HSC in aged and leukemic niches. Larisa Balaian, Leslie
Crews, Anna Kulidjian, Edward Ball, Catriona Jamieson.
4866 Enhanced adipogenesis of bone marrow-derived
stromal cells by ovarian cancer cells via BMP4 and IL8 is
associated with increase in cancer stem/progenitor cells
and cancer cell proliferation. Elissa Wai Pung Wong, Lingbo
Shen, Jae-Hung Shieh, Malcolm A. Moore.
4867 Microenvironment stimuli elicited by fibroblasts
contribute to epithelial mesenchymal transition and
acquisition of stemness phenotype in lung cancer.
Francesca Andriani, Tiziana Caputo, Giulia Bertolini, Federica
Facchinetti, Erika Baldoli, Massimo Moro, Roberto Caserini,
Gabriella Sozzi, Luca Roz.
4868 Large oncosomes are internalized and functionally
modulate transcription factors in recipient cells. Valentina R.
Minciacchi, Matteo Morello, Sungyong You, Wei Yang, Mariana
Sobreiro, Cristiana Spinelli, Mandana Zandian, Mirja Rotinen,
Samantha Morley, Rosalyn Adam, Michael R. Freeman, Dolores
Di Vizio.
4869 Bone marrow-derived stromal cells contribute to a
protumorigenic inflammatory environment that promotes
drug resistance. Lucia Borriello, Rie Nakata, Hong-Wei Wu,
Robert C. Seeger, Yves A. DeClerck.
4870 Proteomics of phyllodes tumor revealed that
decorin increase in the extracellular matrix by periostin
deficiency decreased cancer cell motility and invasion.
Toshiyuki Ishiba, Akira Nakanishi, Takanobu Sato, Tsuyoshi
Nakagawa, Makoto Nagahara, Ryo Oono, Hiroyuki Uetake,
Kenichi Sugihara, Yoshio Miki.
4871 Obesity-mediated regulation of HGF/c-Met and
reduced basal-like breast cancer latency in parous mice.
Sneha Sundaram, Alex J. Freemerman, Erin L. Kirk, Joseph A.
Galanko, Kirk K. McNaughton, Katharine M. Bendt, David B.
Darr, Melissa A. Troester, Liza Makowski.
4872 A DKK1 dependent crosstalk between TGF␤2snail1 and miRNAs contributes to chemoresistance in
mesenchymal-like breast cancer. Guopei Zheng, Xiaoting Jia,
Zijuan Zhang, Zhijie Zhang, Chen Qu, Jiang Yin, Zhimin He.
4873 IKK␣ bridges central tolerance to innate immunity
and inflammation. Feng Zhu, Zhisong Chen, Jami WilletteBrown, Dakshayani Lomada, Sean R. Davis, Timothy Back, Teizo
Yoshimura, Zhonghe Sun, Xiaolin Wu, Robert Wiltrout, Ellen
Richie, Ulrich Siebenlist, Giorgio Trichieri, Yinling Hu.
4874 CXCR2 signaling axis- a helping hand to
KRAS(G12D) mutation in pancreatic cancer initiation.
Abhilasha Purohit, Michelle Varney, Satya Rachagani, Michel
Ouellette, Surinder K. Batra, Rakesh K. Singh.
4875 In vivo and in vitro generation and characterisation
of EGFR-TKI resistance in patient-derived xenograft (PDX)
and cell line-derived xenograft (CDX) models of NSCLC with
activating EGFR mutations. Andrew McKenzie, Nektaria
Papadopoulou, Simon Jiang, Martin Page, Henry Li, Rajendra
Kumari, Jane Wrigley.
4876 Characterization of malignant melanoma growth
triggered by the brain microenvironment in experimental
metastasis models. Vigdis Nygaard, Lina Prasmickaite, Kotryna
Vasiliauskaite, Trevor Clancy, Eivind Hovig.
4877 MMP-3 generates a novel PTHrP peptide that
impacts osteoblast behavior and contributes to metastatic
tumor growth in bone. Jeremy S. Frieling, Lizzie Atomi Pamen,
Shengyu Yang, Conor C. Lynch.
Poster Abstract
Board Number
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
4878 Modification of gene expression in tumor cells by
the culture microenvironment. Seung Wook Kim, Sun Jin Kim,
Ho-jeong Lee, Junqin He, Qiuyu Wu, Erica J. Lawson, Isaiah J.
Fidler.
4879 Targeting the seed and the soil of cancers with
selective small-molecule inhibitors of CDK8/19:
Chemopotentiating, chemopreventive, anti-invasive and
anti-metastatic activities. Donald C. Porter, Jiaxin Liang,
Vimala Kaza, Alexander A. Chumanevich, Serena Altilia, Elena
Farmaki, Mengqian Chen, Gary P. Schools, Ioulia Chatzistamou,
Marj M. Pena, Lawrence T. Friedhoff, Mark P. Wentland,
Eugenia Broude, Hippokratis Kiaris, Igor B. Roninson.
4880 Regulation of extracellular microvesicles secretion
by Rab27b in glioblastoma multiforme. Bruna R. Rodrigues,
Fernanda S. Giudice, Marcos S. Dias, Antuani R. Baptistella,
Rafael R. Malagoli, Paulo I. Sanematsu, Sergio Suzuki, Mariana
Reis, Vilma R. Martins.
4881 Targeting the CXCR4 chemokine receptor thwarts
stromal cell mediated drug resistance in B-cell acute
lymphoblastic leukemia (B-ALL). Shubhchintan Randhawa,
Dipanjan Ghosh, Amnon Peled, Richard E. Davis, Jan A. Burger.
4882 Expression profiles of proinflammatory chemokines
in prostate cancer cell supernatants. Niradiz Reyes, Oscar
Correa, Alfonso Bettin, Raj K. Tiwari, Jan Geliebter.
4883 CDK8: A new druggable mediator of NF␬B activity.
Mengqian Chen, Martina McDermott, Zhengguan Yang, Jiaxin
Liang, Gary P. Schools, Chang-uk Lim, Tao Lu, Stark R. George,
Deborah K. West, Donald C. Porter, Eugenia V. Broude, Igor B.
Roninson.
4884 Determination of sphingosine-1-phosphate levels in
tissue interstitial fluid and lymphatic fluid utilizing novel
collection techniques. Masayuki Nagahashi, Akimitsu Yamada,
Hiroshi Miyazaki, Jeremy C. Allegood, Tomoyoshi Aoyagi, WeiChing Huang, Krista P. Terracina, Sheldon Milstien, Sarah
Spiegel, Kazuaki Takabe.
4885 Changes in abundance of oral microbiota
associated with oral cancer. Donna G. Albertson, Justin
Kuczynski, Aditi Bhattacharya, Bing Huey, Patricia M. Corby,
Erica L. Queiroz, Kira Nightingale, Alexander R. Kerr, Mark D.
DeLacure, Ratna Veeramachaneni, Adam Olshen, Brian L.
Schmidt.
4886 Targeting WNT1-inducible signaling pathway
protein 2 (WISP2) alters human breast cancer cell
susceptibility to specific lysis through regulation of KLF-4
and miR-7 expression. Intissar Akalay, salem chouaib, jeanpaul thiery.
4887 Omentin: A novel adipokine in the omental
microenvironment associated with ovarian cancer
progression. Chi Lam Au Yeung, Ngai Na Co, Michaela Onstad,
Tsz-Lun Yeung, Cecilia S. Leung, Rosemarie Schmandt, Karen
H. Lu, Samuel C. Mok.
4888 The novel cytokine IL17D at the intersection of
cellular stress and tumor immunity. Robert Saddawi-Konefka,
Jack Bui.
4889 Oncolytic adenovirus coated with stimuli
responsive block copolymer mPEG-b-poly(His) induces
tumor microenvironment-specific antitumor efficacy. ChaeOk Yun.
4890 Collagen 1 fibers are a key component in the
establishment of distant pulmonary metastasis by breast
cancer cells. Desmond Jacob, Samata M. Kakkad, Balaji
Krishnamachary, Ioannis Stasinopoulos, Meiyappan Solaiyappan,
Flonne Wildes, Kristine Glunde, Zaver M. Bhujwalla.
4891 Dormancy and growth of metastatic breast cancer
cells in a bone-like microenvironment. Yu-Chi Chen, Andrea
M. Mastro, Donna M. Sosnoski, Robert J. Norgard, Cassidy D.
Grove, Erwin A. Vogler.
4892 PYK2 mediates microenvironment-specific
myeloma survival. Mark B. Meads, Bin Fang, Linda Mathews,
Jennifer Gemmer, Liang Nong, Robert MacCleod, Lori
Hazlehurst, John Koomen, Kenneth H. Shain.
3
3
573
POSTER SESSION
Tumor Biology 48
Poster
Section
4
4
Modifiers and Predictors of Tumor Response to Radiation and Other DNADamaging Agents 2
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
574
4893
USP7 modulates UV-induced PCNA
monoubiquitylation by regulating DNA polymerase eta
stability. Jiang Qian, Qianzhen Zhu, Kyle Pentz, Jinshan He,
Qien Wang, Altaf A. Wani.
4894
The HSP90 inhibitor ganetespib potentiates
effect of ionizing radiation in human non-small cell lung
cancer. Roberto Gomez Casal, Chitralekha Bhattacharya,
Michael Epperly, Mark Socinski, Vera Levina.
4895
P16INK4A, a surrogate marker of HPV infection
and prognosis for head and neck cancer, delays DNA
damage repair and enhances radiation response. Li
Wang, Peijing Zhang, David P Molkentine, Hailong Piao,
Chunyan Chen, Jessica M Molkentine, Jinsong Zhang, David
R Valdecanas, Heath Skinner, Thomas A Buchholz, Junjie
Chen, Li Ma, Kathy A Mason, Kie-kian Ang, Raymond E
Meyn.
4896
Identification of the mechanisms of
radiosensitization by human papillomavirus (HPV) in
head and neck cancers cell lines. Vanesa Bol, Vincent
Grégoire.
4897
Genetic variants and expression of AEG-1 in
relation to clinical outcome and radiotherapy response
in colorectal cancer patients and cell lines. Sebastian
Gnosa, Veronika Patcha Brodin, Ivana Ticha, Gunnar Adell,
Gunnar Arbman, Hong Zhang, Xiao-Feng Sun.
4898
High content clonogenic survival assay for drug
library screening identifies potent radiation sensitizers
for non-small cell lung cancer. Steven H. Lin, Hui Liu,
Yawei Qiao, Uma Giri, Jing Zhang, Clifford Stephan, Mary
Sobieski, John V. Heymach, Stephen S. Yoo.
4899
Small proline rich protein 3 (SPRR3) is a
potential mediator of radiation resistance in HPV
negative head and neck squamous cell carcinoma.
Joshua A. Martin, Dana Gunderson, Randall J. Kimple.
4900
The role of Interleukin (IL)-22 on the UVBinduced proliferation and inflammation of human
keratinocyte cell line, HaCaT. Yejin Kim, Hyemin Kim,
Jiwon Choi, Mirim Jang, Jiyea Choi, Jae Seung Kang, Wang
Jae Lee.
4901
Clostridium cluster XIVa species an early
biomarker in radiation injury. Ishfaq Ahmed, William
McLauglin, Shrikant Anant, Shahid Umar, Rao V. Papineni.
4902
Low dose Ganetespib (STA-9090) enhances
radiotherapy effects on lung cancer cells by
synergistically altering levels of cell cycle progression
proteins. Hui Liu, Adam Potter, Jingya Wang, Uma Giri,
Steven H. Lin.
4903
Luteolin’s role as a radiosensitizer by
promoting cell death and ROS modulation. Kwang-Chul
Ahn, Jae Yeon Choi, Sang-Gu Hwang, Hong-Duck Um, Jong
Kuk Park.
4904 ␤-catenin silencing enhances radiation
sensitivity through antagonizing effect of AMPK against
Ku70/80 in head and neck cancer cells. Hyo Won Chang,
Hae Yun Nam, Mi Ra Kim, Hyang Ju Lee, Ji Hyun Seo, So
Yeon Lee, Seong Who Kim, Sang Yoon Kim.
4905
Targeting NPM1 for the radiosensitization of
NSCLC. Konjeti R. Sekhar, Mouadh Benamar, Amudhan
Venkateswaran, Narsimha R. Penthala, Peter A. Crooks,
Stephen R. Hann, Ling Geng, Ramesh Balusu, Tarek Abbas,
Michael L. Freeman.
4906
mTOR kinase inhibition enhances
radiosensitivity in glioblastoma. Anita T. Tandle, Philip
Tofilon, Kevin Camphausen.
Poster Abstract
Board Number
15.
16.
17.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
4907
Upregulation of furin is associated with the
invasiveness of cumulatively irradiated cancer cells.
Myungjin Lee, Changhwan Rhu, Seong Who Kim, Sang Yoon
Kim.
4908
Fusional radiosensitization effects of
hyperthermia and nitric oxide (NO) produced by
ultrasonication during simultaneous radiotherapy. Yoichi
Sugita, Yohane Ishiguro, Nobuko Nozaki, Hiroyuki Takahashi,
Norio Fukuyama, Teruo Ishikawa, Jun Kubota, Masatoshi
Hashimoto.
4909
Novel radiation mitigators and cancer
chemoprevention drugs. Robert H. Schiestl, Yelena Rivina,
Michael Davoren.
4911
NSCLC cells demonstrate differential mode of
cell death in response to the combined treatment of
radiation and a DNA-PKcs inhibitor. Yu Lan, Zengfu
Shang, Feng-Ming Hsu, Vasu Tumati, Benjamin P. Chen,
Debabrata Saha.
4912
Hyperthermia induced NO repressed NF␬B
regulates IR-induced EMT, CSC self-renewal and
pluripotency. Corinne Dinges, Mohan Natarajan, Sheeja
Aravindan, Terence S. Herman, Natarajan Aravindan.
4913
Development of Fe3O4@TiO2 core-shell
nanocomposites as radiosensitizers. Tamer Refaat, Derek
West, kathleen R. Harris, Vamsi Parini, William Liu, Beau
Wanzer, Lydia Finney, Andrew C. Larson, Jonathan Bautista,
Vythialinga Sathiaseelan, Bharat Mittal, Tatjana Paunesku,
Gayle Woloschak.
4914
AKT- and ERK signaling inhibition does not
sensitize GBM cells to chemo-/radiation in vitro. Ravi
Narayan, Rogier Dik, Jaap van den Berg, Lukas J. Stalpers,
Brigitta G. Baumert, Ben J. Slotman, Peter Sminia.
4915
High degree of G2/M arrest induced by Pololike kinase 1 (PLK1) inhibition is associated with
radiosensitization. Nelson Wong, Mohamed Khan.
4916
Efficiacy of NU7441-encapsulated PLGA
nanoparticles in radiation sensitization of prostate
cancer cells. Jyothi U. Menon, Vasu Tumati, Jer-Tsong
Hsieh, Kytai T. Nguyen, Debabrata Saha.
4917
Smart brachytherapy spacers eluting
nanoencapsulated radiosensitizers for chemo-radiation
therapy. Rajiv Kumar, Jodi B, Stacey Markovic, Mark
Niedre, Wilfred Ngwa, Houari Korideck, Robert Cormack,
Paul Nguyen, Anthony D’Amico, Mike Makrigiorgos, Srinivas
Sridhar.
4918
In vitro radiosensitization of human
neuroblastoma cells with iron oxide - titanium dioxide
core-shell nanocomposites conjugated with 3,4Dihydroxyphenylacetic acid (DOPAC). Salida Mirzoeva,
William Liu, James R. Bolling, Karna R. Shah, Carol
Hirschmugl, Julia Sedlmair, Tatjana Paunesku, Gayle E.
Woloschak.
4919
Visible/NIR-activatable prodrug strategy for
treating local tumors by the combination of
photodynamic therapy and local chemotherapy. Pallavi
Rajaputra, Moses Bio, Gregory Nkepang, Youngjae You.
4920
Luminol-based in situ photodynamic therapy for
breast adenocarcinoma. Hamad S. Alshetaiwi, Tej B.
Shrestha, Sivasai Balivada, Matthew T. Basel, Marla Pyle,
Hongwang Wang, Stefan H. Bossmann, Deryl L. Troyer.
4921
X-ray irradiation induced bio luminescence: Ex
vivo and endoscopic imaging of radiobioluminescence.
Rao V. Papineni.
4922
The feasibility of evaluation method for the
newly developed Photomultiplier-tube-based singlet
oxygen detection system in photodynamic therapy. InWook Kim, Ju hee Kim, Jae Myung Park, Myung-Gyu Choi.
POSTER SESSION
Tumor Biology 49
Nuclear Fluorescence, Intravital Imaging, and Preclinical Probe Development
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
4923 Gallium-68- and Copper-64-labeled LLP2A
conjugates for PET-CT imaging of integrin ␣4␤1 in
melanoma. Wissam Beaino, Carolyn J. Anderson.
4924 Mucolytic drug N-Acetylcystein improves 89Zrtrastuzumab HER2-immunoPET imaging by restoring
accessibility to HER2 hampered by membrane mucin
overexpression in a HER2 positive MUC4 overexpressing
xenograft mouse model. Zena Wimana, Geraldine Gebhart,
Renato Morandini, Patrick Flamen, Ghanem Ghanem.
4925 Targeted metabolic profiling of gliomas and glioma
stem cells identifies methionine as a differentially regulated
metabolite: Proof of principle supporting methionine-pet
imaging. Kamalakannan Palanichamy, Thirumoorthy Krishnan,
Nikhil Sebastian, Rajbir Singh, Suman Kanji, Arnab Chakravarti.
4926 Molecular imaging of colorectal cancer in the
setting of colitis. N. S. TURKER, Umar Mahmood, Melani H.
Kucherlapati, Raju Kucherlapati.
4927 68Ga/177Lu-Peptide antagonist targeting of breast
cancer: A xenograft evaluation. Tammy L. Rold, Ashley F.
Berendzen, Nicole E. Bernskoetter, Jillian C. Rushin, Lixin Ma,
Timothy J. Hoffman.
4928 Cyclooxygenase-1 as a target for molecular
imaging of high grade serous ovarian cancer. Andrew J.
Wilson, Brian D. Lehmann, MD J. Ussin, Anna Elleman, Brenda
Crews, Jeanette Saskowski, Jennifer Pietenpol, Lawrence J.
Marnett, Dineo Khabele.
4929 Radiolabelled cCPE for molecular imaging of tight
junction changes during breast oncogenesis. Michael Mosley,
James Knight, Albrecht Neesse, Patrick Michl, Veerle
Kersemans, Bart Cornelissen.
4930 Quantitative PET imaging of tissue factor
expression using 18F-labeled active site inhibited factor
VIIa. Carsten H. Nielsen, Maria Erlandsson, Mette M. Jensen,
Jacob Madsen, Lars C. Petersen, Andreas Kjaer.
4931 ImmunoPET and fluorescence imaging with
Zirconium-89 and IRDye 800CW labeled glycoengineered
epidermal growth factor receptor antibody GA201. Martin
Pool, Arjan Kol, Marjolijn N. Lub-De Hooge, Christian A. Gerdes,
Steven de Jong, Elisabeth G. de Vries, Anton G. Terwisscha van
Scheltinga.
4932 Kaposi’s sarcoma represents a dynamic
pathogenic process involving ongoing macrophage
replenishment with both tumor cells as well as
macrophages expressing CD206, a target for the recently
approved imaging agent, Tilmanocept. Michael S. McGrath,
Paige M. Bracci, Frederick O. Cope, Rongzhen Zhang.
4933 In vivo visualization of heterogeneous cancer cell
populations by fluorescence molecular tomography. Ciro
Zanca, Maria del Mar Inda, Rudy Bonavia, Jill Wykosky,
Vladislav Verkhusha, Webster Cavenee, Frank Furnari.
4934 Imaging and quantification of bombesin receptor
expression in vivo using a NIR-labeled bombesin peptide.
Jeffrey D. Peterson, Nara Narayanan, Jeannine Delaney, Jeffrey
Morin, Milind Rajopadhye, Wael Yared, Sylvie Kossodo.
4935 Hypoxia targeting fluorescent nanobodies for
optical molecular imaging of preinvasive breast cancer.
Aram S. van Brussel, Arthur Adams, Sabrina Oliveira, Mohamed
El Khatabbi, Jeroen F. Vermeulen, Elsken Van der Wall, Willem
P. Mali, Patrick W. Derksen, Paul J. Van Diest, Paul M. Van
Bergen en Henegouwen.
4936 Tumor PaintTM technology detects naturally
occurring solid tumors in dogs. William S. Dernell, Janean
Fidel, Katie Kennedy, Stacey Hansen, Valorie Wiss, Mark Stroud,
Julia E. Parrish-Novak.
Poster Abstract
Board Number
15.
16.
17.
18.
19.
20.
21.
23.
24.
25.
26.
27.
4937 Fluorescence imaging using Clostridium
Perfringens Enterotoxin carboxi-terminal fragment (c-CPE)
to target metastatic chemotherapy-resistant human ovarian
cancer in xenograft mice. Emiliano Cocco, Sara Gasparrini,
Erik M. Shapiro, Carlton Schwab, Stefania Bellone, Ileana
Bortolomai, Salvatore Lopez, Natalia J. Sumi, Elena Bonazzoli,
Roberta Nicoletti, Yang Deng, William M. Saltzman, Caroline J.
Zeiss, Dan-Arin Silasi, Thomas J. Rutherford, Peter E. Schwartz,
Alessandro D. Santin.
4938 In vivo visualization using two-photon laser
scanning microscopy of anti-c-MET antibody in peritoneal
metastatic gastric cancer. Shozo Ide, Koji Tanaka, Tadanobu
Shimura, Masato Okigami, Satoru Kondo, Takahito Kitajima,
Hiroki Imaoka, Yoshinaga Okugawa, Susumu Saigusa, Yuji
Toiyama, Hiromi Yasuda, Masaki Ohi, Yasuhiro Inoue, Toshimitsu
Araki, Keiichi Uchida, Yasuhiko Mohri, Masato Kusunoki.
4939 Detection and quantification of enzymatically
active tissue prostate-specific antigen in vivo. Jeffrey D.
Peterson, Guojie Ho, Jeffrey Morin, Jeannine Delaney, Wael
Yared, Milind Rajopadhye, Sylvie C. Kossodo.
4940 Perivascular macrophages induce localized,
transient blood vessel permeability and tumor cell
intravasation. Allison S. Harney, Esther N. Arwert, David
Entenberg, Yarong Wang, Joan G. Jones, John S. Condeelis.
4941 A humanized bone model for preclinical monitoring
of prostate cancer lesions by intravital multiphoton
microscopy. Eleonora Dondossola, Stephanie Alexander, Steve
Alexander, Boris M. Holzapfel, Christopher J. Logothetis, Dietmar
W. Hutmacher, Peter Friedl.
4942 Metastatic tumor migration in lymphatic vessels
revealed by real-time intravital imaging. Darci M. Fink, Alicia
L. Connor, Philip M. Kelley, Richard M. Tempero, Michael A.
Hollingsworth.
4943 Visualization of endogenous melanoma initiation
and progression using intravital microscopy. James E. Bear,
Hailey E. Brighton, Norman E. Sharpless, David B. Darr, Kelly S.
Clark.
4945 Evaluating the feasibility and throughput of
quintuple modality imaging in a prostate cancer bone
metastasis model with PET, SPECT, CT, MRI, and
bioluminescence imaging. John L. Chunta, Deanne Lister,
Chris Bull, Deepa Balagurunathan, Erin Trachet, Chris Chiodo,
Scott Wise, Dick Leopold, Patrick McConville.
4946 Developing anti-angiogenic therapies for human
hepatocellular cancer (HCC)- studies of suntinib in the
woodchuck model of hepatitis B related HCC. Alexander
Pomakov, Ilia Toshkov, Sandra Buitrago, Leslie Curtin, Donald
Trump, Candace Johnson, Edward Ashton, Bud Tennant, Renuka
Iyer.
4947 Quantitative in vivo imaging of oncolytic virus
replication. Mi-Yeon Jung, Matthew K. Ennis, Chetan P. Offord,
David Dingli.
4948 PET/CT clinical protocol design for the novel, first
in class 68Ga labeled guanylyl cyclase C targeted peptide
MLN6907 ([68Ga]MLN6907). Jacob Y. Hesterman, Kelly D.
Orcutt, Ozlem Yardibi, Jerome T. Mettetal, Shu-Wen Teng,
Donna Cvet, Jack Hoppin, Thea Kalebic, Daniel P. Bradley.
4949 In vitro and in vivo investigation of the novel, firstin-class, Guanylyl Cyclase C (GCC) targeted 68Ga labeled
heat stable peptide MLN6907 ([68Ga]MLN6907) for tumor
imaging. Donna Cvet, Robert Robertson, Melissa Saylor,
Jennifer Terkelsen, Ozlem Yardibi, Maria Borland, Nicolas
Salem, Petter Veiby, Todd Sells, Mary Carsillo, Johnny Yang,
Shu-Wen Teng, John Hoppin, Kelly Orcutt, Jacob Hesterman,
Jeffery Norenberg, Tamara Anderson, Mike Schulz, Mary
Ruscowski, Marc Berridge, Steven Mather, Daniel P. Bradley.
Poster
Section
5
5
575
POSTER SESSION
Tumor Biology 50
Poster
Section
6
6
Tumor Metastasis
Poster Abstract
Board Number
1.
2.
4951
Platelet cloaking of CTCs is a universal
phenomenon, which drives metastasis. Cathy D. Spillane,
Niamh M. Cooke, Karl Egan, Sharon O’Toole, Stephen Finn,
Dermot Kenny, Orla Sheils, John J. O’Leary.
3.
4952
Germline variation modulates susceptibility to
aggressive disease development in a mouse model of
prostate tumorigenesis. Kendra A. Williams, Sujata Bupp,
Shashank Patel, Jonathan Andreas, Suiyuan Zhang, Alfredo
Molinolo, Silvio Gutkind, Nigel Crawford.
4.
4953
Establishment and validation of models for
metastasis developed from patient xenogragrafts (PDX).
Jens Hoffmann, Andrea Orthmann, Annika Hoffmann, Reiner
Zeisig, Iduna Fichtner.
5.
4954
Hematogenous metastasis of ovarian cancer:
Re-thinking mode of spread. Sunila Pradeep, Seung W.
kim, Sherry Wu, nishimuara masato, Takahito Miyake, choi
Hyun-Jin, Rajesha rupaimoole, jinsong liu, Isahai Fidler,
Gabriel Lopez, Anil Sood.
6.
4955
Role of Angiotensin II in prostate cancer
metastasis. Debanjan Chakroborty, Chandrani Sarkar.
8.
4957
Role of tumor-derived exosomes in growth and
metastasis of breast cancer. Radha Munagala, Ramesh
Gupta.
9.
4958
Fluorescent barcoding offers increased
dimensionality in tracking tumor cells in vitro and in
vivo. Katie E. Hebron, Tatiana Ketova, Shanna Arnold, H.
Charles Manning, Julie Sterling, Florent Elefteriou, Andries
Zijsltra.
10.
4959
High-resolution MALDI imaging mass
spectrometry demonstrated the correlation between
phosphatidylinositol profiles and invasion/metastasis in
human breast cancer. Masahiro Kawashima, Nobuko
Kawaguchi-Sakita, Masahiro Sugimoto, Taka-Aki Sato,
Koichi Tanaka, Masakazu Toi.
11.
4960
Serial in vivo orthotopic passage of human
pancreatic cancer cells selects for increased stem celllike behavior. Cristina Metildi, Sharmeela Kaushal, Robert
M. Hoffman, Michael Bouvet.
12.
4961
Longitudinal bioluminescence imaging of
primary versus abdominal metastatic tumor growth in
orthotopic pancreatic tumor models in NOD/SCID␥(-/-)
mice. Harlan E. Shannon, Melissa L. Fishel, Jingwu Xie,
Dongsheng Gu, Brian P. McCarthy, Amanda A. Riley,
Anthony L. Sinn, Jayne M. Silver, Mark R. Kelley, Helmut
Hanenberg, Murray Korc, Karen E. Pollok, Paul R. Territo.
13.
576
4950
Hypercholesterolemia promotes prostate cancer
PC-3 metastases in orthotopic xenograft mice.
Hyeongsun Moon, Laura Sharpe, Eunju Choi, Helle
Bielefeldt-Ohmann, Zeyad Nassar, Marie-Odile Parat,
Mathias Francois, C Soon Lee, Andrew Brown, Pamela
Russell, Kerry Inder, Michelle Hill.
4962
Derivation of bone trophic human prostate
cancer cells. Erin N. Howe, Ryan M. Brown, Russell Z.
Szmulewitz, Carrie W. Rinker-Schaeffer.
Poster Abstract
Board Number
14.
4963
In vivo and in vitro effect of a nutrient mixture
on murine 4T1 breast cancer. M. W. Roomi, John Cha,
Nusrath Roomi, Aleksandra Niedzwiecki, Matthias Rath.
15.
4964
TGM2 in inflammation-regulated progression of
pancreatic cancer. Kapil Mehta, Santosh Kumar.
16.
4965
Hypoxia has different effects on proliferation,
migration and metastasis of various types of tumor
cells. EnikŐ Tátrai, Alexandra Bartal, Zsuzsanna Fehér, Ákos
Farkas, Sándor Paku, István Kenessey, József Tóvári.
17.
4966
Establishment and characterization of a paired
human non-small cell lung cancer cell lines from
primary cancer and metastasis lymph node. Jun Chen,
Min Wang, Lingling Zu, Yongwen Li, Weiqiang Wang,Ying Li,
Hongyu Liu.
18.
4967
ESRP1 regulated alternative splicing of
CD44mRNA enhances lung colonization of metastatic
cancer cell. Kenji Tsuchihashi, Osamu Nagano, Toshifumi
Yae, Takatsugu Ishimoto, Takeshi Motohara, Momoko
Yoshikawa, Go J Yoshida, Takeyuki Wada, Takashi Masuko,
Kaoru Mogushi, Hiroshi Tanaka, Tsuyoshi Osawa, Yasuharu
Kanki, Takashi Minami, Hiroyuki Aburatani, Mitsuyo Ohmura,
Akiko Kubo, Makoto Suematsu, Kazuhisa Takahashi, Eishi
Baba, Koichi Akashi, Hideyuki Saya.
19.
4968
Msi2 directly linked to Hedgehog and Wnt
signalling in non-triple negative breast cancer. Moustafa
Abdalla, Nisha Kanwar, Yanglong Zhu, Ranju Nair, Bruce J.
Youngson, Naomi A. Miller, Tianyu Liu, Susan J. Done.
20.
4969
Hypo adenosine-to-inosine editing of microRNA455 promotes melanoma metastasis. Einav Shoshan,
Aaron Mobley, Russell Braeuer, Takafumi Kamiya, Li Huang,
Mayra Vasquez, Lee Ho Jeong, Sun Jim kim, George Calin,
Anil Sood, Gal Markel, Isaiah Fidler, Menashe Bar-Eli.
21.
4970
The role of POU5F1B in prostate cancer.
Hongmei Jiang, Man-Tzu Wang, Daotai Nie.
22.
4971
Splicing factor kinase regulates metastatic
dissemination of human prostate cancer. David J. Bond,
Konstantin Stoletov, Hon Sing Leong, Emma Woolner,
Shuhong Liu, Tarek Bismar, Andries Zijlstra, John D. Lewis.
23.
4972
In vivo whole genome shRNA screen reveals
novel targets to block cancer metastasis. Konstantin
Stoletov, David Bond, Hon Sing Leong, Emma Woolner,
Srijan Raha, Amy Robertson, Francis Wong, Andries Zijlstra,
John D. Lewis.
24.
4973
Long non-coding RNA promotes metastatic
behavior in Ewing sarcoma. Sheetal A. Mitra, Anirban P.
Mitra, Jonathan D. Buckley, William A. May, Philipp
Kapranov, Robert J. Arceci, Timothy J. Triche.
26.
4975
Identification of a novel interaction between
EZH2 and p38 in triple negative breast cancer. Talha
Anwar, Heather Moore, Maria E. Gonzalez, Celina Kleer.
27.
4976
Novel ovarian cancer transplantable models
generated from MUC1KrasPten tumors show in vitro and
in vivo heterogeneity. Lixin Zhang, Raluca Budiu, Joan
Brozick, Anda M. Vlad.
POSTER SESSION
Tumor Biology 51
Tumor Microenvironment
Poster
Section
Poster Abstract
Board Number
1.
4977
Chronic mastitis in North Africa: Geographic
overlap and a potential precursor comorbidity of
inflammatory breast cancer. Steven G. Allen, Hanna
Oltean, Kathy Toy, Omar S. Omar, Tamer Youssef, Mehdi
Karkouri, Azza Abdel-Aziz, Ahmad Hablas, Ali Tahri, Celina
Kleer, Amr Soliman, Sofia D. Merajver.
2.
4978
Targeting of phosphatidylserine by monoclonal
antibodies enhances activity of immune checkpoint
inhibitors in tumors. Jian Gong, Van Nguyen, Shen Yin,
Rich Archer, Jeff Hutchins, Bruce Freimark.
3.
4979
A6B1 integrin internalization is increased by
loss of A3B1 expression and promotes migration of
human prostate cancer cells. Lipsa Das, Todd A.
Anderson, Jaime M. Gard, Isis C. Sroka, Stephanie R.
Strautman, Raymond B. Nagle, Beatrice S. Knudsen, Anne
Cress.
4.
4980
Inhibiting carbonic anhydrase IX targets
hypoxic small cell lung cancer cells. Jennifer L. Bryant,
Suzanne L. Meredith, Roben G. Gieling, Brian A. Telfer,
Muhammad Babur, Claudiu T. Supuran, Kaye J. Williams,
Anne White.
Poster Abstract
Board Number
5.
4981
Evaluating the contribution of heterogeneity and
the tumor microenvironment in companion diagnostic
approaches. Joseph S. Krueger, Brian Laffin, Holger Lange,
Anthony Milici, Mirza Peljto, Eric Neeley, Mahipal Suraneni,
David Young.
6.
4982
Characterization of novel ␣-ketoamide
derivatives as potent inhibitors against cathepsin S
induced by acidic extracellular pH in pancreatic cancer
cells. Wun-Shaing W. Chang, Tzu-Yuan Chang, Tzu-Chin
Wu, Chien-Yu Liao, Chun-Cheng Lin.
7.
4983
IRAK4 and breast cancer cell migration in
culture and zebrafish xenografts. K. S. Kimbro, Karine
Ferri-Lagneau, Jamil Haider, Susan Yeyeodu, Xiaohe Yang,
TinChung Leung.
8.
4984
Contribution of MMP13 to tumor development in
the steatotic liver microenvironment. Alisha M.
Mendonsa, Michael N. VanSaun, Lee Gorden.
9.
4985
Cellular dormancy in residual disease following
oncogene inhibition. Jason Ruth, Dhruv Pant, Blaine
Keister, Christopher Sterner, Lewis Chodosh.
7
7
577
POSTER SESSION
Tumor Biology 52
Poster
Section
8
8
Tumor Motility and Invasion 3
Poster Abstract
Board Number
1.
4986
APG101 inhibits CD95-Ligand induced invasion
of glioblastoma in 3D-models in vitro and ex vivo.
Christian Merz, Alexander Strecker, Jaromir Sykora, Oliver
Hill, Gieffers Christian, Harald Fricke, Peter Angel, Heike
Peterziel.
13.
4998
In-depth analysis of myoma organotypic model
can determine potential markers of oral cancer
invasion. Nilva K. Cervigne, Carolina Bitu, Bianca A.
Pauletti, Adriana F. Paes Leme, Tuula Salo, Ricardo Della
Coletta.
2.
4987
Stathmin regulates cell migration, invasion and
transendothelial migration via RhoA activation in
neuroblastoma. Christopher M. Fife, Frances L. Byrne,
Sharon M. Sagnella, Thomas P. Davis, Joshua A. McCarroll,
Maria Kavallaris.
14.
4999
Paracrine regulation of glioma invasion by
astrocytes is mediated by glial derived neurothropic
factor. Moran Amit, Ayelet Shabtay-Orbach, Yoav
Binenbaum, Ziv Gil.
15.
3.
4988
Clues for targeted therapies in inflammatory
breast cancer (IBC). Sandra V. Fernandez, Fredika M.
Robertson, Sankar Addya, Zhaomei Mu, Massimo
Cristofanilli.
5000
Upregulation of WDR26 promotes breast cancer
cell growth, migration and invasion via enhancing PI3K/
AKT signaling. Yuanchao Ye, Songhai Chen.
16.
5001
GATA3 abrogates TGFbeta-mediated breast
cancer invasion and metastasis. Jianwei Sun, Huifang He,
Smitha Pillai, Srikumar Chellappan, Shengyu Yang.
17.
5002
Modulation of E-cadherin transcription
mediated by nuclear localization of ABCG2. Shu-Ching
Liang, Chih-Yung Yang, Chi-Hung Lin.
18.
5003
Functional significance of TIGAR expression in
nasopharyngeal carcinoma. Elaine Y. Wong, SC Cesar
Wong, Charles M. Chan, Emily K. Lam, Louisa Ho, Cecilia P.
Lau, Thomas C. Au, Amanda K. Chan, CM Tsang, George S.
Tsao, Vivian W. Lui, Anthony T. Chan.
19.
5004
Iqgap2 is downregulated in colorectal cancer
(crc) and involved in cellular migration . Benedikt
Gröschl, Marcus Bettstetter, Tamara Widmann, Ferdinand
Hofstädter, Wolfgang Dietmaier.
20.
5005
The histone demethylase JMJD1A induces cell
migration and invasion by up-regulating the expression
of the long noncoding RNA MALAT1. ANDREW E. TEE,
BELAMY CHEUNG, GLENN M. MARSHALL, TAO LIU.
21.
5006
A 3-dimensional cell invasion assay compatible
with high content screening. Jennifer A. Fronczak,
Matthew S. Gajeski, Erica L. Beckman, Laura Vollmer,
Andreas Vogt, Gopal Krishnan.
4.
4989
Desmocollin 2 suppresses lung cancer cell
migration and invasion through down-regulation of
NDRG1 expression. Yu-Chih Hsu, Po-Chun Ou, Yu-Yi Chen,
Meng-Feng Tsai.
5.
4990
Epidermal growth factor-induced expression of
PTX3 regulates metastasis of head and neck squamous
cell carcinoma. Ben-Kuen Chen, Shuo-Lun Wu, Jhih-Peng
Tsai.
6.
4991
Identifying a highly-aggressive DCIS subgroup
by studying intra-individual DCIS heterogeneity among
invasive breast cancer patients. Zhengyu Jiang, Dana
Pape-Zambito, Karthik Devarajan, Hong Wu, Carolyn Slater,
Lauren Dolinsky, Mary Daly, Xiaowei Chen.
7.
4992
Zkscan3 facilitates invasion of colorectal
cancer associated with ceacam5. Seon Ae Roh, Chan
Wook Kim, Ka Hee Tak, Jin Cheon Kim.
8.
4993 IFI27 and NOV, downstream regulated genes by
S100A4, are playing important roles in pancreatic
carcinogenesis. Na Chen, Yuriko Saiki, Hitoshi Sekine,
Makoto Sunamura, Shinichi Fukushige, Fuyuhiko Motoi,
Shinichi Egawa, Michiaki Unno, Akira Horii.
9.
4994
E2F1 deficiency causes increased migration
through upregulation of MYLK. Peng Meng, Rita Ghosh.
22.
10.
4995
Role of MICAL1 in NEDD9 invasive signaling.
Casey O. Holmes, Amanda M. Brock, Philip T. Sobash,
Jessica A. Tiedeken, Steven A. Rosenzweig.
5007
RSK isoform regulation of migration and
invasion in glioblastoma. Amanda Prechtl, Florian
Sulzmaier, Pengfei Jiang, Santosh Kesari, Joe Ramos.
23.
5008
The acetylenic tricyclic bis(cyanoeneone), TBE31 inhibits non-small cell lung cancer cell migration
through direct binding with actin. Eddie Chan, Akira
Saito, Tadashi Honda, John Di Guglielmo.
24.
5009
Thymoquinone downregulates n-cadherin, twist
and snail expression and inhibits migration and
invasion in cancer cells. Md. Asaduzzaman Khan, Manman
Yang, Chunli Wei, Lin Gan, Junjiang Fu.
25.
5010
Osteoblasts-derived WISP-1 increases prostate
cancer metastasis through VCAM-1 upregulation. AnChen Chang, Shih-Wei Wang, Chih-Hsin Tang.
11.
12.
578
Poster Abstract
Board Number
4996
Interferon consensus sequence binding protein
(ICSBP) promotes epithelial to mesenchymal transition
(EMT)-like phenomena, cell motility, and invasion via
TGF-␤ signaling in U2OS cells. Jee Young Sung, Seog-Yun
Park, June Hyuk Kim, Hyun Guy Kang, Jong Hyung Yoon,
Yoon Sook Na, Yong-Nyun Kim, Byung-Kiu Park.
4997
MMP14 as PTP4A3 downstream target is
involved in uveal melanoma cell dissemination. Selma
Maacha.
POSTER SESSION
Immunology 11
Immune Checkpoint Inhibition
Poster
Section
Poster Abstract
Board Number
1.
2.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
5011 Cancer immunotherapy targeting CD47: Wild type
SIRP␣Fc is the ideal CD47-blocking agent to minimize
unwanted erythrocyte binding. Robert A. Uger, Karen Dodge, Xinli
Pang, Penka S. Petrova.
5012 A combination trial of vaccine plus ipilimumab in
metastatic castration-resistant prostate cancer patients:
Immune correlates. Geraldine O’Sullivan Coyne, Caroline Jochems,
Christopher Heery, Harpreet Singh, Ira Surolia, Robin Riley, Ravi
Madan, William Dahut, Seth Steinberg, James Gulley, Jeffrey
Schlom.
5014 MK-3475 (anti-PD-1 monoclonal antibody) for nonsmall cell lung cancer (NSCLC): Antitumor activity and
association with tumor PD-L1 expression. Leena Gandhi, Ani
Balmanoukian, Rina Hui, Omid Hamid, Naiyer A. Rizvi, Natasha
Leighl, Matthew Gubens, Jonathan W. Goldman, Gregory M.
Lubiniecki, Kenneth Emancipator, Marisa Dolled-Filhart, Jared K.
Lunceford, Michelle Niewood, Kevin Gergich, Edward B. Garon.
5015 TCR usage analysis in blood reveals different
mechanisms of action of CTLA-4 and PD-1 blockade in patients.
Lidia Robert, Christina L. Harview, Ryan Emerson, Stephen Mok,
Blanca Homet, Begonya Comin-Anduix, Richard C. Koya, Harlan
Robins, Paul C. Tumeh, Antoni Ribas.
5016 Antitumor activity of anti-PD-1 in combination with
tyrosine kinase inhibitors in a preclinical renal cell carcinoma
model. Gregg Masters, Gennaro Dito, Becky Penhallow, Anne Lewin,
Henry Kao, Maria N. Jure-Kunkel.
5017 T-cell repertoire turnover induced by anti-CTLA-4
antibody treatment in cancer patients. Lawrence H. Fong, Edward
Cha, Mark Klinger, Yafei Hou, Craig Cummings, Antoni Ribas, Malek
Faham.
5018 Combination immunotherapy with PD-L1 blockade and
Poly I:C in a murine breast cancer model. Hatem Soliman, Ashley
R. Nelson.
5019 Irradiation and anti-B7-H1 provide synergistic
treatment effects in murine cancer. Liufu Deng, Hua Liang, Byron
Burnette, Micheal Beckett, Thomas Darga, Ralph Weichselbaum,
Yang-Xin Fu.
5020 Cooperative effects of programmed cell death-1
blockade and radiation in a model of a poorly immunogenic
breast carcinoma. Karsten Pilones, Joseph Aryankalayil, Silvia
Formenti, Sandra Demaria.
5021 Regulatory T-cells and effects of anti-CTLA4 and antiPD1 therapy in a transgenic murine model of neuroblastoma.
Randall Chan, Soheila Shirinbak, Sakunthala Muthugounder, Long
Hung, Janahan Gnanachandran, Michael Hajidaniel, Shahab
Asgharzadeh.
5022 Peptide therapeutic inhibiting PD1 immune checkpoint
ligands: Potential for greater anti-tumor immune response and
better management of immune-related adverse events. Murali
Ramachandra, Pottayil G. Sasikumar, Rajeev K. Shrimali, Sreenivas
Adurthi, Raghuvir Ramachandra, Leena K. Satyam, Amit A.
Dhudashia, Samiulla Dhodheri, K B. Sunilkumar.
5023 Synergistic antitumor effects of combinatorial immune
checkpoint inhibition with anti-PD-1/PD-L antibodies and the
IDO pathway inhibitors NLG-919 and indoximod in the context of
active immunotherapy. Mario R. Mautino, Charles J. Link, Nicholas
N. Vahanian, James T. Adams, Clarissa Van Allen, Madhav D.
Sharma, Theodore S. Johnson, David Munn.
5024 mDX400, the murine analog against the anti-PD1
antibody MK-347 is active in immunocompetent, autochthonous
murine models of melanoma and breast cancer. David Darr, Kelly
S. Clark, Joseph H. Phillips, Elaine Pinheiro, Venkataraman Sriram,
Jessie Xiong, Jamie Jordan, Norman E. Sharpless, Charles Perou,
Stergios Moschos.
Poster Abstract
Board Number
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
5025 Dissecting the dynamics of anti-PD1 immunotherapy in
preclinical tumor models. Venkataraman Sriram, Michael E. Bigler,
Holly Cherwinski, Erin Murphy, Terrill K. McClanahan, Joseph H.
Phillips.
5026 B7-H1 confers tumor chemoresistance by regulating
MAPK/ERK activation. Amanda Orzechowski, Haidong Dong.
5027 Identification of novel immune checkpoints as
potential targets for cancer immunotherapy. Galit Rotman, Ofer
Levy, Amir Toporik, Gady Cojocaru, Liat Dassa, Ilan Vaknin, Shirley
Sameah-Greenwald, Inbal Barbiro, Jinhong Fan, Susan Watson, John
Hunter, Eyal Neria, Zurit Levine.
5028 Metronomic cyclophosphamide enhances the
immunogenicity and anti-tumour activity of a DepoVax based
vaccine and may be further enhanced with inhibitors of CTLA-4
or PD-1. Genevieve Weir, Olga Hrytsenko, Marianne M. Stanford,
Neil L. Berinstein, Mohan Karkada, Robert S. Liwski, Marc Mansour.
5029 Comparative combination cancer immunotherapy with
vaccination, checkpoint inhibition and TNFRSF stimulation.
Taylor H. Schreiber, Neal Schilling, Vadim Deyev, Eckhard R. Podack.
5030 Antibody blockade of Semaphorin 4D promotes tumor
rejection and improves response to immune checkpoint
blockade and chemotherapy. Elizabeth E. Evans, Holm Bussler,
Sebold Torno, Janaki Veeraraghavan, Alan S. Jonason, Michael A.
Doherty, Christine Reilly, Crystal Mallow, Jennifer Seils, Mark Paris,
Terrence L. Fisher, William J. Bowers, Maria Scrivens, Leslie Balch,
Renee Kirk, Alan Howell, Valerie Iddison, John E. Leonard, Ernest S.
Smith, Maurice Zauderer.
5031 Effects of BRAF and MEK inhibitors, dabrafenib and
trametinib, on the immune system and in combination with
immunomodulatory antibodies targeting PD1, PD-L1 and CTLA-4.
Li Liu, Patrick Mayes, Stephen Eastman, Hong Shi, Sapna Yadavilli,
Xiaoyu Pan, Jingsong Yang, Laura Seestaller-Wehr, Shu-Yun Zhang,
Chris Hopson, Lyuben Tsvetkov, Junping Jing, James Smothers,
Drew M. Pardoll, Axel Hoos.
5032 Synergy between an engineered cytokine, NKTR-214,
and CTLA-4 blockade in murine colon and breast tumor models.
Steve Lee, Murali Addepalli, Ute Hoch, Rhoneil Pena, Payal Shirsat,
Yolanda Kirksey, Stephen K. Doberstein, Deborah Charych, Seema
Kantak.
5033 Down-regulation of PD-1 ligands by chemotherapeutic
agents via inhibition of STAT3 activity enhances T cellstimulating ability of dendritic cell. Masato Okamoto, Tomoyuki
Tano, Hiroyuki Goda, Yohei Fujita, Koh-ichi Nakashiro, Hiroyuki
Hamakawa.
5034 The antitumor immune response generated by
radiation therapy may be limited by tumor cell adaptive
resistance and can be circumvented by PD-L1 blockade. Simon
J. Dovedi, Graznya Lipowska-Bhalla, Eleanor Cheadle, Edmund Poon,
Michelle Morrow, Ross Stewart, Robert Wilkinson, Jamie
Honeychurch, Timothy Illidge.
5035 Blockade of VEGF with ziv-aflibercept (VEGF Trap)
enhances anti-tumor efficacy of CTLA-4 blocking antibody in an
Fc dependent manner. Elena Burova, Ella Ioffe, Chandrika
Taduriyasas, Omaira Allbritton, Gaurav Tyagi, Lekan Oyejide, John
Rudge, Israel Lowy, Gavin Thurston.
5036 Blockade of the CD39 immunoregulatory pathway by
monoclonal antibodies. Jeremy Bastid, Cécile Dejou, Jérôme
Giustiniani, Stéphanie Cochaud, Gilles Alberici, Armand Bensussan,
Jean-François Eliaou, Nathalie Bonnefoy.
5037 Targeting MICA with therapeutic antibodies for the
treatment of cancer. Mathieu Blery, Cécile Bonnafous, Valentine
Peri, Sylvia Trichard, Ivan Perrot, Stéphanie Cornen, Ariane Thielens,
Violette Breso, Yannis Morel, François Romagne, Benjamin Rossi,
Carine Paturel, Laurent Gauthier.
10
10
579
POSTER SESSION
Prevention Research 7
Poster
Section
12
12
Cancer Prevention and Control
Poster Abstract
Board Number
1.
5038
Telomere length linking social contexts and
cancer risk in Mexican Americans. Lixia Han, Hua Zhao,
Sara Strom, Carrie R. Daniel, David Chang, Hui Zhang,
Yuanqing Ye, Jian Gu, Wong-Ho Chow, Xifeng Wu.
12.
5048
Racial/ethnic diversity in pediatric oncology
clinical trial enrollment at Rady Children’s Hospital San
Diego. Paula Aristizabal, Jenelle Singer, Renee Cooper,
Mehrzad Milburn, Deborah Schiff, M. Elena Martinez.
2.
5039
Physical activity is associated with improved
quality of life in cancer survivors: A population-based
analysis. Apoorva Tewari, Melinda Irwin, Anees Chagpar.
13.
3.
5040
Weight loss prevents obesity-associated basallike breast cancer progression: role of hepatocyte
growth factor/c-Met. Sneha Sundaram, Trinh Le, Luma
Essaid, Kirk K. McNaughton, Katharine M. Bendt, David B.
Darr, Melissa A. Troester, Liza Makowski.
5049
Physician preferences in tobacco cessation
support for cancer patients: a survey of physicians at
National Cancer Institute Designated Cancer Centers.
Alix Pommerenke, Anthony Alberg, Thomas H. Brandon,
Ivana Croghan, Michael K. Cummings, Carolyn Dresler, Ellen
R. Gritz, Roy Herbst, Scott Leischow, James R. Marshall,
Benjamin Toll, Graham Warren.
14.
4.
5041
The effect of YOCAS©® Yoga on prescription
sleep medication and over-the-counter sleep medication
usage in cancer survivors with impaired sleep quality.
Luke J. Peppone, Michelle Janelsins, Jonathan Friedberg,
Mohamed Tejani, Charles Kamen, Marie Flannery, Anita
Peoples, James Atkins, Marianne Melnik, Karen Mustian.
5050
A meta-analysis of lifestyle factors with MPO
and GSTM1 human genes in lung cancer prevention.
PoJui P. Yu, S. Pamela Shiao, Maria Suarez.
15.
5051
Retrospective analysis of direct inpatient
charges and mortality of leukemia pediatric patients
with Methicillin-resistant Staphylococcus aureus,
Candida, or Aspergillus infections in the United States.
Tomas Nuño, Grant H. Skrepnek.
16.
5052
The knowledge of cervical cancer screening
among women of reproductive age in Sub-Saharan
Africa: Nigerian experience. Yemisi C. Gold.
17.
5053
Preliminary results from the Reproducibility
Project: Cancer Biology - a replication of 50 high-impact
cancer cell biology papers from 2010 –2012. Gunn
William, Elizabeth Iorns, Elizabeth Silva, Brian Nosek.
18.
5054
Smoking prevention intervention with school
classes at a university hospital by thoracic surgeon und
pulmonologist. Sandra Tomaszek, Macé M. Schuurmans,
Didier Schneiter, Walter Weder, Sven Hillinger.
19.
5055
Referral patterns, geographical distribution and
socio-economic status of African Americans and
European Americans with family or personal history of
cancer visiting a genetic counseling center in the
greater Cleveland area. Paola Raska, Anna Mitchelll.
20.
5056
Perceptions related to breast cancer prevention
and behavioral practices in underserved women
participated in a CBPR intervention. Saleh M. Rahman,
Cynthia M. Harris, Miaisha Mitchell, Karam F. Soliman.
21.
5057
The role of health locus of control and selfefficacy beliefs in sunscreen use: Evidence from 2012
Health Information National Trends Survey. Xiaofei He.
22.
5058
MTHFR and health behaviors: A meta-analysis
of epigenetic risks for breast cancer prevention. Mildred
C. Gonzales, S. Pamela Shiao, Amanda Lie.
5.
5042
Using a statewide collaborative approach to
improve tobacco cessation referral rates for cancer
patients. Jane Severson, Hilary Baca, Douglas Blayney,
Karen Brown, Grayce Galiyas, Mara Minasian, Joan Schmidt,
Anna Schulze, Graham Warren.
6.
5043
Physical activity and the risk of lung cancer
death: Results from the Third National Health and
Nutrition Examination Survey. Marisa A. Bittoni, Randall E.
Harris, Janet Buckworth, Steven K. Clinton, Brian C. Focht.
7.
5044
Role of obesity in Leptin-Notch crosstalk
(NILCO) in endometrial cancer from African American
and Chinese women. Danielle Daley-Brown, Regina Lee,
Gabriela Oprea-Ilies, Emerald Screws, Roland Matthews,
Roland Pattillo, Ruben R. Gonzalez-Perez.
8.
5045
Genetic and social determinants of quality of
life in lung cancer patients. Jeanne A. Pierzynski, Michelle
Hildebrandt, Yuanqing Ye, Alma Rodriguez, Xifeng Wu.
10.
5046
What do they do? Patient navigator actions and
timely treatment within 30 days of diagnosis in Latinas
with breast cancer: The Six Cities Study. Amelie G.
Ramirez, Eliseo J. Perez-Stable, Gregory A. Talavera, Frank
Penedo, Emilio J. Carrillo, Maria E. Fernandez, Alan E.
Holden, Edgar Munoz, Kipling J. Gallion.
11.
580
Poster Abstract
Board Number
5047
Impact of parental origin of BRCA1/ 2 mutation
on age at breast and ovarian cancer diagnosis. Carolina
Ellberg, Helena Jernstrom, Per Broberg, Ake Borg, Hakan
Olsson.
POSTER SESSION
Epidemiology 12
Molecular and Genetic Epidemiology of Genitourinary, Hematopoietic, and
Brain Cancers
Poster Abstract
Board Number
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
5060 Dietary sodium, potassium and fluid intake and clear cell
renal cell cancer: heterogeneous effects by DNA methylation of
genes involved in renal salt homeostasis. Ivette A. Deckers, Piet A. van
den Brandt, Manon van Engeland, Patricia M. Soetekouw, Marcella M.
Baldewijns, András P. Keszei, Leo J. Schouten.
5061 Post-GWAS functional characterization of the 12p11.23
renal cancer susceptibility locus implicates BHLHE41. Lea Jessop,
Pierre Bigot, Mitchell Machiela, Timothy Myers, Nilabja Sikdar, Leandro
Colli, Stephen Chanock.
5062 Serum microRNA profiling in non-muscle invasive bladder
cancer. Jie Lian, Shu-Hong Lin, Sherri Luo, Maosheng Huang, Jian Gu,
Ashish M. Kamat, Colin P. Dinney, Xifeng Wu.
5063 PSCA as a potential therapeutic and prognostic biomarker
for common cancer. Koichi Matsuda, Chizu Tanikawa, Yusuke Nakamura.
5064 Pleiotropy analysis identifies a novel prostate cancer
variant at 6p21.33: The PAGE, PRACTICAL, and BPC3 Consortia. Ying
Han, Shelly-Ann Love, William S. Bush, Daniele Campa, Anne M. Butler,
Logan Dumitrescu, Konstantinos Tsilidis, Iona Cheng, Lynne R. Wilkens,
Jay H. Fowke, Jose Luis Ambite, Steve Buyske, S. Lani Park, The
PRACTICAL Consortium, The BPC3 Consortium, Christopher A. Haiman,
Loic Le Marchand, Lucia A. Hindorff, Federico Canzian, Fredrick R.
Schumacher.
5065 Fine-mapping the HOXB region detects common variants
tagging a rare coding allele: evidence for synthetic association in
prostate cancer. Zsofia Kote-Jarai, Edward Saunders, Tokhir Dadaev,
Daniel Leongamornlert, Sarah Jugurnauth-Little, Malgorzata Tymrakiewicz,
Koveela Govindasami, Fredrik Wiklund, Ali Amin Al Olama, Sara Benlloch,
The PRACTICAL Consortium, Douglas Easton, Keneth Muir, Rosalind Eeles.
5066 Generalizability of established prostate cancer risk
variants in men of African ancestry. Ying Han, Lisa B. Signorello, Sara
S. Strom, Rick A. Kittles, Benjamin A. Rybicki, Janet L. Stanford, Phyllis J.
Goodman, Sonja I. Berndt, John Carpten, Graham Casey, Lisa Chu, David
V. Conti, Kristin A. Rand, Ryan Diver, Anselm J. Hennis, Esther M. John,
Adam S. Kibel, Eric A. Klein, Suzanne Kolb, Loic Le Marchand, M C.
Leske, Adam B. Murphy, Christine Neslund-Dudas, Jong Y. Park, Curtis A.
Pettaway, Timothy R. Rebbeck, Susan M. Gapstur, Siqun L. Zheng, SuhYuh Wu, John S. Witte, Jianfeng Xu, William B. Isaacs, Sue A. Ingles, Ann
W. Hsing, The PRACTICAL Consortium, The ELLIPSE GAME-ON Consortium,
Douglas F. Easton, Rosalind A. Eeles, Fredrick R. Schumacher, Stephen
J. Chanock, Barbara Nemesure, William J. Blot, Daniel O. Stram, Brian E.
Henderson, Christopher A. Haiman.
5067 An expressed retrogene of master embryonic stem cell
factor OCT4 alters prostate cancer susceptibility. Joan Breyer, Daniel
Dorset, Travis Clark, Kevin Bradley, Tiina Wahlfors, Kate McReynolds,
William Maynard, Sam Chang, Michael Cookson, Joseph Smith, Johanna
Schleutker, William Dupont, Jeffrey R. Smith.
5068 1-stearoylglycerol is associated with risk of prostate
cancer: Results from serum metabolomic profiling. Alison M. Mondul,
Steven Moore, Stephanie Weinstein, Satu Mannisto, Johsua Sampson,
Demetrius Albanes.
5069 Circulating 25-hydroxyvitamin D and prostate cancer
survival. Stephanie J. Weinstein, Alison Mondul, Satu Männistö,
Demetrius Albanes.
5070 Role of p73 di-nucleotide polymorphism in prostate cancer
and p73 protein isoform balance. L. Michael Carastro, Hui-Yi Lin, Hyun
Y. Park, Donghwa Kim, Selina Radlein, Kaia K. Hampton, Ardeshir Hakam,
Babu Zachariah, Julio M. Pow-Sang, Jong Y. Park.
5071 A Genome wide association study suggests evidence of
variants at 6p21.32 associated with marginal zone lymphoma. Joseph
Vijai, Zhaoming Wang, Sonja I. Berndt, Susan L. Slager, James R. Cerhan,
Christine Skibola, Sophia S. Wang, Angela R. Brooks-Wilson, Silvia de
Sanjose, Paige M. Bracci, Mads Melbye, Bengt Glimelius, Rebecca D.
Jackson, Wendy Cozen, Nikolaus Becker, Lauren R. Teras, John J.
Spinelli, Jenny Turner, Qing Lan, Mark P. Purdue, Kimberly A. Bertrand,
Kenneth Offit, Paolo Vineis, Brian K. Link, Graham G. Giles, Anne
Zelenuich-Jacquotte, Alain Monnereau, Maria Grazia Ennas, Demetrius
Albanes, Laurie Burdett, Nathaniel Rothman, Stephen J. Chanock,
Alexandra Nieters, On behalf of the NHL GWAS Consortium.
Poster Abstract
Board Number
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
Poster
Section
13
13
5072 Meta-analysis of genome-wide association studies
identifies novel susceptibility loci for follicular lymphoma. Christine F.
Skibola, Sonja I. Berndt, James R. Cerhan, Zhaoming Wang, Joseph Vijai,
Lucia Conde, Paul de Bakker, Sophia S. Wang, Claire M. Vajdic, Brenda
M. Birmann, Susan L. Slager, James McKay, Paige M. Bracci, Alexandra
Nieters, Qing Lan, Angela R. Brooks-Wilson, Martha S. Linet, Demetrius
Albanes, John J. Spinelli, Roel C. Vermeulen, Mark P. Purdue, Meredith
Yaeger, Lauren R. Teras, Silvia de Sanjose, Alain Monnereau, Simon
Crouch, Jia Nee Foo, Henrik Hjalgrim, Gianluca Severi, Brian K. Link,
Kimberly A. Bertrand, Yawei Zhang, Karin E. Smedby, Stephen
J. Chanock, Nathaniel Rothman, NHL GWAS Consortium.
5073 Serum sCD23 and sCD30 associated with non-Hodgkin
lymphoma risk as far as 15 to 23 years after blood collection. Mark
P. Purdue, Qing Lan, Troy J. Kemp, Allan Hildesheim, Stephanie J.
Weinstein, Demetrius Albanes, Ligia A. Pinto, Nathaniel Rothman.
5074 Elevated serum free light chains and risk of non-Hodgkin
lymphoma and the subtype follicular lymphoma in a prospective
cohort study. Wei Hu, Ola Landgren, Bryan Bassig, Mark Purdue, Eric
Engels, Qing Lan, Nathaniel Rothman.
5075 B-cell expression of AICDA and MME [CALLA, CD10] is
predictive of a subsequent non-Hodgkin lymphoma diagnosis.
Shehnaz K. Hussain, Marta Epeldegui, Larry I. Magpantay, Elizabeth Crabb
Breen, Emilee Knowlton, Steven Wolinksy, Lisa P. Jacobson, Jay H.
Bream, Roger Detels, Zuo-Feng Zhang, Otoniel Martinez-Maza.
5076 Rapid assessment of AML genes for mutation detection
and copy number variation. Mark Andersen, Kate Rhodes, Steve Roman,
Cristina VanLoy, Adam Broomer, Michael Allen, Denise Topacio, Guoying
Liu, Fiona Hyland.
5077 Common, germline genetic variants within the Wnt/betacatenin stem cell pathway as determinants of multiple myeloma risk.
Michelle A. Hildebrandt, Yuanqing Ye, Yeling Zhou, Robert Orlowski, Xifeng
Wu.
5078 Genome wide association study identifies variants at
16p13 associated with survival in multiple myeloma patients. Elad
Ziv, Eric Dean, Donglei Hu, Alessandro Martino, Daniel Serie, Daniele
Campa, Blake Aftab, Paige Bracci, Gabriele Buda, Jennifer Caswell,
Charles Dumontet, Marek DudziÅ„ski,, Laura Fejerman, Alexandra
Greenberg, Scott Hunstman, Artur Jurczyszyn, Krzysztof Jamroziak, Shaji
Kumar, Herlander Marques, Thomas Martin, Joaquin Martinez-Lopez,
Vincent Rajkumar, Juan Sainz, Annette Juul Vangsted, Marzena Watek,
Jeffrey Wolf, Susan Slager, Federico Canzian, Celine Vachon.
5079 Adjudicating complex phenotypes for use in GWAS: A
study of transplant-related mortality (TRM) after unrelated donor
hematopoietic cell transplantation (URD-HCT). Lara SuchestonCampbell, Theresa Hahn, Leah Preus, Kenan Onel, Xiaochun Zhu, Song
Liu, Li Yan, Alyssa Clay, David Tritchler, Marcelo Pasquini, Philip
McCarthy.
5080 Clinical next generation sequencing of adolescents and
young adult (AYA) patients with cancer reveals aggressive biology: A
preliminary report from a major cancer center. Manojkumar Bupathi,
David S. Hong, Pete M. Anderson, Vivek Subbiah.
5081 Systematic identification of germline mutations in
rhabdomyosarcoma and neuroblastoma using massively paralleled
sequencing. Jun S. Wei, Rajesh Patidar, John Shern, Shile Zhang, Trevor
Pugh, Sharon J. Diskin, Sivasish Sindiri, Young K. Song, Hongling Liao,
Xinyu Wen, Jianjun Wang, Stephen X. Skapek, James R. Anderson,
Frederic G. Barr, Robert C. Seeger, John M. Maris, Douglas S. Hawkins,
Javed Khan.
5082 Whole-exome sequencing of an adult pituitary atypical
teratoid rhabdoid tumor (AT/RT) - A not so simple genome as
pediatric AT/RT. Swethajit Biswas, Madeleine Wood, Abhijit Joshi, Nick
Bown, Lisa Strain, Philip Kane, Tommy Martinsson, Javier Garrido, James
Campbell, Amanda Swain, Alan Ashworth.
581
POSTER SESSION
Molecular and Cellular Biology 64
Poster
Section
15
15
582
Cell Cycle 2
Poster Abstract
Board Number
1.
5083
Metaphase delays lead to chromosome
cohesion fatigue, a novel mechanism underlying
chromosome instability and aneuploidy. John R. Daum,
Sushama Sivakumar, Aaron R. Tipton, Michael W. Davidson,
Gary J. Gorbsky.
3.
5085
Inducing multipolarity of acentrosomal mitotic
spindles as a novel tumor-specific targeting strategy
revealed by the antimitotic effect of mdivi-1. jingnan
wang, Wei Qian, Masahiro Shuda, Jianfeng Li, Lucas
Santana-Santos, Robert W. Sobol, Bennett Van Houten.
4.
5086
BEX protein attenuates the mitotic checkpoint
and induces preneoplastic aneuploidy. Jin-Kwan Lee,
Geun-Hyoung Ha, Janet Lee, Chang-Woo Lee.
5.
5087
Peli 1 targets BubR1 for ubiquitinational
degradation and induces aneuploidy transformation.
Suhyeon Kim, Hye-Young Park, Ha Rim Song, Heounjeong
Go, Hyeseong Cho, Doo Hyun Chung, Chang-Woo Lee.
6.
5088
A synthetic genetic interaction screen in yeast
identifies Plk1 as a promising therapeutic target in
cancer cells that overexpress Cks1b. Robert J. Reid, Xing
Du, John C. DIttmar, Vinayak Rayannavar, Ivana Sunjevaric,
Matthew Maurer, Rodney Rothstein.
7.
5089
Survivin safeguards chromosome numbers and
protects from aneuploidy. Ralf Wiedemuth, Barbara Klink,
Evelin Schroeck, Gabriele Schackert, Achim Temme.
8.
5090
Estrogen receptor-alpha promotes multicentrosomes by inhibition of BRCA1-Rad51 binding.
Youn-Sang Jung, Ho-Young Chun, Tae-Gyun Woo, BumJoon Park.
9.
5091
Aneuploidy is in stomatin overexpressed cells.
Jui-Hao Lee, Chi-Hung Lin.
10.
5092
Geminin regulates pre-replicative complex
formation through the stabilization of CDT1 in mitosis.
Yasusei Kudo, Takaaki Tsunematsu, Naozumi Ishimaru.
11.
5093
Nucleolin phosphorylation profiling under
normal and cellular stress conditions. Kenneth Ng, Allana
Rodriguez, Anjana D. Saxena.
12.
5094
Investigating the role of CDC25B in inhibition of
cellular proliferation. Caleb C. Lee, James Manfredi.
13.
5095
Real-time FUCCI imaging of cell cycle phase in
tumors demonstrates why cancer chemotherapy is not
effective in solid cancers. Shuya Yano, Yasunori Tome,
Yong Zhang, Yukihiko Hiroshima, Shinji Miwa, Fuminari
Uehara, Atsushi Suetsugu, Hiroyuki Kishimoto, Hiroshi
Tazawa, Ming Zhao, Toshiyoshi Fujiwara, Robert M.
Hoffman.
Poster Abstract
Board Number
14.
5096
Quiescence induced checkpoint activation in
the absence of CIZ1. Rosemary H. Wilson, Jo-An Roulson,
Sumia Bageghni, Ghadeer Albadrani, Justin F. Ainscough,
Dawn Coverley.
15.
5097
Co-targeting of convergent, switchable
nucleotide biosynthetic pathways induces synthetic
lethality in leukemia. Caius G. Radu, David A. Nathanson,
Johannes Czernin.
16.
5098
GFP compatibility with EdU cell proliferation
assay. Scott T. Clarke, Zhichao Song, Kelvin Y. Kwan,
Carolyn DeMarco, Aleksey Rukavishnikov, Upinder Singh,
Kyle Gee.
17.
5099
Automated rapid and accurate cell cycle
analysis. Larisa Yurlova, Jacqueline Gregor, Oksana
Sirenko, Evan Cromwell, Kourosh Zolghadr.
18.
5100
Development of a direct-measurement
molecular assay to determine telomere length in human
samples. Daniel C. Edelman, David Petersen, Allison
Gomez, Shahinaz Gadalla, Philippa Webster, Lucas Dennis,
Mike Krouse, Sharon Savage, Paul S. Meltzer.
19.
5101
Common mutations in the hTERT promoter
cause instability in quadruplex DNA which is overcome
by quadruplex stabilizing agents and targeted
oligonucleotides. Alexandra Sokolova, Shelia Thomas,
Francine Rezzoug, Johnathan Chaires, William Dean, Robert
Buscaglia, Donald M. Miller.
20.
5102
Telomeres and survival in stage III colon
cancers: Findings from NCCTG N0147 (Alliance) study.
Nivedita Basu, Ruth A. Johnson, Qian Shi, Garth D. Nelson,
Julie M. Cunningham, Richard M. Goldberg, Frank A.
Sinicrope, Daniel J. Sargent, Steven R. Alberts, Gloria M.
Petersen, Stephen N. Thibodeau, Halcyon G. Skinner, Kristin
Litzelman, Songwon Seo, Russell J. Vanderboom, Ronald E.
Gangnon, Corinne D. Engelman, David N. Rider, Lisa A.
Boardman.
21.
5103
RNA editing enzyme induces accelerated cell
cycle in normal hematopoiesis. Qingfei Jiang, Marianna
Zipeto, Angela Cournt, Heather Leu, Leslie Crews, Sheldon
Morris, Catriona Jamieson.
POSTER SESSION
Drug-induced Apoptosis
Poster
Section
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
5104
Identification of cancer-specific COPI inhibitors
and their associated apoptotic cell death pathways.
David J. Oliver, Anusha Chaparala, Emeka Okafor, Carlos J.
Camacho, Alexander S. Doemling, Felix T. Wieland, Igor B.
Roninson, Michael Shtutman.
5105
A novel metabolite from an extremophile
Streptomyces with apoptosis regulator function. Nasrin
Moazami, Fatoulah Hakami, Hamideh Ofoghi, Massoud
Ghaffarpour.
5106
Induction of reactive oxygen species-dependent
mitotic arrest and apoptosis by sulforaphane in human
bladder cancer 5637 cells. Yung Hyun Choi.
5107
The role of PERIOD2 for radioprotection against
ionizing radiation in mice bone marrow. Aris Alexandrou,
Cheikh Menaa, Chris Liu, Steven Pai, Kai Xiao, Ming Fan,
Shuaib Juma, Loning Fu, William J. Murphy, Jian Jian Li.
5108
The Hsp90 inhibitor ganetespib is a potent
chemosensitizer in preclinical colorectal cancer models.
Suqin He, Don Smith, Manuel Sequeira, John-Paul Jimenez,
Chaohua Zhang, Jim Sang, Timothy Korbut, Jaime
Acquaviva, Masazumi Nagai, Richard Bates, David A. Proia.
5109
Chemosensitization of tumor cells by fish oil
involves regulation of cell proliferation and apoptotic
pathway in experimentally induced colon
carcinogenesis. Isha Rani, Navneet Agnihotri.
5110
The role triptolide in sensitizing lung tumor
cells to cisplatin-induced apoptosis. Gan Wang, Xiaoxin
S. Xu, Yi Zhang.
5111
Nitric oxide and its role in photodynamic
therapy. Marco Monroy, Pooncharas Tipgunlakant, Ursula
Simonis, Raymond Esquerra.
5112
Histone deacetylase and proteasome inhibitors
synergistically induce apoptosis in colon cancer,
multiple myeloma and CTCL cells through induction of
the immediate early genes ATF3 and JUN. Janson W.
Tse, Anderly C. Chueh, Ian Y. Luk, Fiona Chionh, Yvonne
Yeung, Georgia A. Corner, Dominic C. Ng, Hoanh Tran,
Amardeep S. Dhillon, John M. Mariadason.
5113
Synergistic effects of Deferasirox and Imatinib
in chronic myeloid leukemia cells. Dae Sik Kim, Myoung
Hee Kang, Yoo Jin Na, Jung Lim Kim, Bo Ram Kim, Kyong
Hwa Park, Sang Cheul Oh, Jae Hong Seo, Chul Won Choi,
Jun Suk Kim.
5114
The chemomodulatory effects of resveratrol and
didox on herceptin cytotoxicity in breast cancer cell
lines. ghada A. abd ellatif, marianne G. tadros, ashraf B.
abd el naim, amany I. khalifa, ahmad M. alabd.
5115
The Bcl-2 Homology Domain-3 Mimetic,
Obatoclax, chemosensitizes muscle invasive bladder
cancer cell lines to cisplatin treatment. Thomas Steele,
Dan Pham, Kathy Phan, Paramita Ghosh, Ralph deVere
White, Ruth L. Vinall.
5116
Inhibition of PI3K/AKT signaling by NVPBKM120 promotes ABT-737-induced toxicity in
established and primary cultured glioblastoma cells.
Esther P. Jane, Daniel R. Premkumar, Alejandro Morales,
Kimberly A. Foster, Ian Pollack.
5117
Cytotoxic effects of hypericum extracts on
breast and colorectal tumors. Carla Gibbs, Johnette S.
Duggans, Erin Malone, Elbert L. Myles.
5118
Decursin synergistically enhances TRAILinduced apoptosis through CHOP dependent DR5
signaling in TRAIL resistant lung cancer cells. Kim Jae
Kwang.
Poster Abstract
Board Number
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
5119
Smac mimetic inhibits tumorigenicity and
growth of glioblastoma by promoting differentiation of
glioblastoma cancer stem-like cells. Aurelie
Tchoghandjian, Claudia Jennewein, Ines Eckhardt, Stefan
Momma, Dominique Figarella-Branger, Simone Fulda.
5120
Monitoring antioxidant induced
chemosensitization in triple negative breast cancer cells
by Nrf2-luciferase fusion protein. Kira Foygel, Thillai V.
Sekar, Ramasamy Paulmurugan.
5121
Omega-3 polyunsaturated fatty acids induce
apoptotic and autophagic cell death through inhibition
of Akt/mTOR pathway in human oral cancer cells. Kyu
Lim, Soyeon Shin, Tae-Hwa Hong, Kaipeng Jing, Soyeon
Jeong, Soyeon Kim, Gi-Ryang Kweon, Seung-Kiel Park,
Jong-Il Park.
5122
A novel topical candidate for chemotherapy and
radiotherapy-induced alopecia (CRIA) through local
modulation of apoptosis. Jiawei Liu, Saad Harti.
5123
Design, synthesis and evaluation of bivalent
Smac mimetics as novel anti-cancer agents. Haiying
Sun, Shaomeng Wang, Liu Liu, Jianfeng Lu, Donna
McEachern, Dajun Yang, Ming Guo, Sanmao Kang, Jianfeng
Wen, Rong Sheng.
5124
Identification and characterization of novel
regulators of TRAIL-induced apoptosis in breast cancer
cells. Jennifer Dine, Sireesha Garimella, Kristie Gehlhaus,
Magda Grandin, Natasha Caplen, Stanley Lipkowitz.
5125
Defining the minimal ING1b-derived peptide that
is pro-apoptotic. Oleksandr Boyko, Karl T. Riabowol.
5126
Does genetic background in glioma influence
the sensitivity of tumor cells to a PARP inhibitor in the
presence of different DNA damaging agents. Jennifer H.
Carlson, Brian Leyland-Jones, David Martin, Pradip De,
Nandini Dey.
5127
Reprogramming of EMT and stemness by
human recombinant CCN5 in triple negative breast
cancer cells. Amlan Das, Archana De, Snigdha Banerjee,
Sushanta K. Banerjee.
5128
Different effect of Irinotecan induced apoptosis
in k-Ras wild and mutant type colon cancer cell lines.
Myoung Hee Kang, Jung Lim Kim, Bo Ram Kim, Yoo Jin
Jang, Sun Il Lee, Jun Suk Kim, Sang cheul Oh.
5129
Role of PRKD2 in HSP90 inhibition-mediated
suppression of cancer growth. Ninel Azoitei, Kristina
Diepold, Felicitas Genze, Arefeh Rouhi, Susanne Brobovich,
Stefan Froehling, Gabriela Chiosis, Cornelia Brunner, Johan
van Lint, Marcus Cronauer, Claudia Scholl, Thomas
Seufferlein.
5130
Functional role of the crosstalk between
arginine methylation and phosphorylation of hnRNPK
during DNA damage. Jen-Hao Yang.
5131
Cadmium induces cytotoxicity in human
bronchial epithelial cell in a p53-independent, nuclear
factor NF-kappaB-dependent manner. Ji-Ying Du, De-Ju
Chen, Yan-Ming Xu, Andy T. Lau.
5132
Targeting hypoxia-mediated gene transcription
with a novel polyamide drug designed to disrupt the
HIF1␣/␤ heterodimer binding overcomes resistance to
hypoxia in myeloma cell lines. Veena S. Mysore, Nicholas
G. Nickols, Jerzy Szablowski, Peter Dervan, Alan
Lichtenstein, Patrick J. Frost.
5133
Identification of FC101-interacting proteins by
immunoprecipitation. Dominique C. Washington, Amber D.
Williams, Tara Williams-Hart.
16
16
583
POSTER SESSION
Poster
Section
17
17
Epigenetics 5: Histone Modifications
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
584
5134
Histone deacetylase 8 is a novel chromatin
modulator in NAFLD-associated hepatocarcinogenesis.
Yuan Tian, Ka F. To, Paul B. Lai, Yue S. Cheung, Vincent W.
Wong, Henry L. Chan, Alfred S. Cheng.
5135
A chromatin modifier from the 8p11 amplicon
in luminal breast cancer. Brittany T. Ivey, Steve Guest,
Stephen P. Ethier.
5136
HDACi inhibits liposarcoma via targeting of the
MDM2-p53 signaling axis and PTEN, irrespective of p53
mutational status. Wen-bin Ou, Hailong Li, Li Liu,
Shengmei Zhou, Ye Kuang, Ziqin Yan, Zhe Jiang, Si Shi,
Fanguo Meng, Qing Sheng, Haimeng Zhou, Jonathan A.
Fletcher.
5137
Parallel approaches to the discovery of novel
BRD4 inhibitors. David H. Jones, Marcel J. de Groot,
Robert Heald, Ebenezer Arhin, Ria Goodwin, Brenda Burton,
Jan Kulagowski, David Brown, Steven Irving, Richard Bazin,
Deborah Bruce, Rene Devos, Steven Price, Nick Ray, Peter
Lockey, John Montana, Mark R. Albertella, Simon R. Green.
5138
Histone deacetylase 2 and N-Myc reduce p53
protein phosphorylation at serine 46 by repressing gene
transcription of tumor protein 53-induced nuclear
protein 1. jeyran Shahbazi, Christopher J. Scarlett, Murray
Norris, Bing Liu, Michelle Haber, Andrew E. Tee, Alice
Carrier, Andrew V. Biankin, Wendy B. London, Glenn M.
Marshall, Richard Lock, Tao Liu.
5139
MOF cooperates with DNA polymerase eta to
repair intrastrand break induced by crosslinking agents.
Mayank Singh, Arun Gupta, Komal Komal, Tej K. Pandita.
5140
The novel Sirtuin inhibitor AS4.064 induces
apoptosis in lymphoid malignancy lines and regulates
transcription of spliceosome components and the
metabolic enzyme IDH2. Kimberly A. Scata, Arun K.
Sharma, Dhimant Desai, Shantu Amin, Mark H. Kirschbaum.
5141
Inhibition of HDAC1 leads to subtype switching
in the SW13 adrenal adenocarcinoma line. Jessica M.
Lam, Juliane Daggett, Kathryn J. Leyva, Elizabeth E. Hull.
5142
Probing the molecular mechanism of EZH2 in
rhabdoid tumors. Michelle Lira, Ho Man Chan, Veronica
Gibaja.
5143
KDM3A promotes cell growth and cisplatinresistance in ovarian cancer cells. Sivakumar Ramadoss,
Suvajit Sen, Gautam Chaudhuri, Robin Farias-Eisner.
5144
Epigenetic reprogramming by tumor-derived
EZH2 gain of function mutants leads to aggressive 3Dcell morphologies in both epithelial and melanoma cells.
Robert A. Rollins, Anthony M. Barsotti, Michael Ryskin,
Wenyan Zhong, Wei-Guo Zhang, Andreas Giannakou,
Christine Loreth, Veronica Diesl, Maximillian T. Follettie,
Jonathon Golas, Michelle Lee, Timothy Nichols, Conglin Fan,
Gary Li, Stephen Dann, Paul A. Rejto, Kim T. Arndt,
Dominique Verhelle.
5145
KDM2B expression regulates ribosome
biogenesis and cancer cell growth in a p53-dependent
manner. Marianna Penzo, Lucia Casoli, Laura Sicuro, Alice
Galibiati, Daniela Pollutri, Marzia Govoni, Claudio Ceccarelli,
Donatella Santini, Mario Taffurelli, Davide Treré, Lorenzo
Montanaro.
5146
The histone demethylase KDM2A is a new
promoter of tumorigenesis, drug target and negative
prognostic biomarker for non-small cell lung cancer.
Klaus W. Wagner, Hunain Alam, Shilpa S. Dhar, Uma Giri,
Na Li, Yongkun Wei, Tina Cascone, Dipak Giri, Jae-Hwan
Kim, Yuanqing Ye, Asha Multani, Chia-Hsin Chan, Baruch
Erez, Babita Saigal, Hui-Kuan Lin, Xifeng Wu, Mien-Chie
Hung, John Heymach, MinGyu Lee.
5147
Deregulation of G9a and its functional roles in
liver cancer. Lai Wei, Felice Ho-Ching Tsang, Jeffery ChiFai Lau, Sandy Leung-Kuen Au, Joyce Man-Fong Lee,
Carmen Chak-Lui Wong, Irene Oi-Lin Ng, Chun-Ming Wong.
Poster Abstract
Board Number
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
5148
Overexpression of histone methyltransferase
WHSC1L1 regulates expression of ER-alpha in SUM44
breast cancer cells. Jonathan C. Irish, Alexandria
Rutkovsky, Stephen P. Ethier.
5149
EZH2 as a novel therapeutic target in melanoma
treatment. Jessamy Tiffen, Dilini Gunatilake, Stuart
Gallagher, Kavitha Gowrishankar, Peter Hersey.
5150
JMJD3 suppresses progression of colorectal
carcinoma by regulating cell cycle and anti-apoptosis.
Ryuma Tokunaga, Shigeki Nakagawa, Yasuo Sakamoto,
Ryuichi Karashima, Satoshi Ida, Yu Imamura, Takatsugu
Ishimoto, Shiro Iwagami, Yoshifumi Baba, Yuji Miyamoto,
Naoya Yoshida, Hideo Baba.
5151
A687V EZH2 is a driver of histone H3 lysine 27
(H3K27) hyper-trimethylation. Heidi Ott, Alan Graves,
Melissa Pappalardi, Ryan Kruger, Peter Tummino, Caretha
Creasy, Michael T. McCabe.
5152
Mechanism and therapeutic potential of the
histone demethylase GASC1 in castration-resistant
prostate cancer. Roselyne M. Labbe, Qin Ye, Andreana
Holowatyj, Lihong Zhang, Zeng Quan Yang.
5153
Wolf-Hirschhorn syndrome candidate 1 as a
potential novel therapeutic target for head and neck
cancer. Vassiliki Saloura, Makoto Nakakido, Houda
Alachkar, Tanguy Seiwert, Mark Lingen, Ezra Cohen, Yusuke
Nakamura, Ryuji Hamamoto.
5154
Targeting the histone demethylase KDM4
subfamily as a potential therapeutic strategy in breast
cancer. Andreana Holowatyj, Qin Ye, Lihong Zhang, Jack
Wu, Zeng-Quan Yang.
5155
RapidFire MS/MS enables both rapid evaluation
of multiple histone methyltransferases and label-free
high throughput screening of targeted compound
libraries. Patrick J. Bingham, Karen Maegley, Cody T.
Krivacic.
5156
The oncogenic polycomb histone
methyltransferase EZH2 methylates lysine 120 on
histone H2B and competes ubiquitination in human
cancer. Ryuji Hamamoto, Yusuke Nakamura.
5157
Structure-function studies and drug-design on
the histone lysine methyltransferases NSD1,
NSD2/MMSET/WHSC1, and NSD3/WHSC1L1. Eric Di
Luccio, Damiaan Mevius, Masayo Morishita, Yunpeng Shen.
5158
The H3K9 demethyltransferase gene JMJD1C
has tumor suppressor functions in multiple myeloma.
Danielle DiPerna, Gerald C. Gooden, Brooke Hjelm, Sara
Nasser, Janine LoBello, Aprill Watanabe, Bodour Salhia.
5159
The histone methyltransferase SUV39H2 is a
novel target of anticancer therapy. Kembun Sone, Yusuke
Nakamura, Ryuji Hamamoto.
5160
Development of a non-radioactive method to
determine Protein-Methyl-Transferase activity in-vitro.
Daniel Mueller, Christian Beisenherz-Huss, Carolin
Heidemann-Dinger, Constance Ketterer, Diane Krämer,
Michael H. Kubbutat.
5161
The development of therapeutic inhibitors of the
KDM5 histone demethylases. Heidi R. Hudlebusch, Bo
Heinemann, Jesper M. Nielsen, Daniela Kleine-Kohlbrecher,
Camilla Hauge, Thomas Boesen, Marc Labelle, Lars-Ole
Gerlach, Peter Staller, Peter Birk.
5162
Effects of combined epigenetic therapy with
histone methyltransferase EZH2 inhibitor 3deazaneplanocin and histone deacetylase inhibitor SAHA
on non-small cell lung cancer cells. Taichi Takashina,
Ichiro Kinoshita, Junko Kikuchi, Yasushi Shimizu, Jun S.
Konishi, Satoshi Oizumi, Masaharu Nishimura, Hirotoshi D.
Akita.
5163
JMJD1a: A potential target for prevention and
therapy in pancreatic cancer. Kanagaraj Palaniyandi,
Santanu Paul, Parthasarathy Rangarajan, Deep Kwatra,
Satish Ramalingam, Dharmalingam Subramaniam, Tomoo
Iwakuma, Subhash Padhye, Shrikant Anant, Animesh Dhar.
POSTER SESSION
Genomic and Molecular Characterization of Cancer 3
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
5164 Lacking clonal relationship in 20% of relapsing diffuse
large B-cell lymphomas. Darius Juskevicius, Alexander Rufle,
Christian Ruiz, Stephan Dirnhofer, Alexandar Tzankov.
5165 Molecular features reflecting biological and functional
ages in elderly colorectal cancer patients. Woo Sun Kwon, Park
Daeui, Hye Ryun Kim, Hei-Cheul Jeung, Hyoung Oh Jeong, Jin-Hyuk
Choi, Joong Bae Ahn, Hyun Cheol Chung, Hae Young Chung, Sun
Young Rha.
5166 Characterization of somatic mutation spectrum in
gastric cancer cases from Hispanic populations. Rodrigo Prieto,
Paul Lott, Ruta Sahasrabudhe, Mabel Bohorquez, Jorge Castro,
Gilbert Mateus, Magdalena Echeverry, Luis G. Carvajal Carmona.
5167 Identification of inactivating mutations in stepwise
hepatocarcinogenesis using next generation sequencer. Yutaka
Midorikawa, Shogo Yamamoto, Hiroo Ueda, Kotaro Sonoda, Shingo
Tsuji, Kenji Tatsuno, Tatsuhiro Shibata, Kyle Covington, David
Wheeler, Tadatoshi Takayama, Hiroyuki Aburatani.
5168 Gastric adenocarcinomas show pervasive loss of
heterozygosity and enrichment for “STOP” genes in regions of
hemizygous deletion. Ioana Cutcutache, Alice Yingting Wu, John R.
McPherson, Zhengdeng Lei, Niantao Deng, Wai Keong Wong, Khee
Chee Soo, Weng Hoong Chan, London Lucien Ooi, Roy E. Welsch,
Patrick Tan, Steven G. Rozen.
5169 Diagnostic yield of clinical tumor and germline exome
sequencing for newly diagnosed children with solid tumors.
Donald W. Parsons, Angshumoy Roy, Federico A. Monzon, Yaping
Yang, Dolores H. López-Terrada, Murali M. Chintagumpala, Stacey L.
Berg, Susan G. Hilsenbeck, Tao Wang, Robin A. Kerstein, Sarah
Scollon, Katie Bergstrom, Richard L. Street, Laurence B. McCullough,
Amy L. McGuire, Uma Ramamurthy, Jeff G. Reid, Donna M. Muzny,
David A. Wheeler, Christine M. Eng, Richard A. Gibbs, Sharon E.
Plon.
5170 Linking tumor evolution and therapy response using
diagnostic targeted next generation sequencing in colorectal
cancer. Soulafa Mamlouk, Liam Childs, Thorben Redmer, Pawel
Durek, Dirk Schumacher, Hendrik Bläker, Daniela Aust, Moritz von
Winterfeld, Volker Heinemann, Dominik Modest, Kerstin Möhr,
Markus Morkel, Reinhold Schäfer, Christine Sers.
5171 An integrated analysis of copy number alteration and
global gene expression reveals potential oncogenes underlying
stomach cancer. Kyoung Song, Ryong N. Kim, Sinyoung Jeon, Hae
I. Kim, Yoon-La Choi, Young K. Shin.
5172 Whole exome mutation landscape of 70 commonly
used colorectal cancer cell lines. Oliver Sieber, Dmitri Mouradov,
Clare Sloggett, Robert Jorissen, Chris Love, Shan Li, Antony Burgess,
Diego Arango, Robert Strausberg, Daniel Buchanan, Samuel
Wormald, Liam O’Connor, Jenny Wilding, David Bicknell, Ian
Tomlinson, Walter Bodmer, John Mariadason.
5173 Identification of single-nucleotide variants by highthroughput RNA sequencing in endemic Burkitt Lymphoma.
Maria Antonella Laginestra, Francesco Abate, Maryam Etebari, Giulia
De Falco, Fabio Fuligni, Maura Rossi, Sakellarios Zairis, Maria
Rosaria Sapienza, Anna Gazzola, Claudia Mannu, Federica Melle,
Claudio Agostinelli, Mohsen Navari, Cristiana Bellan, Sara Gazaneo,
Lucia Mundo, Martin Ogwang, Valeria Calbi, Lorenzo Leoncini,
Stefano A. Pileri, Raul Rabadan, Pier Paolo Piccaluga.
5174 Towards understanding the genomic alterations in
human gastric cancer. Juan Cui, Ying Xu.
5175 Re-analysis of breast invasive carcinoma (BRCA) TCGA
copy number data improves tumor profiles. Louis J. Culot, Andrea
O’Hara, Raja Keshavan, Zhiwei Che, Soheil Shams.
5176 Implications of clonality relationship and CD133
expression between cancer synchronous/preceding adenomas
and their colorectal adenocarcinoma pairs. Chih-Yung Yang, JuYu Tseng, Chi-Hung Lin.
5177 Genome-wide profiling of somatic mutations in liver
cancers revealed significantly mutated genes and non-coding
regions in liver cancers. Mayuko Furuta, Akihiro Fuimoto, Yuichi
Shiraishi, Satoru Miyano, Tatsuhiko Tsunoda, Hidewaki Nakagawa.
Poster Abstract
Board Number
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
5178 Pharmacological and genomic profiling identifies
NFkB-targeted treatment strategies for mantle cell lymphoma.
Frank P. Stegmeier.
5179 Context-specific dependence of ovarian cancer on
IKK␧ and CHEK1. Marianne K. Kim, Dong Joon Min, George Wright,
Christina M. Annunziata.
5180 Profiling signaling pathways in chronic lymphocytic
leukemia using reverse phase protein array. Satish Kumar R.
Noonepalle, Austin Shull, Farrukh T. Awan, Leah Pei, Zhiyong Ding,
Huidong Shi.
5181 Genomic and transcriptomic somatic alterations of
hepatocellular carcinoma in non-cirrhotic livers. Obi L. Griffith,
Yiing Lin, Malachi Griffith, Jasreet Hundal, Allison Regier, Robert
Fulton, Elizabeth M. Brunt, Richard K. Wilson, William Chapman,
Elaine R. Mardis.
5182 Identifying differential gene expression and splicing
events in chronic lymphocytic leukemia patients through whole
transcriptome profiling. Austin Y. Shull, Junfeng Luo, Jeong-Hyeon
Choi, Lirong Pei, Farrukh T. Awan, Eun-Joon Lee, Jimei Liu, Phillip J.
Buckhaults, Xiao-Jie Yan, Nicholas Chiorazzi, Huidong Shi.
5183 Modulation of miR-29 expression by alpha-fetoprotein
is linked to the hepatocellular carcinoma epigenome. Sonya T.
Parpart, Stephanie Roessler, Fei Dong, Vinay Rao, Junfang Ji, Lun–
Xiu Qin, Qing–Hai Ye, Zhao–You Tang, Hu–Liang Jia, Xin Wei Wang.
5184 Distinct mutational patterns in liver fluke-related and
non-infection-related bile duct cancers revealed by whole
exome sequencing. Choon Kiat Ong, Waraporn Chan-on, MaarjaLiisa Nairismagi, Weng Khong Lim, Simona Dima, Chawalit Pairojkul,
Paiboon Sithithaworn, Irinel Popescu, Steve Rozen, Patrick Tan, Bin
Tean Teh.
5185 Redefining the somatic landscape of pancreatic
adenocarcinoma. Andrew M. Brown, Faiyaz Notta, Mathieu Lemire,
Ilinca Lungu, Robert E. Denroche, Christina Yung, Kristen Geras,
Lincoln Stein, John M. Bartlett, Thomas J. Hudson, Michael H.
Roehrl, Steven Gallinger, John D. McPherson.
5186 Reduced expression of BRM in hepatocellular
carcinoma. Kohichiroh Yasui, Yasuyuki Gen, Akira Tomie, Tomoko
Kitaichi, Yoshito Itoh.
5187 Feasibility study of genomic biomarker profiling for
patients with metastatic colorectal cancer. Bradley L. Smith,
Philip Breitfeld, Jennifer Cubino, Victor Weigman, Donald P. Richards,
Ki Y. Chung.
5188 Integrated exome analysis in childhood
hepatoblastoma: Biological approach for next clinical trial
designs. Eiso Hiyama, Sho Kurihara, Yoshiyuki Onitake, Nagisa
Morihara, Kyoko Ikeda, Keiko Hiyama.
5189 RNA editing in rhoq promotes invasion potential in
colorectal cancer. Hwang-Phill Kim, Sae-Won Han, Kyung-Hun Lee,
Kyu Joo Park, Jeong-Sun Seo, Jong-Il Kim, Tae-You Kim.
5190 Detection of radioresistant gene of esophageal cancer
by the new cyclopedic gene analysis with transposon. Tomoko
Takesue.
5191 Genome-wide mutational analysis reveals core
signaling pathways in mucinous neoplasms of the appendix.
Hakan Alakus, Michele Babicky, Pradipta Ghosh, Shawn Yost, Kristen
Jepsen, Yang Dai, Angelo Arias, Michael Samuels, Evangeline Mose,
Michael Peterson, Andrew Lowy, Kelly Frazer, Olivier Harismendy.
5192 Mutational analysis of primary central nervous system
lymphoma. Aurélie Bruno, Blandine Boisselier, Karim Labreche,
Yannick Marie, Marc Polivka, Anne Jouvet, Clovis Adam, Dominique
Figarella-Branger, Catherine Miquel, Anne Vital, Caroline Houillier,
Carole Soussain, Karima Mokhtari, Romain Daveau, Khê Hoang-Xuan.
5193 Novel candidate oncogenes with mutation hot spots in
microsatellite unstable colorectal cancer. Alexandra E. Gylfe, Sari
Tuupanen, Ulrika Hänninen, Johanna Kondelin, Heikki Ristolainen,
Riku Katainen, Esa Pitkänen, Minna Taipale, Jussi Taipale, Claus
Lindbjerg Andersen, Laura Renkonen-Sinisalo, Heikki Järvinen, Jan
Böhm, Jukka-Pekka Mecklin, Pia Vahteristo, Lauri A. Aaltonen.
Poster
Section
18
18
585
POSTER SESSION
Poster
Section
19
19
MicroRNA Targets 2
Poster Abstract
Board Number
1.
5194
MiR-200c expression and methylation status
determines epithelial characteristics of NSCLC. Kazuhiko
Shien, Shinichi Toyooka, Junichi Soh, Hiromasa Yamamoto,
Shinsuke Hashida, Ken Suzawa, Tomoaki Otsuka, Hiroaki
Asano, Kazunori Tsukuda, Shinichiro Miyoshi.
2.
5195
Claudin-1, a novel target of miR-375 in nonsmall cell lung cancer. Satoshi Yoda, Kenzo Soejima,
Hiroyuki Yasuda, Takashi Sato, Daisuke Arai, Keiko Ohgino,
Kota Ishioka, Tetsuo Tani, Ayano Oashi, Aoi Kuroda, Makoto
Nishino, Masayoshi Miyawaki, Junko Hamamoto, Katsuhiko
Naoki, Tomoko Betsuyaku.
3.
4.
5.
6.
7.
8.
9.
586
5196
Different miRNAs expression in leiomyosarcoma
and undifferentiated pleomorphic sarcoma. Laura
Pazzaglia, Mohamed Guled, Ioana Borze, Maria Serena
Benassi, Piero Picci, Sakari Knuutila.
5197
MiR-629 targets TRIM33 to promote TGF-␤/
Smad signaling in clear cell renal cell carcinoma.
Kentaro Jingushi, Wataru Nakata, Yuko Ueda, Kaori Kitae,
Kazutoshi Fujita, Motohide Uemura, Norio Nonomura,
Kazutake Tsujikawa.
5198
Identification of microRNAs involved in DNA
damage response in malignant B cells and their
biological and clinical relevance. Katerina Cerna, Jan
Oppelt, Lenka Radova, Katerina Musilova, Nikola Tom, Filip
Pardy, Jitka Malcikova, Karla Plevova, Boris Tichy, Yvona
Brychtova, Michael Doubek, Martin Trbusek, Jiri Mayer,
Jaroslav Koca, Raffaele Calogero, Sarka Pospisilova, Marek
Mraz.
5199
Distinct expression pattern of microRNAs
bioinformatically predicted to target SATB1 in human
breast cancer. Weiming Duan, Zixing Chen, Li Yao, Min
Tao, Kai Chen, Wei Liu, Jiannong Cen.
5200
MicroRNA-634 induces caspase-dependent
apoptosis by targeting anti-apopotic and mitochondriarelated genes in human cancer cells. Naoto Fujiwara, Jun
Inoue, Tatsuyuki Kawano, Ken-ichi Kozaki, Johji Inazawa.
5201
MicroRNA 760 regulates gastric cancer
progression by downregulation of histone mRNA
expression. Takeshi Iwaya, Takeo Fukagawa, Yutaka
Suzuki, Tomoya Sudo, Kaoru Ishida, Kohei Kume, Satoshi
Nishizuka, Hisae Iinuma, Masaki Mori, Mitsuru Sasako, Go
Wakabayashi, Koshi Mimori.
5202
Yin Yang 1 is a target of miR-34 family and
contributes to gastric carcinogenesis. An-Ming Wang,
Tzu-Ting Huang, Kai-Wen Hsu, Chin-Wen Chi, Tien-Shun
Yeh.
Poster Abstract
Board Number
14.
5207
miR-491 and miR-218: Two possible tools to
reduce FOXP3 expression in breast carcinomas. Martina
Di Modica, Tiziana Triulzi, Viola Regondi, Marilena V. Iorio,
Andrea Balsari, Elda Tagliabue, Patrizia Casalini.
15.
5208
MiR-22 is frequently down-regulated in
medulloblastomas, and inhibits cell proliferation via the
novel target PAPST1. Qing-Fu Xu, Jesse Chung-sean Pang,
Hui Yang, Sheng-Qing Lv, Hiroko Ohgaki.
16.
5209
MicroRNA-193a-5p suppresses tumor
proliferation and enhances radio-sensitivity through
ERBB2 in esophageal squamous cell carcinoma. PeiJung Lu.
17.
5210
MicroRNA miR-17–92 impairs TGF␤ signaling
responsiveness in BRAF oncogene-activated thyroid
cells. Cesar S. Fuziwara, Felipe E. Martins, Edna T. Kimura.
19.
5211
Regulation of SRC kinases by microRNA-3607
located in a frequently deleted locus in prostate cancer.
Sharanjot Saini, Sumit Arora, Shahana Majid, Varahram
Shahryari, Laura Z. Tabatabai, Soichiro Yamamura, Yuichiro
Tanaka, Rajvir Dahiya, Guoren Deng.
20.
5212
Regulation of androgen receptor expression by
andro-miRs in prostate cancer. Jey Sabith Ebron, Kavleen
Sikand, Jagjit Singh, Girish C. Shukla.
21.
5213
microRNA-mediated loss of KDM5B expression
leads to suppression of the malignant bladder cancer
phenotype. Abhimanyu Veerakumarasivam, Radha
Kodiappan, Soon Choy Chan, Azad Hassan Abdul Razack,
Teng Aik Ong.
22.
5214
miR-424(322)/503 cluster orchestrates
remodeling of the epithelium in the involuting mammary
gland and plays a role in breast cancer development.
David Llobet Navas, Ruth Rodriguez Barrueco, Jose Silva.
23.
5215
miR-200b/c/429 sub-family negatively
regulating Rho/ROCK signaling pathway and suppresses
HCC metastasis. Chun-Ming Wong, Lai Wei, Sandy L. Au,
Sandy L. Au, Dorothy N. Fan, Joyce M. Lee, Carmen C.
Wong, Irene O. Ng.
24.
5216
Epigenetic characterization and specific
targeting of breast cancer stem cells. Huiping Liu.
25.
5217
The role of miR-526b in COX-2 mediated breast
cancer progression via EP4 signaling. Erin O. Landman,
Mousumi Majumder, Ling Liu, Peeyush K. Lala.
5203
Long non-coding RNA H19 as a novel
therapeutic target for pancreatic cancer. Hisashi
Yoshimura, Yoko Matsuda, Taeko Suzuki, Zenya Naito,
Toshiyuki Ishiwata.
26.
10.
5218
TGF␤ regulates miR-182 control of BRCA1.
Haydeliz Martinez-Ruiz, Sangeetha Vijayakumar, Mary H.
Barcellos-Hoff.
27.
11.
5204
MicroRNA-6734 induces p21 gene expression by
targeting a complementary p21 promoter sequence and
inhibits colon cancer cells. Moo Rim Kang, Jieun Yun, Soo
Jin Oh, Chang Woo Lee, Ki Hwan Park, Jong Soon Kang.
5219
MicroRNA-874 impedes angiogenesis in nonsmall cell lung cancer. Chandramu Chetty, Dilip R.
Maddirela, Venkateswara R. Gogineni, Subramanyam
Chittivelu, Jasti S. Rao, Bhagavatula Moorthy.
28.
12.
5205
CCND1 is a miR-193b target in prostate cancer.
Kirsi M. Tuppurainen, Hanna E. Rauhala, Mauro Scaravilli,
Robert L. Vessella, Tapio Visakorpi.
13.
5206
Mir-134/487b/655 cluster regulates TGF-␤induced epithelial-mesenchymal transition and drug
resistance to gefitinib by targeting MAGI2 in lung
adenocarcinoma cells. Masahiro Seike, Kazuhiro Kitamura,
Akihiko Miyanaga, Testuya Okano, Rintaro Noro, Akihiko
Gemma.
5220
Reciprocal regulation of MYC and LKB1
modulates cell survival and differentiation in lung
cancer. Maria A. Cortez, Chao Yang, Lauren A. Byers, Lixia
Diao, Thaddeus Allen, Uma Giri, Jing Wang, James Welsh,
John V. Heymach.
30.
5221
Association of miR-17–92 cluster and its target,
Frabin, with development of aggressive prostate cancer.
Richard J. Ottman, Jenna Levy, Ratna Chakrabarti.
POSTER SESSION
MicroRNAs in Hematopoietic Malignancies and in Diagnostics/Prognostics
Poster Abstract
Board Number
3.
5222
microRNA-148a is a prognostic oncomiR that
targets MIG6 and BIM to regulate EGFR and apoptosis in
glioblastoma. Jungeun Kim.
4.
5223
Prognostic value of microRNA signature in nonsmall-cell lung cancer: A microRNA expression analysis.
Heng-Ying Pu, Da Fu, Mei-Yin Zhang, Yin-Lian Cha, HaiShan Peng, Lan-Jun Zhang, Wei-Hua Jia, Yi-Xin Zeng, WanQing Liu, Steven X.F. Zheng, Guo-Hong Hu, Hui-Yun Wang.
5.
5224
MicroRNA mediated regulation of TGF-␤
signaling leads to stem cell alterations in
myelodysplastic syndromes. Tushar D. Bhagat, Li Zhou,
Lubomir Sokol, Ioannis Mantzaris, Sanchari Bhattacharyya,
Shanisha A. Gordon, Yiting Yu, Krishna Gundabolu, Sangeeta
Nischal, Rahul Polineni, Carolina Schinke, Grigorios
Chrysofakis, Amittha Wickrema, Andrea Pellagatti,
Jacqueline Boultwood, Ulrich Steidl, Gang Liu, Alan F. List,
Markus Bitzer, Amit Verma.
6.
5225
MicroRNA profiling in serum samples from
donors with germ cell cancer. Kathy Y. Lee, Sunali Patel,
Kathleen Hayashibara, Shirley Chu, Ad J. Gillis, Martin
Rijlaarsdam, Lambert C. Dorssers, Leendert H. Looijenga.
7.
5226
Liver and blood miRNA alterations as putative
biomarkers of hepatotoxic response to short-term furan
exposure in mice. Brian N. Chorley, Gail Nelson, Gleta
Carswell, Holly Mortensen, James Crooks, William Ward,
Charles Wood, Anna F. Jackson, Carole Yauk, Les Recio,
Susan Hester.
8.
5227
The microRNA profile is altered in fibrosisassociated hepatocarcinogenesis in mice. April K.
Marrone, Volodymyr Tryndyak, Grace Chappell, Frederick A.
Beland, Ivan Rusyn, Igor P. Pogribny.
Poster Abstract
Board Number
16.
5234
Serum microRNAs reflect microRNA expression
in tumor tissues as well as systemic response to
disease in HRAS-driven mouse models of HCC. Adam
Pavlicek, Vladyslava Ratushna, Shirley Phillips, Cynthia
Heinlein, Jian Li, Vivek Kaimal, Sonya Zabludoff, Nelson
Chau.
17.
5235
Identification of microRNA-3662 as a novel
tumor suppressor miR. Sophia Maharry, Sujay Mehta,
Sandya Liyanarachchi, Guido Marcucci, Clara D. Bloomfield,
Albert de la Chapelle, Ann-Kathrin Eisfeld.
18.
5236
Identification of miR-888 as the first miRNA
cancer-testis antigen. Adriann M. Hovey, Eric J. Devor,
Donghai Dai, Kimberly K. Leslie.
19.
5237
The long intergenic noncoding RNA LINC00340
is a neuroblastoma susceptibility gene. Mike R. Russell,
Annalise Penikis, Derek Oldridge, Maura Diamond, Sharon
Diskin, John Maris, Kristina Cole.
20.
5238
Integrative analysis of functional long
noncoding RNAs during prostate cancer progression.
Teng Fei, Yiwen Chen, Zhou Du, Xiaole S. Liu, Myles Brown.
21.
5239
MiR-148a promotes apoptosis in urothelial cell
carcinoma of the bladder cells in part by targeting
DNMT1. Alan Lombard, Ben Mooso, Steve Libertini, Rebecca
Lim, Nicole Costanzo, Paramita Ghosh, Maria Mudryj.
23.
5240
Epigenetic dysregulation of miR-196b in breast
cancer. Rebecca T. Marquez, Amber R. Smith, Bryan Tsao,
Liang Xu.
24.
5241
Accurate quantitation of micro RNA by chipbased digital PCR. Yalei Wu, Victoria Dahlhoff, Lin He,
Caifu Chen.
25.
5242
miR-10b functions as a novel tumor suppressor
in uterine leiomyosarcoma by promoting overexpression
of SDC1. Matthew L. Anderson, Gyoung Eun Kim, Claire M.
Mach, Chad J. Creighton, Dina Lev.
9.
5228
Characterization of miR-21 as a potential
circulating biomarker for osteosarcoma. Manjula Nakka,
Yiting Li, Colin McGee, Ching Lau, Tsz Kwong Man.
11.
5229
Profiling of circulating miRNAs is a critical
prognostic biomarker tool for high-risk neuroblastoma.
Satish Kumar Ramraj, Vijayabaskar Pandian, Faizan H. Khan,
Sheeja Aravindan, Terence S. Herman, Mohan Natarajan,
Natarajan Aravindan.
26.
5243
MicroRNAs-449a and -449b exhibit tumor
suppressive effects in retinoblastoma. Aunica A. Jones,
Alissa Martin, Paul Bryar, Marilyn Mets, Joanna Weinstein,
Gang Zhang, Nikia A. Laurie.
27.
12.
5230
Circulating miRNA in acute myeloid leukemia: A
pilot study. Rafael A. Quintana-Ortiz, Sharon FonsecaWilliams, Hector Perez-Cantalapiedra, Mercedes LacourtVentura, Cristina Munoz-Masso, Raul D. Bernabe-Dones,
Maribel Tirado-Gomez.
5244
MicorRNA-27a functions as a tumor suppressor
in colorectal cancer through targeting SPGG1 and
Smad2. Yonghua Bao, Zhiguo Chen, Yongchen Guo, Tiesuo
Zhao, Yansheng Feng, Yunjuan Jiao, Zexin Li, Jianguo
Wang, Weixing Zhao, Kai Li, Qian Wang, Jiaqi Wang,
Huijuan Zhang, Wancai Yang, Wancai Yang.
28.
13.
5231
Prognostic significance of miR-23b and miR-31
expression in non-small-cell lung cancer. Begum
Shahnaz, Masamichi Hayashi, Takenori Ogawa, Mariana
Brait, William H. Westra, Mohammad O. Hoque, David
Sidransky.
5245
A network of microRNAs contolled by
oncogenic B-Raf signaling in melanoma cells. Kasey L.
Couts, Emily M. Anderson, Maren M. Gross, Kevin Sullivan,
Natalie G. Ahn.
29.
5246
The role of mir-21 and Let-7a in HMGA2
associated colorectal cancer pathogenesis with different
APC/k-ras status. Ya-Wen Cheng, I-Chien Chen.
30.
5247
Comprehensive and systematic identification of
miR-215 targets in colon cancer via a novel translation
capture immunoprecipitation (TrIP) approach. Andrew
Fesler, Xiao Xu, Emily Chen, Jingfang Ju.
15.
5233
MicroRNA in biofluid as robust biomarkers for
cancer. Thorarinn Blondal, Anni Thomsen, Jörg
Krummheyer, Peter Mouritzen, Ditte Andreasen, Maria
Theilum, Jan Stenvang, Claus L. Andersen, Hans J. Nielsen,
Nils Brünner.
Poster
Section
20
20
587
POSTER SESSION
Poster
Section
21
21
Oncogenes, Growth Factors, and Signal Transducers 2
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
14.
588
5248
Targeted suppression of interleukin-1 signaling
inhibits growth of primary human acute myeloid
leukemia cells. Anupriya Agarwal, Alyssa Carey, Elie Traer,
Jeffrey Tyner, Grover C. Bagby, Brian J. Druker.
5249
Butterfly effect in cancer: How a single base
mutation of PIK3CA remodels multiple pathways.
Jonathan R. Hart, Yaoyang Zhang, Lujian Liao, Lisa Du,
John R. Yates, Peter K. Vogt.
5250
The effect of introducing a C118S mutation into
the endogenous Kras gene on early tumorigenesis. Lu
Huang, Christopher M. Counter.
5251
ASCL1 and RET expression define a clinically
relevant subgroup of lung adenocarcinoma
characterized by neuroendocrine differentiation. Farhad
Kosari, Cristiane M. Ida, Marie Christine Aubry, Lin Yang,
Irina V. Kovtun, Janet L. Schaefer Klein, Sandra C.
Tomaszek, Stephen J. Murphy, Ping Yang, Dennis Wigle,
George Vasmatzis.
5252
Inhibition of FGFR3-BAIAP2L1 fusion kinase
oncogenic potential by CH5183284/Debio 1347, a
compound that inhibits FGFR3 kinase activity
constitutively activated by BAIAP2L1 BAR domain
dimerization. Nukinori Akiyama, Yoshito Nakanishi,
Toshiyuki Tsukaguchi, Yasuko Satoh, Yasue Nagata,
Tsutomu Takahashi, Yukari Nishito, Motoki Ashihara, Nobuya
Ishii, Masahiro Aoki.
5253
PTEN represses oncogene expression by
regulating Daxx-H3.3 deposition in the chromatin. Jorge
A. Benitez, Webster K. Cavenee, Frank F. Furnari.
5254
Regulation of mutant KRAS protein stability via
SMURF2-mediated ␤-TrCP1 degradation. Shirish Shukla,
Uday Sankar Allam, Aarif Ahsan, Guoan Chen, Pranathi M.
Krishnamurthy, Katherine Marsh, Matthew Rumschlag,
Sunita Shankar, Christopher Whitehead, Matthew Schipper,
Venkatesha Basrur, Daniel R. Southworth, Arul M.
Chinnaiyan, Alnawaz Rehemtulla, David G. Beer, Theodore
S. Lawrence, Mukesh K. Nyati, Dipankar Ray.
5255
EGFR is a conspiring kinase in gene fusion
positive lung cancer. Aria Vaishnavi, Anh T. Le, Stephen B.
Keysar, Christine M. Lovly, Severine Kako, Marileila VarellaGarcia, Antonio Jimeno, Robert C. Doebele.
5256
Mechanism of field cancerization. Bogdan A.
Czerniak, Sangkyou Lee, Jolanta Bondaruk, Sooyong Lee,
Tadeusz Majewski, Shizhen Zhang, Li Shen, Yuexin Liu,
Charles Guo, Colin Dinney, H. B. Grossman, Wei Zhang,
Menashe Bar-Eli, Keith Baggerly, Richard Behringer, David
McConkey, David McConkey, Margaret Knowles, Woonbok
Chung, Jean-Pierre Issa.
5257
Cancer cells have not only sweet tooth but also
large mouths: Evidence for uptake of ATP into KRas
oncogene-expressing cancer cells by macropinocytosis.
Yanrong Qian, Xuan Wang, Yi Liu, Yunsheng Li, Robert A.
Colvin, Xiaozhuo Chen.
5258
Overexpressed TYRO3 in colorectal cancer
regulates tumorigenesis and metastasis. Chun Wei Chien,
Yen-Yu Lai, Bo-Wen Lin, Shao-Chieh Lin, Jenq-Chang Lee,
Shaw-Jenq Tsai.
5259
Gene expression array and pathway profiling
analyses distinguish HGF/Met pathways driving cell
proliferation from invasion and identify events
correlated with prostate cancer progression. Fabiola
Cecchi, Jason Lih, Young Lee, William Walsh, Mickey
Williams, Donald P. Bottaro.
5261
Aberrant expression of HDAC6 sustains
malignant progression by preventing epidermal growth
factor receptor degradation in gastric cancer. Se Jin
Park, Hyun Jin Bae, Jung Woo Eun, Qinngyu Shen, Hyung
Seok Kim, Woo Chan Shin, Won Sang Park, Jung Young
Lee, Suk Woo Nam.
Poster Abstract
Board Number
15.
16.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
5262
Activating transcription factor 4 regulates RET
autophosphorylation and ubiquitin-dependent
degradation. Rozita Bagheri-Yarmand, Gilbert J. Cote,
Robert F. Gagel.
5263
Identification of a lipid raft protein that is
required for H-Ras activation and breast cancer
aggressiveness. Hae-Young Yong, Eun-Sook Kim, Minsoo
Koh, Hwajin Son, You Rim Jeon, Jin-Sun Hwang, MyeongOk Kim, Yujin Cha, Wahn Soo Choi, Dong-Young Noh,
Kyung-Min Lee, Ki-Bum Kim, Jae-Seon Lee, Hyung Joon
Kim, Hong-Hee Kim, Eun Joo Kim, So Yeon Park, HyeongReh Choi Kim, Aree Moon.
5265
S100P increases Twist expression and triggers
FAK/AKT signaling in lung cancer. Yung-Yu Liang, Po-Lin
Kuo, Ya-Ling Hsu.
5266
Role of nuclear Met receptor in hepatocellular
carcinoma. Judy W. Yam, Sze Keong Tey.
5267
Pro-inflammatory CXCL8 signaling potentiates
survival of K-Ras mutant colorectal cancer cells. Laura
M. Campbell, Olabode Oladipo, Pamela J. Maxwell, Daniel
Longley, Richard H. Wilson, David J. Waugh.
5268
The expression of lemur tyrosine kinase-3 in
high grade paediatric tumors. Nektarios K. Mazarakis,
Stuart Smith, Aikaterini Vraka, Donald Macarthur, Richard
Grundy, Justin Stebbing, George Giamas.
5269
Impact of K-ras status on differential
expression of TIMP-1 in lung adenocarcinoma. Ammar
Kutiyanawalla, Sampa Gupta-Ghoshal, Byung Rho Lee,
Ravindra Kolhe, Amyn M. Rojiani, Mumtaz V. Rojiani.
5270
Prevalence of inactivating protein kinase C
mutations in human cancers. Corina E. Antal, Emily Kang,
Natalie L. Stephenson, Eleanor W. Trotter, Tony Hunter,
John Brognard, Alexandra Newton.
5271
Homozygous deletion of the activin A receptor,
type IB gene is associated with an aggressive cancer
phenotype in pancreatic cancer. Yosuke Togashi, Hiroki
Sakamoto, Hidetoshi Hayashi, Masato Terashima, Marco A.
de Velasco, Yoshihiko Fujita, Yasuo Kodera, Kazuko Sakai,
Shuta Tomida, Masayuki Kitano, Masatoshi Kudo, Kazuto
Nishio.
5272
The tumor suppressor, calcium sensing
receptor, regulates proliferation and promotes
differentiation in colon cancer. Abhishek Aggarwal,
Samawansha Tennakoon, Maximilian Wohlgenannt, Cedric
Boudot, Romuald Mentaverri, Sabina Baumgartner-Parzer,
Enikö Kállay.
5273
VBIM technology identifies beta-catenin-like
protein (BCLP) as a novel negative regulator of NF-kB.
Rasika Mundade, Tao Lu.
5274
Wnt inhibitory factor 1 reduces the growth and
migration of human adenoid cystic carcinoma cells.
Ilangovan Ramachandran, Vengatesh Ganapathy, Lurdes
Queimado.
5275 ␤II-spectrin(SPTBN1) suppresses tumor
progression by inhibiting Wnt signaling via kallistatin in
hepatocellular carcinoma. Xiuling Zhi, Ling Lin, Narayan
Shivapurkar Shivapurkar, John L. Marshall, Lynt Johnson,
Aiwu R. He.
5276
Phospholipase A/acyltransferase enzyme
activity of H-rev107 inhibits the H-RAS signal pathway.
Fu-Ming Tsai, Chang-Chieh Wu, Chun-Hua Wang, TzungChieh Tsai, Rong-Yaun Shyu, Shun-Yuan Jiang.
5277
Latent transforming growth factor beta-binding
protein-3 interacts with midkine. Chunhua Weng, Haojie
Dong, Zhengping Xu.
POSTER SESSION
Protein Phosphatases / Signaling Pathways
Poster
Section
Poster Abstract
Board Number
1.
2.
5278
Superoxide mediated selective tyrosine nitration
of protein phosphatase 2A-B56␦ stabilizes Bcl-2
phosphorylation and its anti-apoptotic activity. Ivan C.
Low, Thomas Loh, David Virshup, Shazib Pervaiz.
5279
Induced expression of PPM1A in er-negative
breast cancer cells inhibits growth by suppressing cell
cycle. Abhijit Mazumdar, Graham Poage, Jamal Hill, Yun
Zhang, Anna Tsimelzon, Jenny Chang, Gordon Mills, Powel
Brown.
Poster Abstract
Board Number
15.
5292
The functional role of Tensin4 in hepatocellular
carcinoma. Lo Kong Chan.
16.
5293
GSK3␤ phosphorylation at serine9 by RSK2
enhances calcium-induced stress tolerance and cell
survival. Ji-Young Lee, Cheol-Jung Lee, Mee-Hyun Lee, Ji
Hong Song, Yong-Yeon Cho.
17.
5294
Inhibition of mitochondrial transport in neuronal
cells by microtubule-targeting drugs eribulin,
ixabepilone, paclitaxel, and vincristine. Jennifer A. Smith,
Gregoriy Smiyun, Leslie Wilson, Stuart Feinstein, Mary Ann
Jordan.
3.
5280
Dusp3 effects on the proliferation and
differentiation of neuroblastoma cells are mediated by
erk but not jnk via. Felipe F. Gomes, Fabio L. Forti.
18.
4.
5281
Role of SHP-2 tyrosine phosphatase in
colorectal carcinogenesis. Jessica Gagne Sansfacon,
Geneviève Coulombe, Nadia Bourdages, Nathalie Rivard.
5295
MELK enhances gastric cancer progression via
the FAK/paxillin pathway. Bingya Liu, Tao Du, Ying Qu,
Jian-fang Li, Liping Su, Zheng-gang Zhu.
19.
5.
5282
Promotion of skin tumorigenesis by deletion of
Ppp6c gene. Katsuhisa Hayashi, Honami Ogoh, Toshio
Watanabe, Nobuhiro Tanuma, Hiroshi Shima.
5296
The role of SOCS-1 in stimulating melanoma
development through growth factor receptors and MAPK
pathways. Rodrigo Berzaghi, Felipe V. Pereira, Vera S.
Maia, Jorge B. Scutti, Luiz R. Travassos.
6.
5283
Elucidating a novel role for inositol
polyphosphate 4-phosphatase type II (INPP4B) in
mediating chemoresistance in acute myeloid leukemia.
Sewa Rijal, Nhu-Y Nugyen, Tse-Chieh Teh, Natalie K.
Rynkiewicz, Nik Cummings, Lisa Ooms, Sharon Avery, Julie
Mcmanus, Mark A. Guthridge, Catriona Mclean, Christina A.
Mitchell*, Andrew Wei*.
20.
5297
Role of p38 MAPK signaling pathway in the
inhibition of breast tumor progression induced by
Glypican-3 (GPC3). Rocio S. Tascon, Lilian F. Castillo,
Fernanda Roca, Elisa Bal de Kier Joffé, Maria G. Peters.
21.
5298
Regulation of urothelial bladder cancer by
nicotine and stress neurotransmitters. Arokya M. Papu
John, Jheelam Banerjee, Hildegard M. Schuller.
7.
5284
SSU72 functions as a gatekeeper monitoring for
chromosome integrity in mammals. Se-Hyuk Kim, Yoon
Jeon, Hyun-Soo Kim, Han-Jeong Lim, Ho Lee, Chang-Woo
Lee.
22.
5299
The C-terminus of orexin plays a crucial role in
the cellular apoptosis induction mediated by OX1
receptor. Alain Couvineau, Pascal Nicole, Thierry Voisin,
Pierre couvineau.
8.
5285
Protein phosphatases modulate kinase
signaling mediated Wnt activation. Debasish Boral, Daotai
Nie.
23.
9.
5286
Promoter methylation of PTPRT provides a
mechanism for STAT3 activation in HNSCC. Noah D.
Peyser, Lin Wang, Jennifer R. Grandis.
5300
Acetylation of alteration/deficiency in activation
3 (Ada3) is essential for its stability and function.
Shashank Srivastava, Shakur Mohibi, Hamid Band, Vimla
Band.
24.
5301
Rescuing cell polarity with small molecule
inhibitors of de-palmitoylation. Jeannie L. Hernandez,
Dahvid Davda, Jaimeen Majmudar, Kristin J. Labby, Margery
Gang, Sirisha Pasupuleti, Makoto Seita, Brent R. Martin.
25.
5302
CITED2 as a molecular switch for hypoxiamediated proliferation. Yuan-Hung Wang, Ming-Han Kuo,
Chien-Fu Huang, Shih-Hsin Hsiao, Cheng-Wen Wu, Yu-Ting
Chou.
26.
5303
Uptake and Efflux of 2-amino-1-methyl-6phenylimidazo [4, 5-b] pyridine (PhIP) in human
adipocytes. Aiwei Yao-Borengasser, Lora J. Rogers, Susan
A. Kadlubar.
27.
5304
Inhibition of kallikrein-related peptidase-4 by
SPINK1. Hannu Koistinen, Mykola Domanskyy, Ulf-Håkan
Stenman.
10.
5287
Identification of metadherin in a complex with
RACK1/PP2A in mammary epithelial cells. Maeve L. Kiely,
Rosemary O’Connor, Patrick A. Kiely.
11.
5288
PHLPP controls cell polarity by negatively
regulating the activity of atypical PKC in colon cancer
cells. Xiaopeng xiong, Xin li, Tianyan Gao.
12.
5289
Role of notch3 in epithelial-to-mesenchymal
transition of HCC. Selvi Kunnimalaiyaan, T. Clark Gamblin,
Muthusamy Kunnimalaiyaan.
14.
5291
Signaling cross-talks in obesity-associated
pancreatic cancer: Interaction between prostaglandin E2
signaling and mTOR pathway. Hui-Hua Chang, Guido Eibl.
22
22
589
POSTER SESSION
Poster
Section
23
23
Proteomics
Poster Abstract
Board Number
1.
5305
Phosphoproteomics analysis reveals differential
signaling pathways among clear cell and papillary renal
cell carcinoma tumors. Scott M. Haake, Jiannong Li, Yun
Bai, Bin Fang, Julio Pow-Sang, John Koomen, Mayer
Fishman, Eric B. Haura.
2.
5306
Shotgun proteomic analysis of human head and
neck squamous cell carcinoma cell line SQ20B with
diminished AHSG expression. Dana R. Marshall, Victor
Paramov, Siddharth Pratap, Georgina Iyamu, Amos Sakwe,
Pamela Thompson, Josiah Ochieng.
9.
5313
Phosphoproteomic analysis with reverse phase
protein array identifies N-myc downstream regulated
gene 1 (NDRG1) as a biomarker of phosphatidylinositol3-kinase (PI3K)␣ inhibitor activity in a PTEN-deficient
glioma cell line. Takeomi Inoue, Naoko Iwata, Eiji
Nishiwaki, Yasuyuki Kirii.
10.
5314
A proteomic signature predicts response to a
therapeutic vaccine in pancreas cancer; analysis from
the GI-4000 – 02 trial. Donald A. Richards, Peter
Muscarella, Tanios Bekaii-Saab, Lalan S. Wilfong, Vic
Velanovich, Julian Raynov, Patrick J. Flynn, William E.
Fisher, Samuel H. Whiting, Constana Timcheva, Tom
Holmes, Claire Coeshott, Alicia Mattson, Heinrich Roder,
Joanna Roder, Allen Cohn, Timothy C. Rodell.
3.
5307
Development of pIMAGO for universal detection
of protein phosphorylation. Anton Iliuk, Li Li, Li Pan,
Weiguo A. Tao.
4.
5308
A proteome analysis of the cadmium response
in human bronchial epithelial cells: Identification of
potential biomarkers related to cadmium exposure. Andy
T. Lau, De-Ju Chen, Ji-Ying Du, Yan-Ming Xu.
11.
5309
Phospho-reactome profiling reveals the
heterogenic, targetable kinase signature of breast
cancer. Jean-Philippe F. Coppé, Miki Mori, Evelyn Lee, Bo
Pan, Aaron Boudreau, Zhongzhong Chen, Laura van ’t Veer.
5315
Quantitative proteomic assessment of
differential ligand responses downstream of protein
kinase C activation. Jin-Qiu Chen, Noemi Kedei, Michelle
A. Herrmann, Peter M. Blumberg.
12.
5316
Quantitative cancer analysis using digital PCR:
Absolute counting of DNA (solid tumors and liquid
biopsies in glioma, breast, and colon cancer) and RNA
(mRNA and miRNA using One-Step RT-dPCR). Michael L.
Samuels, Valerie Taly, Leonora Balaj, Saumya Das, Ben Ho
Park.
13.
5317
Photonic crystal microarray sensing of breast
cancer cell line lysates. Swapnajit Chakravarty, Naimei
Tang, Hai Yan, Chun-ju Yang, Yi Zou, Qiang Shen, Ray
Chen.
14.
5318
LC-MS/MS quantification of proteins CD47 and
SIRPA in cell subtypes selected by flow cytometry from
blood. Carmen Fernandez-Metzler, Renold Capocasale.
15.
5319
The role of ISBER (The International Society for
Biological and Environmental Repositories) in cancer
research. Debra L. Garcia, Katherine Sexton, William E.
Grizzle, Fay Betsou.
5.
6.
7.
8.
590
Poster Abstract
Board Number
5310
Integrated functional proteomic profiling in
myelodysplastic syndrome (MDS) and acute myeloid
leukemia (AML): MDS-like signature is associated with
favorable outcome in patients with AML. Young Kwang
Chae, Suk Young Yoo, Kevin R. Coombes, Steven M.
Kornblau.
5311
Proteomic characterization of zoledronic acidresistant prostate cancer cells identified key proteins in
cytoskeleton organization and cancer stem cell markers
associated with a very aggressive phenotype. Maria Rita
Milone, Biagio Pucci, Federica Iannelli, Rita Lombardi, Katia
Bifulco, Francesca Bruzzese, Elena Di Gennaro, Antonio
Avallone, Maria Vincenza Carriero, Alfredo Budillon.
5312
Quantitative proteomic analysis of cell-surface
membrane proteins: biomarker discovery in esophageal
squamous cancer. Emi Harada, Satoshi Serada, Tsuyoshi
Takahashi, Minoru Fujimoto, Tetsuji Naka.
POSTER SESSION
Software, Databases, Algorithms, and Modeling
Poster Abstract
Board Number
1.
5320
Novel computational methods reveal subtle
clonal mosaicism. Paul Scheet, Rui Xia, F. A. San Lucas,
Christina Hahn, Jerry Fowler, Selina Vattathil.
2.
5321
BreaKmer: Detection of structural
rearrangements in targeted next-generation sequencing
data using kmers. Ryan P. Abo, Elizabeth P. Garcia,
Matthew Ducar, Ravali Adusumilli, Marc Breneiser, Vanessa
Rojas-Rudilla, Lynette M. Sholl, Neal I. Lindeman, Matthew
L. Meyerson, William C. Hahn, Paul Van Hummelen, Laura
E. MacConaill.
3.
5322
Collections of simultaneously altered genes as
highly predictive markers of cancer cell drug response.
David L. Masica, Rachel Karchin.
4.
5323
Integrated computational cell-line modeling of
drug sensitivity and high-throughput siRNA screening
reveals novel molecular biomarkers for conventional
chemotherapy. Olga H. Nikolova, Mehmet Gönen, Rodrigo
Dienstmann, In Sock Jang, Russell Moser, Silvia Cermelli,
Chang Xu, Ryan M. Mitchell, Eduardo Mendez, Carla
Grandori, Christopher Kemp, Stephen Friend, Justin Guinney,
Adam Margolin.
5.
5324
Pan-cancer identification of mutated pathways
and protein complexes. Mark D. Leiserson, Fabio Vandin,
Hsin-Ta Wu, Jason R. Dobson, Benjamin R. Raphael.
6.
5325
“One Patient-One Pathway”: constructing
personalized signaling pathways for better prediction of
disease conditions and design of treatment strategies.
Guangxu Jin, Stephen T. Wong.
7.
5326
COSMIC: Enhancing the world’s knowledge of
somatic mutations in human cancer. C Boutselakis, S A.
Forbes, P Gunasekaran, M Jia, D Beare, N Bindal, C Y. Kok,
K Leung, D Minjie, R Shepherd, S Bamford, S Ward, C Cole,
J W. Teague, M Stratton, P Campbell, U McDermott.
8.
5327
Using CellMiner for gene expression, DNA copy
number, microRNA transcript levels, variant status, drug
activity, and their integration for systems pharmacology
for the NCI-60. William C. Reinhold, Margot Sunshine, Sudir
Varma, Joel Morris, Kurt Kohn, James Doroshow, Yves
Pommier.
9.
5328
GIAB: Genome reference material development
resources for clinical sequencing. Chunlin Xiao, Justin
Zook, Shane Trask, Stephen Sherry, the Genome-in-a-Bottle
Consortium.
10.
5329
Molecular dynamics simulations of sibiromycin
suggest a role for the c7-sugar in transcription factor
inhibition. Paul J. Jackson, Khondaker M. Rahman, David
E. Thurston.
11.
5330
Defining the role of TGF〉 in osteogenic
prostate cancer to bone metastases: an integrated
biological/mathematical modeling approach. Leah M.
Cook, Arturo Araujo, David Basanta, Conor C. Lynch.
12.
5331
GenomeSpace: An environment for frictionless
bioinformatics. Michael M. Reich, John Liefeld, Marco
Ocana, Donkeung Jang, James Robinson, Peter Carr,
Barbara Hill, Thorin Tabor, Helga Thorvaldsdottir, Aviv
Regev, Jill P. Mesirov.
Poster Abstract
Board Number
13.
5332
Comparison of variant calling from whole
exome and transcriptome sequencing using CLC Cancer
Research Workbench. Anne Arens, Anne-Mette K. Hein,
Uwe Appelt, Anika Joecker, Søren Mønsted, Bjarne
Knudsen, Naomi Thomson, Richard Lussier, Cecilie Boysen,
Roald Forsberg.
14.
5333
A mathematical model for the kinetics of
metastasis formation based on SEER data. Ardith W. ElKareh, Timothy W. Secomb.
15.
5334
Integrated analysis of squamous tumors
identifies novel targets and dissects gene regulation .
Vonn Walter, Ying Du, Xiaoying Yin, Wei Sun, Matthew D.
Wilkerson, Michele C. Hayward, Ashley H. Salazar, Charles
M. Perou, David N. Hayes.
17.
5336
Mathematical models for cellular response to
radiochemotherapy. Katherine S. Williams, Ardith W. ElKareh, Timothy W. Secomb.
18.
5337
Molecular dynamics study on keap1 point
mutations in lung cancer. Chia-Ning Yang.
19.
5338
Inferring evolutionary models of tumor
progression from single-cell heterogeneity data. Salim A.
Chowdhury, Ayshwarya Subramanian, Alejandro A. Schäffer,
Stanley E. Shackney, Darawalee Wangsa, Kerstin
Heselmeyer-Haddad, Thomas Ried, Russell Schwartz.
20.
5339
Deterministic in silico modeling predicts
sensitivity of glioblastoma to targeted therapy. Sandeep
C. Pingle, Sandra Pastorino, Rajesh Muktharavam, Pengfei
Jiang, Ying Chao, Taher Abbasi, Shireen Vali, Santosh
Kesari.
21.
5340
Bioinformatic analyses approaches for
personalized oncogenomics. Katayoon Kasaian, Yaoqing
Shen, Sreeja Leelakumari, Peter Eirew, Yvonne Y. Li, Erin
Pleasance, Richard Corbett, Karen L. Mungall, Jacquie
Schein, Andrew J. Mungall, Yongjun Zhao, Richard A.
Moore, Stephen Yip, Karen Gelmon, Howard Lim, Daniel
Renouf, Robyn Roscoe, Yussanne Ma, Marco A. Marra,
Janessa Laskin, Steven J. Jones.
22.
5341
GlioMath-DD: A multidisciplinary approach to
study glioma evolution and identify targets for
individualized therapies. Evelin Schröck, Khalil Abou-ElArdat, Ralf Wiedemuth, Michael Seifert, Alvaro Köhn-Luque,
Mirjam Ingargiola, Kristin Stirnnagel, Alexander Krüger,
Wolfgang Nagel, Kathrin Geiger, Andreas Beyer, Leoni A.
Kunz-Schughart, Gabriele Schackert, Achim Temme, Barbara
Klink, Andreas Deutsch.
23.
5342
Hardwiring mechanism into predicting cancer
phenotypes by computational learning. Bahman Afsari,
Elana J. Fertig, Laurent Younes, Donald Geman, Luigi
Marchionni.
Poster
Section
24
24
591
POSTER SESSION
Carcinogenesis 4
Poster
Section
26
26
In Vivo Carcinogenesis and DNA Repair
Poster Abstract
Board Number
1.
2.
3.
592
5343
Continuing expression of SHP2E76K is required
to maintain lung tumors induced by the active SHP2E76K
mutant in transgenic mice. Valentina E. Schneeberger,
Noreen Luetteke, Yuan Ren, Parastou Foroutan, Gary V.
Martinez, Eric B. Haura, Domenico Coppola, Jie Wu.
5344
Rapid induction and progression of PhIPⴙDSSinduced colon carcinogenesis in CYP1A-humanized
mice. Jayson X. Chen, Hong Wang, Guangxun Li, Anna Liu,
Chung S. Yang.
5345
DMBA promotes erbB-2 mediated
carcinogenesis through activation of estrogen receptor
and receptor tyrosine kinase pathways. Zhikun Ma,
Stanley Kosanke, Morgan Carrington, Xiaohe Yang.
4.
5346
Identification of essential genes for the
development of hepatitis B virus-associated
hepatocellular carcinoma. CT Lam, ZF Yang, JC Lau, MN
Ng, WC Yu, DW Ho, ST Fan.
5.
5347
DNA repair protein Rev7 is required for
primordial germ cell maintenance in the mouse. Yoshiki
Murakumo, Naoki Watanabe, Shinji Mii, Masato Asai, Naoya
Asai, Kaoru Niimi, Takuya Kato, Atsushi Enomoto, Masahide
Takahashi.
6.
5348
Impaired self-renewal and colitis susceptibility
of colonic mucosa in mice lacking AKR1B8. YI SHEN, Jun
Ma, Ruilan Yan, Hongyan Ling, Xiaoning Li, Wancai Yang,
John Gao, Yiwen Bu, Ahmed Alsalman, Cheifei Huang, Yu
Cao, Shuangbai Zhou, Laxiang Wan, Yingchun He, Zhiqi
Wang, Ali Khazaal, Mei C. Huang, Duan-Fang Liao, Deliang
Cao.
7.
5349
The role of growth hormone receptor in liver
fibrosis and cancer. Patricia Stiedl, Leander Blaas, Viktoria
Stanek, Jasmin Svinka, Robert Mc Mahon, Gernot Zollner,
Thierry Claudel, Mathias Mueller, Wolfgang Mikulits, Harald
Esterbauer, Robert Eferl, Johannes Haybaeck, Michael
Trauner, Emilio Casanova.
8.
5350
Aberrant activation-induced cytidine deaminase
(AID) expression is induced in the process of hepatitis C
virus-associated hepatocarcinogenesis. Soo Ki Kim,
Hiroyuki Marusawa, Tsutomu Chiba.
9.
5351
The carcinogenesis rate is increased in MAL
knock-out mice. Wantao Chen, Xiangbing Wu, Wei Cao, Xu
Wang.
10.
5352
Ultraviolet radiation induces carcinogenesis in a
novel transgenic mouse model of melanoma. Ana Paula
Benaduce, Deannys Batista, Gabriel Grilo, Karen Jorge,
Diana Cardero, Clara Milikowski, Lidia Kos.
Poster Abstract
Board Number
14.
5356
The role of VNN3 gene in nasopharyngeal
carcinoma tumorigenesis. Shang-Yu Huang, Yi-Ying Chen,
Dah-yeou Huang, Cheng-Der Wu, Chin-Tarng Lin.
15.
5357
Targeting mTORC1 suppresses proliferation of
keratinocyte stem cells and inhibits skin tumor
promotion in mice. Okkyung Rho, Jiyoon Cho, John
DiGiovanni.
16.
5358
IL-4/IL-13 induce Duox2/DuoxA2 expression and
reactive oxygen production in human pancreatic and
colon cancer cells. Yongzhong Wu, James H. Doroshow.
17.
5359
TGF␤ promotes the DNA damage response and
repair of DNA damage induced by benzo
pyrene. Ian W. Jarvis, Kristian Dreij, Ulla Stenius.
18.
5360
Ethanol enhances arsenic-induced mutagenesis
in colon. Lei Wang, Lisha Kuang, Young-Ok Son, John
Andrew Hitron, Pratheeshkumar Poyil, Zhuo Zhang, Jia Luo,
Zhigang Wang, Xianglin Shi.
19.
5361
Development of targeted inhibitors against
RecQ1 helicase. Mingxin Zuo, David Maxwell, Basvoju A.
Bhanu Prasad, Zhenghong Peng, William Bornmann, Milind
M. Javle.
20.
5362
Deficiencies in mismatch repair proteins induce
elevated levels of acrolein-derived 1,N2propanodeoxyguanosine and apoptosis in human colon
cancer cells treated with acrolein. Jishen Pan, Zhuoli
Xuan, Marcin Dyba, Yongwei Zhang, Ying Fu, Rabindra Roy,
Louis M. Weiner, Fung-Lung Chung.
21.
5363
Genotoxicity of trace level of hexavalent
chromium existing in city water. Xu Tian, Keyur Patel,
John R. Ridpath, James A. Swenberg, Jun Nakamura.
22.
5364
ATF3 contributes to the DNA damage response
by regulating the histone acetyltransferase Tip60.
Hongmei Cui.
23.
5365
Cdt2-mediated XPG degradation promotes DNA
repair synthesis following DNA damage excision in
nucleotide excision repair. Chunhua Han, Ran Zhao, Jiang
Qian, Nidhi Sharma, Gulzar Wani, Jinshan He, Qianzheng
Zhu, Qi-En Wang, Altaf A. Wani.
24.
5366
Mutation signature of TP53 gene in H. pyloriassociated inflamed gastric mucosa during gastric
carcinogenesis. Takahiro Shimizu, Hiroyuki Marusawa,
Tsutomu Chiba.
25.
5367
DNA repair capacity, gene expression and
epigenomic profiles in bladder cancer. Barbara Pardini,
Alessandra Allione, Simonetta Guarrera, Valentina Turinetto,
Giovanni Fiorito, Fabio Rosa, Alessia Russo, Federica
Modica, Claudia Giachino, Paolo Vineis, Carlotta Sacerdote,
Giuseppe Matullo.
11.
5353
Leptin regulates cell differentiation and
protumorigenic responses in pancreatic stellate cells.
Jun Gong, Raymond Gong, Richard T. Waldron, Aurelia
Lugea, Stephen J. Pandol.
26.
12.
5354
Neuropeptide Y as a prognostic marker of
colorectal cancer. Chandrani Sarkar, Debanjan
Chakroborty.
5368
Genetic susceptibility to cervical cancer: Role of
XRCC1. Deepti Bajpai, Ayan Banerjee, Sujata Pathak,
Sunesh Jain, Neeta Singh.
27.
13.
5355
Twist1 regulates the cell cycle and proliferative
capacity of keratinocytes during tumor promotion. Jaya
Srivastava, Everardo Macias, Kaoru Kiguchi, John
DiGiovanni.
5369
Effects of resveratrol on chemotherapeutic
agent 5-fluorouracil induced DNA damage in prostate
and breast cancer cells. Michael Xiao, Irene Yeung, Gaju
Shrestha, Luis Camberos, Richard A. Robison, Kim L.
O’Neill.
POSTER SESSION
Chemistry 10
Chemical Technologies
Poster
Section
Poster Abstract
Board Number
1.
5370
Use of molecular dynamics simulations to
rationalise the DNA sequence-selectivity of
pyrrolobenzodiazepine-MPB conjugates. Paul J. Jackson,
Khondaker M. Rahman, David E. Thurston.
2.
5371
Drug repositioning with a bioinformatics
platform that integrates the TCGA, cMap and CCLE.
Francis A. San Lucas, Jerry Fowler, Scott Kopetz, Eduardo
Vilar, Paul Scheet.
14.
5383
The plasmonic photothermal therapy efficacy of
Au NRs in vivo using a SCCHN xenograft mouse model.
Xianghong Peng, Megan A. Mackey, Adegboyega Oyelere,
Jun Zhang, Georgia Chen, Shuming Nie, Mostafa A ElSayed, Dong M Shin.
15.
5384
Systematic high-throughput drug sensitivity and
resistance testing (DSRT) of ovarian cancer cell lines
indicates novel therapeutic possibilities with existing
and emerging drugs. Akira Hirasawa, Astrid Murumägi,
Mariliina Arjama, Bhagwan Yadav, John P. Mpindi, Krister
Wennerberg, Tero Aittokallio, Daisuke Aoki, Olli Kallioniemi.
16.
5385
A novel cell-based kinase assay panel paired
with high content phenotypic profiling to correlate
kinase inhibitor specificity and cellular activity. Tom S.
Wehrman, Erika A. O’Donnell, M. Jared Lumpe, Benjamin E.
Osetek, Peter O. Krutzik.
17.
5386
Disrupting p53:Mdm2 and p53:Mdm4 Comparative cell-based assays for drug screening.
Larisa Yurlova, Christopher J. Brown, Maarten Derks, Farid
J. Ghadessy, Ian Hickson, David P. Lane, Eberhard Krausz,
Kourosh Zolghadr.
18.
5387
Dual kinase/bromodomain inhibitors for
rationally designed polypharmacology. Elizabeth R. Quinn,
Pietro Ciceri, Susanne Müller-Knapp, Alison O’Mahony, Oleg
Fedorov, Panagis Filippakopoulos, Jeremy P. Hunt, Elisabeth
A. Lasater, Gabriel Pallares, Sarah Picaud, Christopher
Wells, Lisa M. Wodicka, Neil P. Shah, Stefan Knapp, Daniel
K. Treiber.
19.
5388
High throughput toxicity assay for threedimensional cell cultures. Kari Trumpi, David A. Egan,
Thomas T. Vellinga, Inne H. Borel Rinkes, Onno W.
Kranenburg.
20.
5378
Actions of nanoparticulate tetraiodothyroacetic
acid (Nanotetrac) on human prostate carcinoma
xenograft growth, vascularity and integrin response to
radiation. Shaker A. Mousa, Sudha Thangirala, Murat
Yalcin, John T. Leith, Aleck Hercbergs, Hung-Yun Lin, HengYuan Tang, Mary K. Luidens, Paul J. Davis.
5389
Discovery of small molecule inhibitors of the
interaction between PPAR␥ and SMRT. Jaeki Min, Ramy
Naguib Attia, Leggy A Arnold, Kelly Teske, Michele Connelly,
George Lemieux, Kaveh Ashrafi, Anang Shelat, R. Kiplin Guy.
21.
5379
Targeting epidermal growth factor receptor
positive breast cancer using nanoparticles loaded with
the anti-cancer drug aminoflavone. Ashley M. Brinkman,
Guojun Chen, Nathan Sherer, Shaoqin Gong, Wei Xu.
5390
Development of a high-throughput screening
assay to identify UHRF1 inhibitors via time-resolved
fluorescence resonance energy transfer (TR-FRET). David
A. Walker, Nicolas Wyhs, Hugh Giovinazzo, Srinivasan
Yegnasubramanian, William G. Nelson.
22.
5380
Near-infrared-resonant IONP/Au2S
core/satellites hybrid nanocomposite for imaging-guided
photothermal therapy. Hongwei Chen, Joseph Burnett,
Xiaoqing Ren, Feng Ni, Yi Wei, Hayley Paholak, Duxin Sun.
5391
MT-MMP cleavage profiling using rapid
endopeptidase profiling library (REPLi). Andrew Mitchell,
Javier Giménez-Warren, Steven D. Shnyder, Jason H. Gill,
Robert A. Falconer, Paul M. Loadman.
23.
5392
High-throughput screening of compounds for
targeting system Xc- in human breast cancer cells. Hanxin Lin, Jennifer Fazzari, Katja Linher-Melville, Gurmit Singh.
24.
5393
The advantages of acoustic liquid handling for
drug sensitivity screening. Bonnie Edwards.
26.
5394
A high-throughput screening platform for the
identification of small molecule inhibitors of MAP2K4.
Sankar Narayan Krishna, Chi-Hao Luan, Matthew R. Clutter,
Rama K. Mishra, Karl A. Scheidt, Wayne F. Anderson,
Raymond C. Bergan.
27.
5395
High-throughput cysteine concentration
determination by specific fluorescence sensors in cell
culture medium. Hong Guan.
3.
5372
A molecular docking strategy for identifying
fragment inhibitors of indoleamine 2,3-dioxygenase 1
(IDO1). Simon Fung, Jack U. Flanagan, Christopher J.
Squire, Brian D. Palmer, Lai-Ming Ching.
4.
5373
In silico investigation of FOXM1 binding and
novel inhibitors in epithelial ovarian cancer (EOC). Yi
Chen, Eliza A. Ruben, Marcia M. Bieber, Jayakumar
Rajadas, Nelson N. Teng.
5.
5374
Effect of carbon nanotube amount and
subcellular location on the near infrared (NIR)
photothermal ablation of cells. Vasanth Siruvallur Murali,
Carole Mikoryak, Ruhung Wang, Rockford K. Draper.
6.
5375
Enhanced permeability of nanoscale
chemotherapeutic agents for the treatment of breast
cancer. Oliver Molina, Eugena Yu, Sarah Abdulabbas, Steve
Lopez.
7.
5376
Systematic analysis of peptide linker length and
liposomal polyethylene glycol coating on cellular uptake
of peptide-targeted liposomal nanoparticles. Jared
Stefanick, Jonathan Ashley, Tanyel Kiziltepe, Basar Bilgicer.
8.
5377
Assessing the chemotherapeutic response of
nanoliposomal topotecan in conjunction with
radiotherapy on tumor and its microenvironment. Amar
Jyoti, Pallavi Sethi, Kyle Fugit, Ulrich Langner, William St.
Clair, Ronald C. McGarry, Bradley D. Anderson, Meenakshi
Upreti.
9.
10.
11.
12.
13.
Poster Abstract
Board Number
5381
VLA-4 targeted nanoparticles deliver a cMYCMAX prodrug antagonist extends survival a metastatic
myeloma mouse model. Deepti Soodgupta, Dipanjan Pan,
Grace Cui, Angana Senpan, Xiaoxia Yang, Samuel A.
Wickline, Edward V. Prochownik, Katherine N. Weilbaecher,
Michael H. Tomasson, Gregory M. Lanza.
5382
A breakthrough in application of a drug delivery
nanoparticle system for therapy and diagnosis of solid
tumor. Xin Wu, Hirofumi Yamamoto, Mamoru Uemura,
Taishi Hata, Junichi Nishimura, Ichiro Takemasa, Tsunekazu
Mizushima, Yuichiro Doki, Masaki Mori.
27
27
593
POSTER SESSION
Chemistry 11
Poster
Section
28
28
Targeted Therapies and Nanoparticle Strategies for Selective Drug Delivery
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
594
5396
Nanoparticles loaded with indium (III)
phthalocyanine are more effective in promoting cell
proliferation inhibition on MCF-7 breast cancer cells
when compared to free InPc. Carlos Augusto Z. Souto,
Klesia P. Madeira, Leticia Rangel, André R. da Silva.
5397
Docetaxel-loaded solid lipid nanoparticles
suppress breast cancer cells growth with improved cell
apoptosis and gene expression profile and reduced
myelosuppression toxicity. Qing Yuan, Wenshu Cong,
Zhaoxia Dai, Ying Ge, Xiao-Lin Bi.
5398
Nanoparticles for image guided focused
ultrasound drug delivery. Maya Thanou, Michael Wright,
Miguel Centelles.
5399
A novel treatment for triple-negative breast
cancer using intrinsic magnetized paclitaxel. Masanari
Umemura, Ayako Makino, Itaru Sato, Xianfeng Feng, Kayoko
Oda, Makoto Ohtake, Satoshi Izuka, Maki Iwai, Kosuke
Matsuo, Haruki Eguchi, Yoshihiro Ishikawa.
5400
Photoimmunotherapy (PIT) combined with a
nanosized cancer agent successfully treated
heterogenous antigen-expressing tumors based on
super-enhanced permeability and retention (SUPR)
effect. Hisataka Kobayashi, Kohei Sano, Takahito Nakajima,
Kazuhide Sato, Peter L. Choyke.
5401
Investigation of sub-tumor accumulation of
PRINT nanoparticles reveals dose and route of
administration dependence on particle association. Luke
Roode, Tao Bo, Jillian Perry, J. Chris Luft, James E. Bear,
Ian J. Davis, Joseph M. DeSimone.
5402
Tissue accumulation and toxicity of platinum
released from a novel chitosan hybrid gel for
intraperitoneal drug delivery. Sungpil Cho, Yongen Sun,
Elke A. Jarboe, Andrew P. Soisson, Mark K. Dodson, David
K. Gaffney, C.Mattew Peterson, Margit M. Janat-Amsbury.
5403
Metronomic docetaxel in PRINT nanoparticles
and EZH2 silencing have synergistic antitumor effect in
ovarian cancer. Kshipra M. Gharpure, Kevin S. Chu,
Charles Bowerman, Takahito Miyake, Sunila Pradeep,
Lingegowda S. Mangala, Hee-Dong Han, Rajesha
Rupaimoole, Sherry Y. Wu, Heather J. Dalton, Mary E.
Napier, Gabriel Lopez-Berestein, Joseph M. DeSimone, Anil
K. Sood.
5404
C6-ceramide containing anionic nanoliposomes
are effective chemotherapy delivery vehicles for
pancreatic cancer. Christopher McGovern, Sriram
Shanmugavelandy, Sara Shimko, Samuel Linton, Jenny Dai,
Mark Kester, Gail L. Matters.
5405
Self-emulsifying nanoemulsions target
intracranial glioblastoma tumors: In vivo optical imaging
and fluorescence microscopy evidences. Xinli Liu,
Hussaini S. Qhattal, Tanvirul Hye.
5406
The CendR pathway: a novel cell penetration
and transcytosis pathway regulated by nutrient
availability. Hong-Bo Pang, Gary B. Braun, Tomas Friman,
Pedro Aza-Blanc, Manuel E. Ruidiaz, Kazuki N. Sugahara,
Tambet Teesalu, Erkki Ruoslahti.
5407
Milk derived exosomes: Scalable source of
biologically active drug delivery nanoparticles. Farrukh
Aqil, Radha Munagala, Jeyaprakash Jeyabalan, Ramesh C.
Gupta.
5408
Liposomal doxorubicin with modified EGCG
increased antitumor activity by topical targeting
efficiency into tumor. Ikumi Sugiyama, Kunihiro Kaihatsu,
Nobuo Kato, Yasuyuki Sadzuka.
5409
AZD1152-hQPA Accurins: Nanoparticle
formulations showing extended release and the
potential for improved therapeutic index. Simon T. Barry,
Elaine Cadogan, Rajesh Odedra, Susan Ashton, John Foster,
Young Ho Song, Susan Low, Paula Taylor, Rebecca Ellston,
Urszula Polanska, Joanne Wilson, Colin Howes, Dawn
Trueman, Mike Walker, David De Witt, Marianne Ashford,
Jeff Hrkach, Phil Jewsbury.
Poster Abstract
Board Number
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
5410
Enhanced targeting delivery to tumor cells
using mucoadhesive chitosan and chlorotoxin. Rana
Falahat, Eva Williams, Marzenna Wiranowska, Ryan Toomey,
Norma Alcantar.
5411
Curcumin nanoformulation: A new therapeutic
approach for cervical cancer treatment. Mohd S. Zaman,
Neeraj Chauhan, Diane M. Maher, Murali M. Yallapu, Meena
Jaggi, Subhash C. Chauhan.
5412
Antitumor properties of ouabain in lipid double
emulsion in orthotopic canine osteosarcoma
xenografted mouse model. Jun Wu, Meng-Yin Hsieh, Yan
Wang, Eugene Roberts, Derek Vallejo, Abraham Lee, Richard
Ermel.
5413
Double-targeted theranostic gold nanoparticles
for treatment of brain tumors. Suraj K. Dixit, Yun Zhu,
Alfred Moore, Malcolm Kenney, Ann-Marie Broome.
5414
IG-001 potential as intraperitoneal therapy for
ovarian cancer. Kouros Motamed, Rosemary Kim,
Hyunjoung Yang, Vuong Trieu.
5415
Targeted nanoparticle based therapy for the
treatment of glioblastoma multiforme: Unprecedented
anti-cancer activity in highly drug resistant/refractory
mouse models of glioblastoma with novel apoptotic
nanoparticles which hone to a cell-surface protein
found on tumor endothelia and cancer cells. Sarah
Hudson, Lilach Agemy, Venkata Ramana Kotamraju, Shweta
Sharma, Erkki Ruoslahti, Florence Brunel, Ann MacLaren,
John Muraski, Deborah Slee.
5416
Development of a nanoparticle platform for the
targeted delivery of siRNA to HER2-positive breast
cancers. Shaun M. Goodyear.
5417
Improved tumor targeting by BLD1-ELP. Eun-A
Cho, Vijaya D. Sarangthem, Byung-Heon Lee, In-San Kim,
Rang-Woon Park.
5418
Tumor-targeted nanoparticle delivery of HuRRNAi suppresses lung cancer cell proliferation and cell
migration. Ranganayaki Muralidharan, Anish Babu,
Kanthesh Basalingappa, Anupama Munshi, Rajagopal
Ramesh.
5419
Computationally-inspired engineering of
supramolecular taxane nanoparticles. Ashish A. Kulkarni,
Poornima Rao, Aaron Goldman, Shiladitya Sengupta.
5420
Nano-engineered mesenchymal stem cells as
targeted therapeutic carriers. Swayam Prabha, Tanmoy
Sadhukha.
5421
A novel biologically active acid stable liposomal
formulation of docosahexaenoic acid (DHA) for breast
cancer prevention. Christine G. Skibinski, Arunangshu Das,
Mark Kester, Kun-Min Chen, Andrea Manni, Karam ElBayoumy.
5422
Predictive models of diffusive nanoparticle
transport in 3D tumor spheroids. Mingguang Li, Michael
Wientjes, Bertrand Yeung, M. Guillaume Wientjes, Jessie
L.S. Au.
5423
Novel targeted therapy for neuroblastoma:
Silencing the MXD3 gene using siRNA. Connie Duong,
Cathy Chen, Sakiko Yoshida, Gustavo Barisone, Jan Nolta,
Elva Diaz, Nitin Nitin, Noriko Satake.
5424
Development of selective therapy of childhood
ALL and Ewing’s sarcoma using targeted-hybrid
polymerized liposomal nanoparticles (HPLN). Hyunggyoo
Kang, Violette Shahbazian, Amanda Schafenacker, Jon
Nagy, Timothy Triche.
POSTER SESSION
Experimental and Molecular Therapeutics 40
Biologic Therapy 4
Poster
Section
Poster Abstract
Board Number
1.
5425
L-amino acid oxidase from Crotalas
adamanteus venom induces caspase-independent
apoptosis in human NUGC-3 gastric cancer cells. Jian
Ding, Boon-Huat Bay, P Gopalakrishnakone.
2.
5426
Assessing factors predictive of response to
ADCs for companion diagnostic strategies. Joseph S.
Krueger, Holger Lange, Steve Potts, David Young.
3.
Poster Abstract
Board Number
17.
5441
Debio 1143, an oral antagonist of the inhibitor of
apoptosis proteins, synergistically enhances the effects of
multiple standard of care agents in human lung cancer
models. Casey G. Langdon, Norbert Wiedemann, Mathew A.
Held, James T. Platt, Frédéric Lévy, Denis Robichon, Claudio
Zanna, Grégoire Vuagniaux, Mel Sorensen, Shaomeng Wang,
Marcus W. Bosenberg, David F. Stern.
5427
Inducing tumor apoptosis by redirecting VEGF
to activate cell death receptors. Timothy Quinn, YJ Lu,
Raquel Santos, Tomoko Ozawa, David James, Mary C.
Nakamura.
18.
5442
Biodistribution and antitumor efficacy study of
novel Her2 targeting DARPins. Olivier Raguin, Marie Leblanc,
Bertrand Collin, Alexandra Oudot, Jean-François Mirjolet,
Ulrike Fiedler, Ignacio Dolado.
4.
5428
Inhibition of collagen receptor discoidin domain
receptor-1 (DDR1) tyrosine kinase enhances cytotoxicity
of anti-mesothelin immunotoxin. Fatima Ali-Rahmani,
David Fitzgerald, Scott Martin, Paresma Patel, Craig
Thomas, Ira Pastan.
19.
5.
5429
The combination of Apo2L/Trail and a death
receptor 5 agonist antibody leads to enhanced
antitumor activity in mouse syngeneic tumor models.
Timothy Sullivan, Daniel Branstetter, Pamela Holland,
Tammy L. Bush.
5443
A phase 1 evaluation of 64Cu-DOTA-patritumab to
assess dosimetry, receptor occupancy, and safety in
advanced solid tumors. Albert C. Lockhart, Yongjian Liu,
Farrokh Dehdashti, Richard Laforest, Joel Picus, Andrea WangGillam, Lauren Trull, Stefanie Belanger, Madhuri Desai, Jeanne
Mendell, Syed Mahmood, Barry A. Siegel, Michael J. Welch.
20.
5444
Modulation of ErbB receptors expression by
histone deacetylase inhibitors increased the antitumor
activity of an anti-ErbB3 monoclonal antibody in primary
cultures from non-small cell lung cancer patients. Chiara
Ciardiello, Alessandra Leone, Francesca Bruzzese, Maria Serena
Roca, Alessia Noto, Claudia De Vitis, Luigi Aurisicchio, Gennaro
Ciliberto, Rita Mancini, Alfredo Budillon.
21.
5445
Preclinical anti-tumor efficacy of an anti-C4.4a
(LYPD3) antibody drug conjugate for the treatment of
lung squamous cell carcinoma. Joerg Willuda, Lars
Linden, Hans-Georg Lerchen, Charlotte Kopitz, Sven Golfier,
Ute Bach, Joachim Schumacher, Beatrix Stelte-Ludwig,
Oliver Von Ahsen, Claudia Schneider, Frank Dittmer, Rudolf
Beier, Sherif El-Sheik, Jan Tebbe, Gabriele Leder, Heiner
Apeler, Rolf Jautelat, Bertolt Kreft, Karl Ziegelbauer.
6.
5430
Frizzled-1 receptor, a potential therapeutic
target for atypical teratoid rhabdoid tumor. Madhavi
Chakravadhanula, Victor Ozols, Chris Hampton, Ratan
Bhardwaj.
7.
5431
Tolfenamic acid enhances the therapeutic
efficacy of certain chemotherapeutic agents in
medulloblastoma cell lines. Don Eslin, Umesh T. Sankpal,
Chris M. Lee, Robert M. Sutphin, W. Paul Bowman, Jeffrey
C. Murray, Riyaz Basha.
9.
5433
Binding of multivalent CD147 extracellular
domain on U937 cells induces apoptosis via activation
of caspase-9 and downregulation of MCT-1. Nutjeera
Intasai, Supansa Pata, Khajornsak Tragoolpua, Chatchai
Tayapiwatana.
22.
5434
Combined BCL-2/XL and mTor inhibition
promotes apoptosis in small cell lung cancer. Li Gao,
Brittany Barnwell, Arjun Kalvala, Gregory A. Otterson, Wenrui
Duan, Miguel A. Villalona-Calero.
5446
FPA144: A therapeutic antibody for treating
patients with gastric cancers bearing FGFR2 gene
amplification. Abigael T. Gemo, Amit M. Deshpande,
Servando Palencia, David I. Bellovin, Thomas J. Brennan,
Namrata S. Patil, Carol Huang, Gerrit Los, Kristen L. Pierce.
23.
5447
Targeting vascular endothelial growth factor A
and tumor hypoxia combined with radiation eradicates
sarcomas through destruction of tumor vasculature and
thwarting of the hypoxic response. Changhwan Yoon, HaeJune Lee, Do Joong Park, William D. Tap, T. S. Karin EisingerMathason, David G. Kirsch, M. Celeste Simon, Sam S. Yoon.
24.
5448
PTK7 as a potential therapeutic target in
ovarian cancer. Zhihu Ding, Amanda Lennon, Keli Perron,
David Harper, Hui Su, Meredith Wolfram, Joshua Murtie,
Stuart Licht, Jason Pinckney, Helene Simonds-Mannes,
Kimberly Bishop, Julie-Ann Gavigan, Dinesh Bangari,
Maureen Magnay, William Weber, David Reczek, William
Brondyk, Vicky Drewett, Marc Trombe, Dietmar Hoffmann,
Raffaele Baffa, Serena Silver, Victoria Richon, Christopher
Winter, Venkat Reddy, Richard C. Gregory.
25.
5449
FP-1039/GSK3052230, an FGF ligand trap,
enhances VEGF antagonist therapy in preclinical models
of RCC and HCC. David I. Bellovin, Servando Palencia,
Kevin Hestir, Ernestine Lee, M. P. DeYoung, Thomas
Brennan, Gerrit Los, Kevin Baker.
26.
5449A
PI3K and MEK inhibition in intracranial triple
negative breast cancer: Efficacy of BKM120 and
AZD6244 in preclinical mouse models. Amanda E. Van
Swearingen, Marni B. Siegel, Ryan Bash, Brian Golitz,
Charlene Santos, David Darr, Joel Parker, Gary L. Johnson,
C. Ryan Miller, Carey K. Anders.
10.
11.
5435
Molecular subclasses of human hepatocellular
carcinoma predict sensitivity to fibroblast growth factor
receptor inhibition. Benjamin Schmidt, Lan Wei, Danielle K.
DePeralta, Yujin Hoshida, Michael Lanuti, Kenneth K.
Tanabe, Bryan C. Fuchs.
12.
5436
Potential of asparagine depletion for the
treatment of bladder cancer and other urological
tumors. Willy Berlier, Karine Aguera, Fanny Gallix, Fabien
Gay, Gautam Borthakur, Yann Godfrin.
13.
5437
Dual targeting of ErbB-2 and ErbB-3: a new
potential strategy for the treatment of pancreatic
cancer. Gianluca Sala, Reza Ghasemi, Emily Capone, Ilario
G. Rapposelli, Sara Traini, Cosmo Rossi, Pier Giorgio Natali,
Stefano Iacobelli.
14.
5438
Resistance to ␤1 integrin inhibition in HER2
amplified cancers is mediated by HER3. Catherine C.
Park, Dhara Amin, Hui Zhang, Mark Moasser.
15.
5439
Metabolomic study of EGFR drug resistance
mechanisms. Yang Zhao, Bo Tan, Ming-Shang Kuo, Ling
Liu, Matthew D. Breyer.
16.
5440
Activity of mesothelin-targeted immunotoxin
RG7787 against triple-negative breast cancer. Christine
Alewine, Emily Maon-Osann, Ira Pastan.
30
30
595
POSTER SESSION
Poster
Section
31
31
Cellular Responses to Anticancer Drugs 1
Poster Abstract
Board Number
1.
2.
3.
5451
Profiling inhibitors of MDM2:p53 and MDMX:p53
in relation to MDMX protein levels. Sue Tudhope, Yan
Zhao, Anita Wittner, Elaine Wilmore, Annalisa Bertoli,
Santosh Adhikari, Suzannah J. Harnor, Fabio Del Bello,
Alessandro Piergentili, John Lunec, Ian R. Hardcastle, Roger
J. Griffin, Bernard R. Golding, Celine Cano, David R. Newell,
Stephen R. Wedge.
5452
Whole transcriptome analysis of ovarian cancer
cells reveals the mechanism of action for a potent
organometallic anticancer agent. Jessica M. Hearn, Isolda
Romero-Canelón, Fu Ying, David L. Wild, Peter J. Sadler.
14.
5463
ICG-001 induces cell cycle arrest to inhibit in
vitro and in vivo pancreatic cancer growth. Michael D.
Arensman, Anna R. Lay, David W. Dawson.
15.
5464
Distinct effects of eribulin on axonal
microtubule composition and modifications relative to
paclitaxel, vincristine and ixabepilone in preclinical
models: correlations with lower levels of eribulininduced peripheral neuropathy. Sarah J. Benbow, Brett M.
Cook, Krystyna M. Wozniak, Barbara S. Slusher, Bruce A.
Littlefield, Leslie Wilson, Stuart C. Feinstein, Mary A. Jordan.
16.
5465
The molecular basis of activity of rigosertib (ON
01910.Na) in head and neck cancer cell lines. Anil
Prasad, Nagina Khudaynazar, Paula M. Kuzontkoski, Ramana
V. Tantravahi, Amanda M. Gillum.
17.
5466
The Mdm2 inhibitor, NVP-CGM097, in
combination with the BRAF inhibitor NVP-LGX818 elicits
synergistic antitumor effects in melanoma. Hui Qin
Wang, Matthew Zubrowski, Erling Emerson, Elina Pradhan,
Sébastien Jeay, Marion Wiesmann, Giordano Caponigro,
Jens Wuerthner, Robert Schlegel, Z. Alexander Cao, Alan
Huang, Ensar Halilovic.
18.
5467
Role of the eukaryotic elongation factor eEF1A
in the mechanism of action of Aplidin. Alejandro Losada,
Juan F. Martínez-Leal, Federico Gago, Carmen Cuevas, Luis
F. Garcia-Fernández, Carlos M. Galmarini.
19.
5468
SAR650984, a humanized anti-CD38 antibody
potently modulates intracellular and extracellular
nucleotide levels of cancer cells. Bailin Zhang, Guang
Yang, Shujia Dai, Tim He, Daniel Simard, Zhili Song, Stuart
Licht, Francisco Adrian, Hong Cheng, Ti Cai.
4.
5453
Dual mTOR/PI3K inhibitors induce ERK pathway
overactivation in pancreatic cell lines: rationale for
combinatory therapy. Heloisa P. Soares, Ming Ming,
Michelle Mellon, James Sinnet-Smith, Enrique Rozengurt.
5.
5454
Inhibition of Bcr-Abl tyrosine kinase sensitizes
cells to sapacitabine. Yingjun Jiang, Xiaojun Liu, Adrienne
Chestang, William Plunkett.
6.
5455
Resistance to a MEK inhibitor (AZD6244): Its
association with increased expression of transcription
factor 4. Bon-Kwan Goo, Eun-Hye Hur, Yunsuk Choi, SungDoo Kim, Jung Jin Hwang, Choung-Soo Kim, Kyun Seop
Bae, Jene Choi, Suk Young Cho, Sang-Hwa Yang, Je-Hwan
Lee.
7.
5456
ACY-1215, a selective inhibitor of HDAC6,
synergizes with immunomodulatory drugs (IMiDs) to
induce apoptosis of multiple myeloma (MM) cells.
Steven N. Quayle, David Tamang, Min Yang, Simon S.
Jones.
20.
5469
Trastuzumab resistant HER2ⴙ breast cancer
cells retain sensitivity to poly (ADP-ribose) polymerase
(PARP) inhibition. Monica E. Wielgos, Tiffiny Cooper,
Andres Forero, James A. Bonner, Francisco J. Esteva, C K.
Osborne, Rachel Schiff, Albert F. LoBuglio, Eddy S. Yang.
8.
5457
Cytarabine leaves a mutational fingerprint in
relapsing leukemia. Sarah E. Fordham, Michael Cole, Julie
A. Irving, James M. Allan.
21.
9.
5458
Methylene blue selectively inhibits B cell
development and E2A activity. Eroica Soans, John K.
Choi.
5470
LKB1 loss sensitizes non-small cell lung cancer
cells to aggravation of ER stress. Landon J. Inge,
Jacqueline M. Friel, Aaron Fowler, Amanda Richer, Timothy
Whitsett, Nhan L. Tran, Ross M. Bremner.
22.
5471
Contextual synthetic lethality in human triple
negative breast cancer cells involving a novel
interaction between DNA repair proteins EGFR, PARP1,
and BRCA1. Jennifer A. Stanley, Somaira Nowsheen, Tiffiny
Cooper, Andres Forero, Alfred LoBuglio, Eddy Yang.
23.
5472
Systems pharmacogenomics approach identifies
synergistic molecular action of combined MTOR/HDAC
inhibition on MYC. Benjamin J. Gamache, John K.
Simmons, Aleksandra Michalowski, Jyoti Patel, Ke Zhang,
Shuling Zhang, Wendy DuBois, Adriana Zingone, Michael
Kuehl, Jing Huang, Ola Landgren, Beverly Mock.
24.
5473
The sensitivity of targeting genomic BCL2 by
PNT2258 is linked to chromosomal rearrangements and
proliferative rate of tumor types. Michael J. Woolliscroft,
Abdul-Shukkur Ebrahim, Richard A. Messmann, Shari K.
Gaylor, Mina P. Sooch, Ayad Al-Katib, Wendi V. Rodrigueza.
25.
5474
The formin, DIAPH3, regulates response to MT
stabilizing drugs in prostate and breast cancer.
Samantha Morley, Sara G. Pollan, Sungyong You, Beatrice
S. Knudsen, Michael Freeman.
10.
596
5450
Screening >60 human SCLC lines with
approved and investigational agents indicates complex
patterns of response: Identification of HSP90 and HDACs
as potential targets. David M. Evans, Rene Delosh, Julie
Laudeman, Chad Ogle, Russell Reinhart, Michael Selby,
Thomas Silvers, John Connelly, Anne Monks, Eric Polley,
Gurmeet Kaur, Joel Morris, Beverly Teicher.
Poster Abstract
Board Number
5459
Preclinical efficacy of the novel PIM2 kinase
inhibitor, JP_11646, in human acute leukemia models.
Krista E. Pundt, Carmen M. Baldino, Justin Caserta,
Stephane Dumas, Yvonne Flanders, Eunice S. Wang, Gerald
J. Fetterly.
11.
5460
Intracellular uptake and metabolism of SH7139:
Is it a targeted prodrug for B-cell lymphomas. Monique
C. Balhorn, Gary Mirick, Dong Cheng, Zhengping Ma,
Edmond Y. Lau, Saphon Hok, Gerald L. DeNardo, Rod
Balhorn.
12.
5461
The role of gene body cytosine modifications in
MGMT expression and sensitivity to temozolomide. Erika
L. Moen, Amy L. Stark, Wei Zhang, M. Eileen Dolan, Lucy A.
Godley.
13.
5462
Antiproliferative and cytotoxic activities of 5(nonyloxy)tryptamine derivatives in breast cancer cells.
Clint D. Tavares, Jiney Jose, Ashwini K. Devkota, Jihyun
Park, Tamer S. Kaoud, Eric V. Anslyn, Kevin N. Dalby.
POSTER SESSION
Poster
Section
Poster Abstract
Board Number
1.
Poster Abstract
Board Number
5475
Interrogation of NCI-60 patterns of growth
inhibition in conjunction with investigational oncology
agents kinase profiling for the elucidation of
mechanistic targets. Joel Morris, Mark Kunkel, Eric Polley,
Susan Holbeck, Anne Monks, David Evans, Annamaria
Rapisarda, Jerry Collins, Beverly Teicher.
14.
5488
Everolimus inhibits the proliferation of
aromatase inhibitor-resistant breast cancer cells. Asona
Lui, Joan Lewis-Wambi.
15.
5489
Targeting MYC in multiple myeloma by BET
protein inhibition. Daniel L. Riggs, Marta Chesi, P L.
Bergsagel.
2.
5476
Simultaneous targeting of multiple cancerrelated pathways in HPV-positive head and neck cancer
with demethylating agents. Asel Biktasova, Evgenia
Gubanova, Mi Zou, Wendell G. Yarbrough, Natalia Issaeva.
16.
5490
Poly (ADP-ribose) polymerase inhibitor LT-626
sensitizes lung and pancreatic cancers to fractionated
radiation therapy. Kedar Hastak, Lisa McPherson, Yuqiao
Shen, Renate Parry, James M. Ford.
3.
5477
mTOR inhibitors protect from apoptosis in BALL cells treated with chemotherapeutic drugs. ThanhTrang Vo, David A. Fruman.
17.
5491
Interrogating the mechanism of Wnt pathway
inhibition by niclosamide. Robert A. Mook, Shengli Zhao,
Wei Chen.
4.
5478
A novel chloroquine derivative inhibits
proteasome function, deregulates centrosome cycle and
has selective anti-tumor activity. Sheetal Pundir.
18.
5.
5479
Antitumor effect of KX-01, a novel Src and
tubulin inhibitor, in triple negative breast cancer cells.
Seongyeong Kim, Seock-Ah Im, Ahrum Min, Miso Lee,
Heymin Jang, Kyung-Hun Lee, Hee-Jun Kim, Tae-Yong Kim,
Sae-Won Han, Do-Youn Oh, Tae-You Kim, Young-Kwang
Yoon, David Hangauer, Johnson Lau, Yung-Jue Bang.
5492
Effect of GnRH analogues and pharmacoperone
IN3 treatment in survival of prostatic cancer cells to
radiation. Catherine A. Sanchez, Apolo Salgado, Enrique A.
Castellon.
19.
5493
Metformin synergizes 5-fluorouracil, epirubicin,
and cyclophosphamide (FEC) sensitivity in breast cancer
stem cells and non-stem breast cancer cells. Sian Siu
Soo, Char Hong Ng, Rozita Abdul Malik, Yew Ching Teh,
Boon Shing Tan, Gwo Fuang Ho, Mee Hoong See, Nur
Aishah Mohd Taib, Cheng Har Yip, Soo Hwang Teo, Chee
Onn Leong.
20.
5494
The effect of honokiol combined with PPAR␥
agonists in regulation of cell growth and migration in
human hepatoma cells. Chin-Wen Chi, Hui-Tzu Hsu.
21.
5495
BET bromodomain inhibitors abrogate cell cycle
progression and induces apoptosis in Myc-induced
mouse lymphoma cells without affecting MYC
transcription. Joydeep Bhadury, Lisa M. Nilsson, Lydia
Green, Zhoulei Li, Emily M. Gesner, Somsundar Veppil
Muralidharan, Henrik C. Hansen, Ulrich B. Keller, Kevin G.
Mclure, Jonas A. Nilsson.
22.
5496
Mechanisms of anti-tumurogenic activity of the
brown seaweed, F. vesiculosus. Jacques E. Riby, Lucia
Conde, Xiangqin Cui, Jianqing Zhang, Christine F. Skibola.
23.
5497
Targeting glioblastoma stem cells with
withaferin A. Baoyu Zhang, Branko Cuglievan, Nadia G.
Myrthil, Steven Vanni, Ricardo J. Komotar, Regina M.
Graham.
6.
5480
NSCLC cells with LKB1 mutation are vulnerable
to energetic and oxidative stresses induced by 8Chloroadenosine. Chao Yang, Maria Angelica Cortez, Uma
Giri, Jayanthi Gudikote, William G. Wierda, Varsha Gandhi,
Lauren A. Byers, John V. Heymach.
7.
5481
Differential inhibition of microtubule-dependent
transport and signaling pathways important for cancer
cell growth and survival. Cristina C. Rohena, Susan L.
Mooberry.
8.
5482
Antileukemic activity of 2-deoxy-d-glucose in
acute myeloid leukemia. Clément Larrue, Stéphane
Manenti, Christian Récher.
9.
5483
Implications of the type of BRCA1 germline
mutation in the treatment of patients with hereditary
breast cancer. Tereza Vaclova, Nicholas T. Woods,
Fernando Setién, José María García Bueno, José Antonio
Macías, Alicia Barroso, Miguel Urioste, Manel Esteller, Alvaro
N. Monteiro, Javier Benítez, Ana Osorio.
10.
5484
Dehydroleucodine: A potential sesquiterpene
lactone for targeting castration-resistant prostate
cancer. Souresh Banerjee, Gnanasekar Munirathinam.
24.
11.
5485
Induction of proliferation sensitizes chronic
lymphocytic leukemia cells to apoptosis mediated by
the ATR inhibitor AZD6738. Michael Y. Choi, Jessie-Farah
Fecteau, Jeff Brown, Alan Lau, Thomas J. Kipps.
5498
Changes in expression of DNA repair genes in
human leukemia cells treated with laromustine. Kristen
N. Robinson, Kathryn A. Coe, Justin E. Owumi, Kevin P.
Rice.
25.
5499
Preclinical evaluation of PI3K inhibitor BYL719
as a single agent and its synergism in combination with
cisplatin or MEK inhibitor in nasopharyngeal carcinoma
(NPC) using 3D cell culture system. Hio Teng Cheong, Chi
Hang Wong, Connie Wun Chun Hui, Anthony Tak Cheung
Chan, Brigette Buig Yue Ma.
13.
5487
The requirements for dasatinib sensitivity in
human melanoma cell lines. Jiri Vachtenheim, Jiri Réda,
Lubica Ondrušová, Petra Žáková.
32
32
597
POSTER SESSION
Poster
Section
33
33
Poster Abstract
Board Number
1.
5500
Sensitivity of metastatic breast cancer (4T1)
cells to apoptotic effect by Lactobacillus kefiri P-IF via
a mechanism that involves hole piercing in cancer cells.
Mamdooh H. Ghoneum.
2.
5501
Combined effects of docetaxel-magnetic
nanoparticles with different surface modifications on
prostate cancer cells. Nao Furuta, Sou Yamaguchi, Ayumi
Iwasaki, Daiki Okamoto, Akiko Sato, Yoshihiro Endo,
Daisuke Kurioka, Tadashi Nittami, Hitoshi Ishiguro, Hiroji
Uemura, Yoshinobu Kunota, Masatoshi Watanabe.
3.
5502
Metrics other than potency reveal systematic
variation in responses to cancer drugs. Mohammad
Fallahi-Sichani, Saman Honarnejad, Laura M. Heiser, Joe W.
Gray, Peter K. Sorger.
4.
5503
Microtubule-targeting agents induce differential
myelinated axon degeneration in a mouse model of
peripheral neuropathy. Brett M. Cook, Sarah J. Benbow,
Krystyna M. Wozniak, Barbara S. Slusher, Bruce A.
Littlefield, Leslie Wilson, Stuart C. Feinstein, Mary Ann
Jordan.
5.
6.
5505
Synergistic anticancer activity of clinical stage,
non-genotoxic apoptosis inducing agents RG7388
(MDM2 antagonist) and ABT-199 (GDC-0199, BCL2
inhibitor) in p53 wild-type AML tumor models. Markus
Dangl, Yuchen Chien, Christian Lehmann, Thomas Friess.
7.
5506
Inhibition of Hsp90 as a promising therapeutic
strategy in liposarcoma. Sara Steinmann, Abbas Agaimy,
Pierre Åman, Hala Gali-Muhtasib, Florian Haller, Regine
Schneider-Stock.
8.
5507
Activation of a subset of growth factorassociated genes in cetuximab-sensitive colorectal
cancer GEO cells with KRAS mutation. Yao Dai, Dietmar
Siemann, Wenyin Shi.
9.
5509
The role of WW domain-containing
oxidoreductase in methotrexate-induced cell death in
human squamous cell carcinoma. Li-Jin Hsu.
11.
5510
ABT-737 synergizes with Vorinostat to induce
apoptosis, mediated by Noxa upregulation, Bax
activation and mitochondrial dysfunction in PTEN-intact
malignant human glioma cell lines. Kimberly A. Foster,
Daniel R. Premkumar, Esther P. Jane, Alejandro Morales,
Ian F. Pollack.
13.
14.
5513
Targeting brain tumor initiating cells in atypical
teratoid/rhabdoid tumors: aldehyde dehydrogenase
inhibition with disulfiram. Seung Ah Choi, Jung Won Choi,
Kyu-Chang Wang, Ji Hoon Phi, Ji Yeoun Lee, Yong Hwy
Kim, Young-Hoon Kim, Sung-Hye Park, Seung-Ki Kim.
15.
5514
Metformin sensitizes anticancer effect of
dasatinib through AMPK-dependent ER stress in head
and neck squamous cell carcinoma cells. Yu-Chin Lin,
Meng-Hsuan Wu, Tzu-Tang Wei, Yun-Chieh Lin, Ching-Chow
Chen.
16.
5515
Combining FK228 and cisplatin synergistically
induces cancer cell death and reduces clonogenic
survival. Shambhunath Choudhary, Shilpa Sood, Lenora A.
Pluchino, Hwa-Chain R. Wang.
17.
5516
Fenretinide and safingol synergistic cytotoxicity
in neuroblastoma is, in part, mediated by increase of
dihydroceramides. Mohammad S. Abedi.
18.
5517
PTC596-induced Bmi1 hyper-phosphorylation
via Cdk1/2 activation resulting in tumor stem cell
depletion. Min Jung Kim, Liangxian Cao, Josephine Sheedy,
Nicole Risher, Melissa Dumble, Chang-Sun Lee, Nadiya
Sydorenko, Ramil Baiazitov, Wu Du, Young-Choon Moon,
Marla L. Weetall, Joseph Colacino, Thomas W. Davis.
19.
5518
BPM 31510 exposure alters fluidity and
molecular organization of cancer cell membranes,
influencing signaling and cell fate decisions. Michael
Kiebish, Sumit Garg, Vivek Vishnudas, Fei Gao, Min Du,
Sirisha Dhavala, Katerina Krumova, Leonardo Rodriguez,
Shen Luan, Viatcheslav R. Akmaev, Rangaprasad
Sarangarajan, Niven R. Narain.
20.
5519
Investigation of the cellular mechanisms of
action of maximiscin, a novel natural product with
selective cytotoxic activity against a triple negative
breast cancer molecular subtype. Andrew J. Robles, Lin
Du, Jarrod B. King, Robert H. Cichewicz, Susan L.
Mooberry.
21.
5520
A novel HDAC inhibitor, N-hydroxy-7-(2naphthylthio) heptanomide (HNHA), induces apoptotic
cell death through mitochondrial cytochrome c release
in renal cell carcinoma. Kyung Seok Han, Ki Cheong Park,
Jeong Yong Jeon, Sang Yong Kim, Dami Song, Woong Kyu
Han, Sung Joon Hong.
22.
5521
TTFields reduce cancer cell clonogenic potential
through abnormal chromosome segregation during
mitosis. Rosa S. Schneiderman, Moshe Giladi, Yaara Porat,
Mijal Munster, Eilon D. Kirson, Uri Weinberg, Yoram Palti.
23.
5522
Anticancer activity of novel PI3K inhibitor
BYL719 in head and neck cancer cell lines. Bhumsuk
Keam, Yong-Oon Ahn, Tae Min Kim, Se-Hoon Lee, DongWan Kim, Dae Seog Heo.
24.
5523
Study of the response of melanoma lines to
BRAF/MEK inhibitors and combination drug treatments.
Anahita Dastur, Cyril Benes.
25.
5524
5-aza-2’-deoxycytidine, a DNA demethylating
agent, inhibits metastatic melanoma invasiveness.
Chantal Etiévant, Cécile Desjobert, Arnaud Carrier, Audrey
Delmas, Jorg Tost, Gilles Favre, Joelle Riond, Paola
Arimondo.
26.
5525
Antitumor effect of Realgar in combination with
chemotherapy drugs on human gastric cancer cells.
Lian Zhang, Sungkyoung Kim, Wenping Ding, Leizhen
Zheng, Li Zhang, Yingying Tong, Siyu Chen.
5508
Bromodomain and hegdehog pathway targets in
small cell lung cancer. Gurmeet Kaur, Russell A. Reinhart,
Anne Monks, David Evans, Joel Morris, Beverly A. Teicher.
10.
12.
598
5504
A potential source in oxidative cell death
mediated by thymidylate synthase inhibitors: NADPH
oxidase 2. Ufuk Ozer, Franklin G. Berger, Karen W.
Barbour.
Poster Abstract
Board Number
5511
Direct effect of regorafenib on tyrosine kinase
activities in treatment naive colorectal cancer (CRC)
primary tumor tissue. Maria H. Hilhorst, Rosanne van den
Oord, Hans Pruijt, Adriaan van den Brule, Peet Nooijen, Rik
de Wijn, Liesbeth Houkes.
5512
Pharmacodynamic analysis of PI3K inhibition in
breast tumors: A model to improve early clinical
investigation of novel agents. Wei Yang, Jennifer R. Bean,
Lloye Dillon, Laurent Salphati, Michelle Nannini, Todd W.
Miller.
POSTER SESSION
Epigenetic Targets
Poster
Section
Poster Abstract
Board Number
1.
5526
Inhibition of the histone methyl transferase
EZH2 causes viability defects in multiple myeloma. Shilpi
Arora, Vidya Balasubramanian, Kaylyn Williamson, Victor
Gehling, Chris Nasveschuk, Rishi Vaswani, Jennifer Busby,
Shivani Garapaty, Priya Iyer, Feng Zhao, Robert Campbell,
Richard Cummings, Jim Audia, JC Harmange, Brian
Albrecht, Andrew Cook, Les Dakin, Emmanuel Normant,
Patrick Trojer.
2.
5527
Determining the apoptotic pathways required
for the EZH2 inhibitor, GSK-126, in a mouse model of B
cell lymphoma. Elena Lasorsa, Kevin Schaarschuch,
Zafardjan Dalimov, Leigh Ellis.
3.
5528
The BET Bromodomain inhibitor OTX015 targets
the NFKB, TLR and JAK/STAT pathways and shows preclinical activity as single agent and in combination in
mature B-cell tumors. Eugenio Gaudio, Elena Bernasconi,
Ivo Kwee, Michela Boi, Paola Bonetti, Chiara Tarantelli,
Andrea Rinaldi, Monica Testoni, Maurilio Ponzoni, Anastasios
Stathis, Georg Stüssi, Eugenia Riveiro, Patrice Herait,
Emanuele Zucca, Francesco Bertoni.
4.
5529
In vitro evaluation of OTX015, a novel pan-BETbromodomain (BET-BRD) inhibitor, as single agent and
in combination with standard chemotherapy drugs in
human leukemic cell lines. Lucile Astorgues-Xerri, Ramiro
Vázquez, Mohamed Bekradda, Esteban Cvitkovic, Patrice
Herait, Eric Raymond, María E. Riveiro.
5.
5530
OTX015, a novel pan BET-BRD inhibitor is active
in non-small-cell lung cancer (NSCLC) cell lines bearing
the fusion protein EML4-ALK. Ramiro Vázquez, Lucile
Astorgues-Xerri, Mohamed Bekradda, Esteban Cvitkovic,
Patrice Herait, Michela Boi, Giorgio Inghirami, Maurizio
D’Incalci, María E. Riveiro, Eric Raymond.
Poster Abstract
Board Number
10.
5535
Gcn5 modulates the cellular response to
oxidative stress induced by histone deacetylase
inhibitors. Ann-Christin Gaupel, Thomas J. Begley, Martin
P. Tenniswood.
11.
5536
Short-term romidepsin treatment combined with
MAPK pathway inhibition results in decreased
mitochondrial hexokinase 2, increased mitochondrial
Bim and apoptosis in BRAF mutant cancers. Susan E.
Bates, Victoria Luchenko, Agnes Basseville, Julian Bahr,
Arup R. Chakraborty, Andrew McDonald, Alexandra Zimmer,
Richard L. Piekarz, Robert W. Robey.
12.
5537
Histone deacetylase 11 (HDAC11) regulates B
cell lymphopoiesis and potentiates plasma cell survival
in multiple myeloma. Eva Sahakian, Jason Brayer, John
Powers, Mark Meads, Susan Deng, Allison Distler, Melissa
Alsina, Taiga Nishihori, Rachid Baz, Alejandro Villagra, Javier
Pinilla-Ibarz, Eduardo Sotomayor, Kenneth Shain.
13.
5538
Development of HDACi resistance in DLBCL
leads to a switch in subtype towards a more
differentiated B-cell and is associated with increased
sensitivity to proteasome inhibition. Daphné DupéréRicher, Mena Kinal, Filippa Pettersson, Mona Hassawi, Yang
ShaoNing, Torsten H. Nielsen, Kathleen Klein, Teresa
Ezponda-Itoiz, Jonathan D. Licht, Nathalie Johnson, Sarit E.
Assouline, Leandro Cerchietti, Wilson H. Miller, Koren K.
Mann.
14.
5539
Therapeutic efficacy of novel seleniumcontaining HDACi in acute leukemia. Mansi Sachdev,
Dhimant Desai, Sunil Muthusami, Chandrika Gowda,
Chunhua Song, Shantu G. Amin, Sinisa Dovat.
6.
5531
OTX015, a novel BET inhibitor, is a promising
anticancer agent for multiple myeloma. Maria Todaro,
Michela Boi, Valentina Vurchio, Elisabetta Ercole, Rodolfo
Machiorlatti, Katia Messana, Indira Landra, Susanna Urigu,
Sabrina Aliberti, Eugenia Riveiro, Francesco Bertoni, Giorgio
Inghirami.
15.
5540
Preclinical investigation of the novel histone
deacetylase (HDAC) inhibitor AR-42 in the treatment of
cancer-induced cachexia. Yu-Chou Tseng, Samuel Kulp,
I-Lu Lai, Wei He, Ralf Bundschuh, David Frankhouser,
Pearlly Yan, Denis Guttridge, Guido Marcucci, Ching-Shih
Chen, Tanios Bekaii-Saab.
7.
5532
Discovery of A-366, a novel small molecule
inhibitor that uncovers an unappreciated role for G9a/
GLP in the epigenetics of leukemia. Jun Guo, Marina
Pliushchev, Yupeng He, Debra Ferguson, Sujatha
Jagadeeswaran, Andrew Petros, Chaohong Sun, Niru B.
Soni, Bailin Shaw, Alla Korepanova, David Maag, Ramzi
Sweis, Fritz G. Buchanan, Michael Michaelides, Alex
Shoemaker, Chris Tse, Gary G. Chiang, William N. Pappano.
16.
5541
Proteasome inhibitor synergizes with histone
deacetylase inhibitor to trigger ROS- and ER stressinduced apoptosis of nasopharyngeal carcinoma
independent of aggresome disruption. Alan K. Chiang,
Kwai F. Hui.
17.
5542
Synergistic inhibition of growth of triplenegative breast cancer cells by co-targeting PARP and
HDAC. Helene Marijon, Haibo Sun, Aimery de Gramont,
Sigal Gery, H Phillip Koeffler.
18.
5543
DNA damage response and anti-apoptotic
proteins are predictors of histone deacetylase
inhibitors-mediated radiosensitization of glioblastoma.
Lotte M. Berghauser Pont, Jenneke Kloezeman, Kishan
Naipail, Martin van den Bent, Dik van Gent, Clemens Dirven,
Roland Kanaar, Martine Lamfers, Sieger Leenstra.
8.
9.
5533
RNAi-mediated depletion of histone
deacetylases highlights the potential for isoformspecific inhibitors in B-cell lymphoma and acute
myeloid leukemia. Geoffrey M. Matthews, Leonie Cluse,
Eric Wang, Mareike Roth, Chris Vakoc, Wenyan Miao, James
Rusche, Johannes Zuber, Ricky W. Johnstone.
5534
A novel and oral histone deacetylase inhibitor,
resminostat, effectively suppresses the growth of nonsmall cell lung cancer in a xenograft mouse model.
Akimitsu Takagi, Hiroaki Konishi, Momomi Tsugane, Keisuke
Taniguchi, Hiroyuki Takahashi, Yu Inutake, Akinobu
Watanabe, Hiroshi Kodaira, Takeshi Matsuzaki.
34
34
599
POSTER SESSION
Poster
Section
35
35
Pharmacogenetics and Pharmacogenomics
Poster Abstract
Board Number
1.
5544
Patient-derived xenograft study reveals the
pharmacology and the role of ESR1 gene aberrations in
endocrine therapy resistance of ER positive breast
cancer. Triparna Sen, Shunqiang Li, Jieya Shao, Robert
Crowder, Robert Kitchens, Matthew J. Ellis.
2.
5545
Rare genetic variation association with
neurotoxicity and infection in breast cancer patients
enrolled in PG-SNPS. Ailith Pirie, Jean Abraham, Kyriaki
Michailidou, Jonathan Tyrer, Leila Dorling, Joe Dennis,
Helena Earl, Carlos Caldas, Paul Pharoah.
3.
4.
5547
A genetic variant near KLK3 gene is associated
with aggressive prostate cancer and can stratify
Gleason score 7 patients. Jian Gu, Yonggang He, Sara S.
Strom, Christopher J. Logothetis, Jeri Kim, Xifeng Wu.
5.
5548
Genotype-phenotype discordance of the hepatic
drug metabolism enzyme CYP2C19 in gastrointestinal
cancer patients. Kathryn E. Burns, Wing-Yee Lo, Michael P.
Findlay, George Laking, Nuala A. Helsby.
6.
5549
Recipient-donor contradictory genotype with
impact on anticancer drug pharmacogenetics after liver
transplant: a deadly gift. Cindy Serdjebi, Raphaelle
Fanciullino, Frederic Fina, Arnaud Verschuur, Bertrand
Roquelaure, Bruno Lacarelle, L’Houcine Ouafik, Joseph
Ciccolini, Nicolas André.
7.
8.
9.
10.
11.
600
5546
Impact of DNA repair and apoptosis gene
polymorphisms on clinical outcome in head and neck
cancer patients treated with radiotherapy. MarieChristine Etienne-Grimaldi, Delphine Borchiellini, Laurence
LLorca, Jean-Louis Formento, Patricia Formento, Yann
Château, Gérard Milano.
5550
SNPs in UDP-glucuronosyltransferase1A4
(UGT1A4) and multidrug resistant protein (MRP) and
their influence on anastrozole metabolism and
disposition. Vineetha Koroth Edavana, Rosalind Penney,
Aiwei Yao- Borengasser, Lora Rogers, Ishwori Dhakal,
Suzanne Williams, Susan Kadlubar.
5551
Antitumor activity, gene and miRNA modulation
upon ET-743 treatment in an intrahepatic
cholangiocarcinoma patient-derived xenograft model.
Caterina Peraldo Neia, Giuliana Cavalloni, Giovanna Chiorino,
Paola Ostano, Massimo Aglietta, Francesco Leone.
5552
Extremely high rate of complete hematological
response of elderly Phⴙ acute lymphoblastic leukemia
(ALL) patients by innovative sequential use of Nilotinib
and Imatinib. A GIMEMA Protocol LAL 1408. Giovanni
Martinelli, Cristina Papayannidis, Alfonso Piciocchi, Antonella
Vitale, Ilaria Iacobucci, Simona Soverini, Francesco Di
Raimondo, Stefania Paolini, Massimiliano Bonifacio, Angelo
Michele Carella, Mario Cazzola, Antonio Cuneo, Pietro Leoni,
Mario Luppi, Enrica Morra, Giorgina Specchia, Loredana Elia,
Robin Foà, Michele Baccarani.
5553
Monotherapy efficacy of catalytic and allosteric
inhibitors of AKT in breast cancer models with
AKT1E17K mutations. Barry R. Davies, Nin Guan, Armelle
Logie, Amy Palmer, Vivien Jacobs, Neil James, Emma L.
Jenkins.
5554
Genetic variation in platinating agent and
taxane pathway genes as predictors of outcome and
toxicity in advanced non-small cell lung cancer. Jatinder
K. Lamba, Brooke L. Fridley, Taraswi M. Ghosh, Qing Yu,
Gaurav Mehta, Pankaj Gupta.
Poster Abstract
Board Number
12.
5555
Pharmacogenetics-pharmacokinetics study of
bevacizumab in mCRC patients treated with AvastinFolfiri regimen: search for predictive markers of
response and study of the pharmacokinetics variability.
Anne-Sophie Chantry, Joseph Ciccolini, Camille SibertinBlanc, Laetitia Dahan, Sylviane Olschwang, Jean-François
Seitz, Bruno Lacarelle.
13.
5556
Mice models of three human mesothelioma
histotypes derived from primary patient tumours. Claudio
Pisano, Alison G. Cole, Marcella Barbarino, Erminia
Bianchino, Mario Guglielmi, Carmela Melito, Grazia
Mercadante, Alfonsina Porciello, Assunta Riccio, Ilaria La
Porta, Sara Orecchia, Roberta Libener, Laura Mazzucco,
Simonetta A. Licandro, Pasquale De Luca.
14.
5557
Systematic mapping of drug sensitivity in
hematological malignancies identifies vulnerability of
chronic lymphocytic leukemia with mutant p53. Leopold
Sellner, Malgorzata Oles, Mikolaj Slabicki, Carolin Blume,
Jennifer Hüllein, Tatjana Stolz, Marina Lukas, Martin Sill,
Christopher C. Oakes, Sascha Dietrich, Olaf Merkel, Anna
Jauch, Manfred Hensel, Davide Rossi, Katja Zirlik, Jan
Dürig, Ingo Ringshausen, Marco Herling, Martina Seiffert,
Peter Dreger, Christof von Kalle, Anthony D. Ho, Hanno
Glimm, Wolfgang Huber, Thorsten Zenz.
15.
5558
Potential use of pharmacogenomic modeling for
patient stratification in the Phase II trial of PM01183 in
pancreatic cancer. Manuel Hidalgo, Mark Ricigliano,
Brandon Cooper, Miguel Aracil Avilla, Carlos Galmarini.
16.
5559
Reciprocal expression of miR-125b and miR192/miR-200 families define clinically relevant subtypes of colorectal cancer with differential sensitivity to
EGFR and MEK targeted agents. Christine M. Chresta,
Andreas Schlicker, Garry Beran, Georgia Cerillo, Lodewyk F.
Wessels, George Orphanides.
17.
5560
A high-throughput cellular genetics approach to
identifying genes associated with sorafenib response
and toxicity. Daniel J. Crona, Oscar Suzuki, O. Joseph
Trask, Amber Frick, Bethany Parks, Tim Wiltshire, Federico
Innocenti.
18.
5561
Clinical drug response can be predicted using
baseline gene expression levels and in vitro drug
sensitivity in cell lines. Paul Geeleher, Nancy Cox, R.
Stephanie Huang.
19.
5562
Screening of in vitro cytotoxicity of nucleoside
analogs in HapMap cell lines to identify predictive
markers of drug sensitivity. Taraswi Mitra Ghosh, Tanya
J. Feldberg, Neha Bhise, Jatinder K. Lamba.
20.
5563
Docetaxel-induced mucositis in breast cancer
patients: Association with plasma alpha-1-acid
glycoprotein level and SLCO1B3 genotype. Rafid S. Jabir,
Gwo F. HO, Muhammad Azrif A. Anuar, Johnson Stanslas.
21.
5564
Dual inhibition of TTK and HSPA9 functions to
synergistically decrease viability in triple-negative
breast cancer cell lines. Nicole A. Lavender, Donald Chow,
Holly Yin, John Carpten.
22.
5565
In vitro pharmacogenomic study of ovarian
cancer finds novel genetic variants associated with
response to platinum and taxane therapies. Brooke L.
Fridley, Taraswi M. Ghosh, Alice Wang, Ellen L. Goode,
Jatinder Lamba.
POSTER SESSION
Clinical Research 16
Clinical Endocrinology
Poster
Section
Poster Abstract
Board Number
1.
2.
5566
Functional new insights into the regulation of
the androgen receptor by PMEPA1/NEDD4 –1 in prostate
cancer. Hua Li, Shashwat Sharad, Lakshmi Ravindranath,
Michael Haffner, Daniel Heidenberg, Srinivasan
Yegnasubramanian, Yongmei Chen, Ahmed Mohamed,
Alagarsamy Srinivasan, Gyorgy Petrovics, Shiv Srivastava.
5567
Impact of progesterone receptor (PR) isotypespecific immunohistochemistry (IHC) on the diagnosis of
triple negative breast cancer (BC). Erard Gilles, Jacques
Bosq, Laura Caplier, Alice Bexon, Alexander Zukiwski,
Jacques Bonneterre.
3.
5568
CYP17A1 and abiraterone: Implications for
breast cancer endocrine therapy. Cameron P. Capper,
Michael D. Johnson, José M. Larios, James M. Rae.
4.
5569
Ki67 is an independent prognostic marker in
breast cancer even after accounting for molecular
subtype. Abeer M. Mahmoud, Virgilia Macias, Umaima Alalem, Jacob K. Kresovich, Galina Khramtsova, Andre
Kajdacsy-Balla, Elizabeth L. Wiley, Garth H. Rauscher.
5.
5570
Laminin-5 gamma-2 (LAMC2) is highly
expressed in anaplastic thyroid carcinoma and is
associated with tumor progression, migration and
invasion by modulating signaling of EGFR. Manoj Garg,
Deepika Kanojia, Ryoko Okamoto, Vikas Madan, Wenwen
Chien, Abhishek Sampath, Ling-Wen Ding, Meng Xuan,
Jonathan W Said, Ngan Doan, Li-Zhen Liu, Henry Yang,
Sigal Gery, Gleen D Braunstein, H.Phillip Koeffler.
6.
5571
Genome-wide crosstalk of estrogen and
progesterone signaling in breast cancer. Hari Singhal,
Geoffrey Greene.
7.
5572
Auto-analysis of immunohistochemical findings
and one-day instant quality fluorescence in situ
hybridization increase quality of breast cancer therapy.
Daiki Taniyama.
Poster Abstract
Board Number
8.
5573
p62/IMP2 promotes breast cancer cell
progression. Yang Li, Bo Peng, Jing Ning, Wei Qian, Gulio
Francia, Jianying Zhang.
9.
5574
Gli2 protein and the AR operational switch to
the castration resistant prostate cancer transcription
program. Na Li, Ralph Buttyan, Sarah Truong, Yue Yu,
Mengqian Chen.
10.
5575
Effects of continuous combined oral
contraceptives on mouse mammary gland structure and
tumor progression. Evelyn Esteves, Sherin David, Dawn
Bowers, Brian MacQueen, Melanie Ruszczyk, Dhruv
Chachad, Rajani Marthappa Shenoy, Patricia A. MassoWelch.
11.
5576
Tamoxifen fails to induce regression of
mammary preneoplasia in mice lacking either one or
two intact Brca1 genes in combination with p53
haploinsufficiency but without evidence of in vivo
agonist activity. Sahar J. Alothman, Weisheng Wang,
Priscilla A. Furth.
12.
5577
ERG enhances prostate cancer growth by
upregulating neurotransmitter receptors. Seungtae On.
13.
5578
Breast cancer cell growth regulatory
mechanisms of tamoxifen metabolites. T. Thomas,
Huichen Hsu, PingAr Yang, Mervi T. Hyvonen, Tuomo A.
Keinanen.
15.
5580
TGF-␤1 enhanced cell migration involving
pluripotent transcription factor OCT4 in endometriosis.
Te-Sheng Chang, Heng-Kien Au, Thai-Yen Ling, Ching-Chi
Chi, Chii-Ruey Tzeng, Jui-Hung Chang, Yen-Hua Huang.
36
36
601
POSTER SESSION
Clinical Research 17
Poster
Section
37
37
Novel Molecular Classifiers and Markers of Cancer
Poster Abstract
Board Number
1.
2.
3.
4.
5.
7.
8.
9.
10.
11.
12.
13.
14.
15.
602
5581 Advanced glycation end-products are increased in prostate
cancer and may promote racial disparity. Katherine R. Walter, Dion
Foster, Victoria Findlay, Lourdes Nogueira, Sadia Robinson, Emily KistnerGriffin, Laura Spruill, Ryan Kelly, Mahtabuddin Ahmed, Judith Salley,
Marvella Ford, David Turner.
5582 A targeted molecular classifier of MYC activity and BCL-2
expression in aggressive B-cell lymphomas, designed for clinical
practice. Christopher D. Carey, Daniel Gusenleitner, Bjoern Chapuy,
Heather Sun, Azra Ligon, Alexandra E. Kovach, Long P. Le, Aliyah R.
Sohani, Margaret Shipp, Stefano Monti, Scott J. Rodig.
5583 Integrative genomic analyses on pediatric acute myeloid
leukemia. Daniel H. Wai, Rhonda E. Ries, Michael Considine, David W.
Lee, Sun-Mei Liu, Nicole M. O’Connor, Oliver Pepper, Ranjan Bista, Eiman
Aleem, David O. Azorsa, Tanja M. Davidsen, Toni Farley, Jaime GuidryAuvil, Jason E. Farrar, Malcolm A. Smith, Daniela S. Gerhard, MIchael F.
Ochs, Spyro Mousses, Soheil Meshinchi, Robert J. Arceci.
5584 BRAF mutation testing in cell-free DNA from plasma of
patients with advanced cancers using a novel, rapid, automated
molecular diagnostics prototype platform (IdyllaTM). Helen J. Huang,
Bart Claes, Gerald S. Falchook, Veronica R. Holley, Aung Naing, Sarina A.
Piha-Paul, Apostolia M. Tsimberidou, Ralph G. Zinner, Daniel D. Karp,
Siqing Fu, Vivek Subbiah, David S. Hong, Jennifer J. Wheler, Vanda M.
Stepanek, Goran Cabrilo, Rajyalakshmi Luthra, Agop Y. Bedikian, Bryan K.
Kee, Cathy Eng, Michael J. Overman, Kevin B. Kim, Tania Ivens, Erwin
Sablon, Geert Maertens, Razelle Kurzrock, Funda Meric-Bernstam, Filip
Janku.
5585 Integrated DNA/RNA sequencing for discovery and
orthogonal validation of expressed fusion genes in peripheral T-cell
lymphomas. Andrew L. Feldman, George Vasmatzis, Yan W. Asmann,
Sarah H. Johnson, Bruce W. Eckloff, Sumit Middha, Jaime I. Davila, Paul
J. Kurtin, Brian K. Link, Stephen M. Ansell, James R. Cerhan.
5587 Serial monitoring of EGFR mutations in plasma and
evaluation of EGFR mutation status in matched tissue and plasma
from NSCLC patients treated with CO-1686. Rafal Dziadziuszko, Chris
Karlovich, Wei Wen, Jong-Mu Sun, Sean Chien, Elaina Mann, Patrick
O’Donnell, Philipp Angenendt, Heather Wakelee, Leora Horn, David Spigel,
Lecia Sequist, Jean-Charles Soria, Benjamin Solomon, D. Ross Camidge,
Jonathan Goldman, Shirish Gadgeel, Mitch Raponi, Andrew Allen, Lin Wu,
Keunchil Park.
5588 Epithelial-to-mesenchymal markers of circulating tumor
cells for detection of castration-resistant prostate cancer. Chun-Liang
Chen, Pawel Osmulski, Devalingam Mahalingam, Aaron M. Horning, Rohit
R. Jadhav, Anna D. Louie, Chiou-Miin Wang, Tim H. Huang.
5589 Molecular diagnostic, prognostic and therapeutic role of
mir-221 in pancreatic cancer. Seema Sethi, Shaan Sarkar, Hala
Dubaybo, Shadan Ali, Priscila Goncalves, Spilakshmi Kollepara, Philip
Philip, Yiwei Li.
5590 Molecular characterization of pancreatic tumors arising in
the background of germline BRCA mutations. Susan Hsiao, Anne
Koehne de Gonzalez, Mahesh M. Mansukhani, Robert L. Fine, Helen E.
Remotti.
5591 Simultaneous isolation and quantification of circulating
exosomes for cancer biomarker discovery. Shailender S. Kanwar,
Christopher J. Dunlay, Diane M. Simeone, Sunitha Nagrath.
5592 Molecular classification of triple negative breast cancer via
RNA-sequencing data. Kevin J. Thompson, Xiaojia Tang, Zhifu Sun,
Jason P. Sinnwell, Hugues Sicotte, Douglas W. Mahoney, Steven Hart,
Peter T. Vedell, Poulami Barman, Jeanette E. Eckel Passow, Eric D.
Wieben, James N. Ingle, Judy C. Boughey, Liewei Wang, Richard
Weinshilboum, Krishna R. Kalari, Matthew P. Goetz.
5593 Transcriptome and pathway analysis identifies IRF1 as a
predictor of progression free and overall survival in ovarian
carcinoma. John A. Martignetti, Samantha Cohen, Rebecca Mosig,
Richard Halpert, Jean-Noel Billaud, Peter Dottino.
5594 Cyclin D1 expression correlates with supratentorial
location of ependymomas. Fernanda G. Andrade, Suely K. Marie,
Hamilton Matushita, Sergio Rosemberg, Sueli M. Oba-Shinjo.
5595 Impact of p53 impaired function on outcomes of multiple
myeloma patients carrying deleted TP53 and/or amplified MDM4.
Carolina Terragna, Marina Martello, Enrica Borsi, Lucia Pantani, Elena
Zamagni, Paola Tacchetti, Annamaria Brioli, Beatrice Anna Zannetti,
Flores Dico, Nicoletta Testoni, Giulia Marzocchi, Katia Mancuso, Serena
Rocchi, Giovanni Martinelli, Michele Cavo.
Poster Abstract
Board Number
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
5596 Identification of relapse prediction marker for advanced
gastric cancer using reverse-phase protein arrays. Satoshi S.
Nishizuka, Fumitaka Endo, Kazushige Ishida, Hirokatsu Katagiri, Kei
Sato, Kohei Kume, Kaoru Ishida, Takeshi Iwaya, Keisuke Koeda, Go
Wakabayashi.
5597 Targeted massively parallel sequencing for the diagnosis
of hereditary neuroendocrine disorders. Trish Dwight, Anne Louise
Richardson, Ying Zhu, Bruce G. Robinson, Diana E. Benn, Roderick
J. Clifton-Bligh.
5598 Correlating molecular and histopathologic tumor purity:
an analysis of 816 patients. Heejoon Jo, Nirali M. Patel, Karen E.
Weck, David A. Eberhard, D. Neil Hayes, Joel S. Parker, Michele
Hayward, Ashley Salazar, Juneko E. Grilley-Olson.
5599 Serum biomarkers reflecting specific tumor tissue
remodeling is a valuable diagnostic tool for lung cancer. Nicholas
Willumsen, Cecilie L. Bager, Diana J. Leeming, Victoria Smith, Claus
Christiansen, Morten A. Karsdal, David Dornan, Anne-Christine BayJensen.
5600 Wntless (GPR177) regulates WNT/NF-кB signaling in
leukemia cells, and its expression correlates with poor prognosis
in B-cell precursor acute lymphoblastic leukemia. Shih-Hsien Hsu,
Li-Ting Wang, Shih-Bo Huang, Shyh-Shin Chiou.
5601 Identification of critical steps involved in optimization of
next generation sequencing (NGS) using a retrospective metaanalysis of a large clinical testing cohort. Danielle A. Murphy,
Christopher Scott, Kerry Fitzgerald, Maya Panjikaran, Yu Xia, Armin
Graber, Julie Kines, Adam Baer, Matthew McGinniss, Jason
Christiansen.
5602 BRAF V600 mutated allelic specific imbalance (MASI)
impact on sensitivity to vemurafenib. Amelie Boespflug, Luc Thomas,
Pascal Rousset, Charles Dumontet, Julie Caramel, Carole FerraroPeyret, Pierre Paul Bringuier, Brigitte Balme, Stephane Dalle.
5603 Aryl hydrocarbon receptor, a receptor for environmental
pollutants, promotes tumorigenesis via intestine-specific
homeobox expression in hepatocellular carcinoma. Li-Ting Wang,
Shen-Nien Wang, Shih-Hsien Hsu.
5604 PD-L1 expression identifies a subpopulation of
melanoma cells characterized by enhanced invasiveness and
aggressiveness. Davide Brusa, Daniela Massi, Barbara Merelli, Michela
Ciano, Valentina Audrito, Sara Serra, Gianna Baroni, Romina Nassini,
Daiana Minocci, Laura Cattaneo, Alessandra Carobbio, Silvia Deaglio,
Mario Mandala.
5605 Spectral karyotyping characterization of ovarian
adenocarcinomas and corresponding cell lines and xenografts.
Marileila Varella-Garcia, Isabel M. Bernal, Sakshi Mahale, Evelyn M.
Musselwhite, Victor Stastny, Mahboubeh Papari-Zareei, Jayanthi Lea,
Tito Woodburn, Patrick Reynolds, Adi F. Gazdar.
5606 Detection of circulating tumor DNA in early and late
stage human malignancies. Chetan Bettegowda, Mark Sausen,
Rebecca Leary, Isaac Kinde, Nishant Agrawal, Bjarne Bartlett, Hao
Wang, Brandon Luber, Kenneth Kinzler, Bert Vogelstein, Nickolas
Papadopoulos, Luis Diaz.
5607 BRAF and KRAS mutation testing in plasma cell-free
DNA with ICE COLD-PCR in patients with advanced cancers. Filip
Janku, Ben Legendre, Katherine Richardson, Gerald S. Falchook, Aung
Naing, Veronica R. Holley, Siqing Fu, David S. Hong, Sarina A. PihaPaul, Jennifer J. Wheler, Ralph G. Zinner, Vivek Subbiah, Apostolia M.
Tsimberidou, Daniel D. Karp, Vanda M. Stepanek, Goran Cabrilo,
Rajyalakshmi Luthra, Funda Meric-Bernstam, Agop Y. Bedikian, Bryan
K. Kee, Cathy Eng, Michael J. Overman, Kevin B. Kim, Amy Kruempel,
Jaclyn Pope, Courtney Cubrich, Grant Wu, Marcia Lewis, Razelle
Kurzrock.
5608 Molecular characterization of matched ovarian ascites
and tumors suggests multiple mechanisms for a homologous
recombination defective phenotype. Richard J. Edmondson, Asima
Mukhopadhyay, Leander Van Neste, Wim Van Criekinge, Nicola Curtin.
5609 Next generation sequencing in acute myeloid leukemia:
Correlation with cytogenetic studies highlighting different
spectrums of mutations. Robert B. Daber, Jianhua Zhao, Martin
Carroll, Craig Solderquest, Selina Luger, Gerald B. Wertheim, Adam
Bagg, Jennifer J. Morrissette.
5610 Circulating tumor DNA: FOXL2 402C->G mutation can be
identified in plasma from adult granulosa cell tumor patients with
recurrent disease. Melissa K. McConechy, Anniina Farkkila, Winnie
Yang, Noora Andersson, Ying Ng, Leila Unkila-Kallio, Jessica N.
McAlpine, Blake Gilks, Mikko Anttonen, David G. Huntsman.
POSTER SESSION
This session wil linclude clinical trials submitted at the Late-Breaking Abstract deadline. The full text of all abstracts
in this session will be available online through www.aacr.org and in the print Proceedings, Part 2 distributed to
registrants.
38
Clinical Trials
Early Phase Clinical Trials 2
38
Poster Abstract
Board Number
1.
CT401
NUC-1031: A novel ProTide that overcomes the
key cancer resistance mechanisms associated with
poor survival. Essam A. Ghazaly, Magdalena Slusarczyk,
Malcolm Mason, John Gribben, Christopher McGuigan,
Sarah Blagden.
2.
CT402
A phase I study of inotuzumab ozogamicin
(IO) in combination with temsirolimus (T) in patients
(pts) with relapsed or refractory (R/R) CD22-positive
(pos) B-cell non-Hodgkin lymphomas (NHL). Anastasios
Stathis, Felicitas Hitz, Urban Novak, Francesco Bertoni,
Tatiana Terrot, Laura Moser, Ioanna Xenidou, Luca
Mazzucchelli, Michele Ghielmini, Cristiana Sessa, Emanuele
Zucca, Franco Cavalli.
3.
CT403
A Phase I study of oral administration of
mTOR inhibitor everolimus (E) in association with
cisplatin (C) and radiotherapy (R) for the treatment of
locally advanced cervix cancer (LACC) - PHOENIX I.
Carlos Gil Ferreira, Flávia V. Guerra Alves, Rachele
Grazziotin, Felipe Erlich, Giulliana Moralez, Michel P.
Carneiro, Mariane Fontes Dias, Andréia C. de Melo.
4.
CT404
Phase I/II study of VAL-083 in patients with
recurrent glioblastoma multiforme. Kent C. Shih, Manish
R. Patel, Jeffrey Bacha, Dennis M. Brown, William J. Garner,
Anne Steino, Richard S. Schwartz, Sarath Kanekal, Mike Li,
Lorena M. Lopez, Howard A. Burris.
5.
CT405
A phase 1 study of neoadjuvant chemotherapy
with gemcitabine plus nab-paclitaxel, followed by
concurrent chemoradiation with gemcitabine, sorafenib,
and vorinostat in locally advanced pancreatic cancer.
Haeseong Park, Andrew Poklepovic.
6.
7.
CT406
Aerosol interleukin-2 for the treatment of
patients > 12 years old with osteosarcoma lung
disease: A phase I/II study. Nancy B. Gordon, Najat Daw
Bitar, Peter Anderson, Sergei Guma, Hsuan-Chu Chien,
Lacey M. McQuinn, Joshua P. Hein, Ralph Zinner, Eugenie
S. Kleinerman, Aung Naing.
CT407
Phase I study of preoperative continuous 5-fu
and sorafenib with external radiation therapy in locally
advanced rectal adenocarcinoma. Richard Kim, Kun
Jiang, Xiuhua Zhao, Dung-Tsa Chen, Tiffany Campos, Sara
Hoffe, Ravi Shridhar, David Shibata.
Poster
Section
Poster Abstract
Board Number
8.
CT408
Phase I study of one mixed chelates copper(II)
compound, Casiopeína CasIIIia with antitumor activity
and its mechanism of action. Lena Ruiz-Azuara, Gerard
Bastian, Maria Elena Bravo-Gómez, Roberto Carlos Cañas,
Marcos Flores-Alamo, Ines Fuentes, Carmen Mejia, Juan
Carlos García-Ramos, Alberto Serrano.
9.
CT409
Dexamethasone (dex) and asparaginase
increase triglycerides during acute lymphoblastic
leukemia (ALL) therapy in children. Laura B. Ramsey,
Katherine M. Robinson, Jitesh D. Kawedia, Wenjian Yang,
Chengcheng Liu, John C. Panetta, Sima Jeha, Deepa
Bhojwani, Monika L. Metzger, Cheng Cheng, William E.
Evans, Ching-Hon Pui, Mary V. Relling.
10.
CT410
Immune activation, clinical response and
survival following long-term infusion of anti-GD2
antibody ch14.18/CHO in combination with interleukin-2
in high-risk neuroblastoma patients. Holger Lode,
Christian Jensen, Nikolai Siebert, Silke Kietz, Karoline Ehlert,
Ina Müller, Ruth Ladenstein, Evelyne Janzek, Hans Loibner.
11.
CT411
Immune profiling of patients vaccinated with
the survivin targeted therapeutic vaccine DPX-Survivac
demonstrates durable polyfunctional CD4ⴙ and CD8ⴙ T
cells in ovarian cancer patients. Yoav Peretz, Dominike
Sauvé, Dominic Gagnon, Salim Ahmed Khan, Geneviève
Lévesque, Nathalie Saha, Gilbert Croteau, Valérie Hébert,
Karyne Savard, Bader Yassine Diab, Jean-Francois Poulin,
Claire Landry, Mohan Karkada, Marc Mansour.
12.
CT412
Phase I study of intraveneous docetaxel and
intraperitoneal oxaliplatin in recurrent ovarian, fallopian
tube and peritoneal cancer. Sarah E. Taylor, Ruosha Li,
Jennifer S. Petschauer, Heidi Donovan, William C. Zamboni,
Robert P. Edwards, Kristen K. Zorn.
13.
CT413
Lutetium-177-labeled anti-prostate-specific
membrane antigen (PSMA) monoclonal antibody J591
(177Lu-J591) for metastatic non-prostate solid tumors.
Orrin Pail, Gurveen Kaur, Jonathan Dyke, Yuliya Jhanwar,
Paul Christos, Allyson Ocean, Manish Shah, Tsiporah Shore,
Bryan Schneider, Ronald Scheff, Himisha Beltran, Douglas
Ballon, Brian Robinson, David M. Nanus, Neil H. Bander,
Scott T. Tagawa.
603
LATE-BREAKING POSTER SESSIONS
Wednesday, 8:00 a.m.-12:00 p.m.
Hall A-E, San Diego Convention Center
Abstracts will be available online and in the Proceedings Part 2 beginning Friday, April 4.
Poster Section 40
Late-Breaking Research: Epidemiology
Poster Section 42
Late-Breaking Research: Molecular and Cellular Biology 3
604
AACR-CRI AWARD LECTURE
Ballroom 20A-D, San Diego Convention Center
Second Annual AACR-CRI Lloyd J. Old Award in Cancer Immunology
Cancer Immunoediting: Applying Mechanistic Insights to
Cancer Immunotherapy
Robert D. Schreiber, PhD
Professor, Department of Pathology and Immunology
Washington University School of Medicine, St. Louis, MO
The AACR-CRI Lloyd J. Old Award in Cancer
Immunology was established in honor of the late
Lloyd J. Old, MD, who is considered the “Founding
Father of Modern Tumor Immunology.” Dr. Old’s
outstanding research in the field of cancer immunology,
as well as his decades of leadership in fostering the field,
has had a far-reaching impact on cancer. The award is
intended to recognize an active cancer immunologist
who, like Old, has done outstanding and innovative
research in cancer immunology that has had a farreaching impact on the field.
Dr. Robert D. Schreiber is being recognized for his
pioneering contributions to the field of cancer
immunology, which have helped establish a clearer
understanding of the immune system’s role in tumor
progression. His important discoveries include the
identification of IFNγ as a key cytokine in antitumor
immunity and the development of the cancer
immunoediting concept, which integrates the host
protective and tumor-promoting functions of the immune
system and provides a framework for the design of
cancer immunotherapies.
Recently, Dr. Schreiber pioneered the use of genomics
approaches to define the molecular mechanisms
underlying cancer immunoediting. He used nextgeneration sequencing and epitope prediction
algorithms to identify an immunodominant peptide
derived from a mutant intracellular protein and showed
that it was the antigen for CD8 T cells that controlled the
growth of a fibrosarcoma. As the tumor evolved in the
presence of the immune system, tumor cell variants
emerged that did not express the mutant protein
allowing the tumor to escape immunological recognition
and destruction. This was a telling example of cancer
immunoediting. The take-home message is that Dr.
Schreiber’s approach of using a combination of
genomics and T cell biology can identify tumor-specific
mutational antigens that have the potential for use as
highly specific targets for cancer immunotherapies.
Dr. Schreiber’s work has led to a generalized
appreciation of the profound effect of immunity on
developing tumors and has contributed critical
conceptual and practical support to the fields of tumor
immunology and cancer immunotherapy.
In addition to his academic positions at Washington
University, Dr. Schreiber is also an Affiliate of the Ludwig
Institute for Cancer Research; an Associate Director of
the Scientific Advisory Board to the Cancer Research
Institute; a co-founder of Igenica, a biotech company
focused on producing new monoclonal antibody-based
cancer therapeutics and a senior advisor of Jounce, a
biotech company focused on developing
immunomodulatory cancer therapeutics.
Dr. Schreiber is a member of the National Academy of
Sciences and the American Academy of Arts and
Sciences, and a past member of the board of scientific
advisors at the National Cancer Institute. Other
accolades include election in 1996 as a fellow of the
American Association for the Advancement of Science,
the 2001 William B. Coley Award from CRI, and
the 2007 Charles Rodolphe Brupbacher Prize for
Cancer Research.
Dr. Schreiber received his doctorate from the State
University of New York at Buffalo and completed his
postdoctoral training at the Scripps Institute in La Jolla,
Calif., where he served on the faculty before joining
Washington University.
605
CURRENT CONCEPTS IN DIAGNOSTICS
AND THERAPEUTICS RESEARCH
Quantitative Models of Tumor Heterogeneity: From Clonal Diversity
to Epigenetic Drift to the Microenvironment
Chairperson: Joe W. Gray, OHSU Knight Cancer Institute, Portland, OR
It is now clear that human cancers display variable levels of inter- and intraheterogeneity that
influence clinical behavior and therapeutic response. Drivers of heterogeneity can include intrinsic
genomic, epigenomic aberrations and extrinsic chemical, mechanical, and biological signals. This
symposium will focus on specific classes of heterogeneity drivers and on the impact of
heterogeneity on cellular behavior and therapeutic response. Both inter- and intratumor
heterogeneity will be discussed.
11:00 a.m.
Introduction
Joe W. Gray, OHSU Knight Cancer Institute, Portland, OR
11:05 a.m.
Tumor intrinsic and extrinsic drivers of differentiation state and therapeutic
response
Rosalie C. Sears, Oregon Health and Science University, Portland, OR
11:25 a.m.
Discussion
11:30 a.m.
The role of distinct chromatin states in the heterogeneous response to
anticancer drugs
Jeffrey E. Settleman, Genentech, Inc., South San Francisco, CA
11:50 a.m.
Discussion
11:55 a.m.
Using oncogenic signatures classes to design combinatorial therapy
Chris Sander, Memorial Sloan-Kettering Cancer Center, New York, NY
12:15 p.m.
Discussion
12:20 p.m.
Single-cell heterogeneity of targeted therapy response quantified with a novel
metric, Drug-Induced Proliferation (DIP) rate
Vito Quaranta, Vanderbilt-Ingram Cancer Center, Nashville, TN
12:40 p.m.
Discussion
12:45 p.m.
Panel Discussion
606
CURRENT CONCEPTS IN EPIDEMIOLOGY
AND PREVENTION RESEARCH
Genomics and Cancer Health Disparities
Chairperson: Timothy R. Rebbeck, University of Pennsylvania School of Medicine,
Philadelphia, PA
There are significant disparities in cancer incidence and mortality across racial groups. These
disparities are in part attributable to behavior, socioeconomic status, and access to care.
Disparities are also evident in preneoplastic lesions and early tumors, as well as in tumor
characteristics. Thus, it is likely that disparities involve both biological aggressiveness and late
detection. Few exposures or environmental factors have been consistently associated with CaP
etiology, but many CaP genetic susceptibility loci have been identified. This session will discuss
the pressing need to elucidate the genomic etiology of cancer and disparities in the context of
other relevant determinants of cancer disparities.
11:00 a.m.
Title to be announced
Vivian Ota Wang, National Institutes of Health, Rockville, MD
11:20 a.m.
Discussion
11:25 a.m.
Leveraging population genetics to understand cancer susceptibility
Elad Ziv, University of California,
San Francisco, CA
11:45 a.m.
Discussion
11:50 a.m.
Racial disparities and genetics of prostate cancer
Michael B. Cook, National Cancer Institute, Rockville, MD
12:10 p.m.
Discussion
12:15 p.m.
Multilevel genomic models of cancer disparities
Timothy R. Rebbeck, University of Pennsylvania School of Medicine,
Philadelphia, PA
12:35 p.m.
Discussion
12:40 p.m.
Panel Discussion
607
CURRENT CONCEPTS IN EPIDEMIOLOGY
AND PREVENTION RESEARCH
Leveraging Electronic Medical Records for Cancer Research
Chairperson: Lawrence H. Kushi, Kaiser Permanente, Oakland, CA
The increasingly widespread adoption of electronic medical records in recent years presents both
unparalleled opportunities and major challenges in harnessing this information to conduct
population sciences research in cancer and other diseases. This session will highlight the
experiences of two different settings – Department of Defense medical facilities and the integrated
health care delivery settings of HMOs – in which cancer research that incorporates data from
electronic medical records and other clinical and administrative databases have been conducted
for a number of years. In addition, the session will highlight two key aspects of conducting cancer
research that rely at least in part on electronic medical records. The first of these is the increasing
clinical importance of molecular and genetic information, with the promises and challenges of
harnessing these data to be able to understand genome-phenome relationships and the use of
personalized or precision medicine. The second addresses the challenges of using electronic data
that have been collected for clinical and not research purposes, and statistical methods and
approaches for addressing these challenges. With an understanding of the pitfalls of their use,
electronic medical records and their increasing availability present outstanding opportunities to
improve our knowledge about cancer risk and clinical cancer care in large populations in ways that
were not previously possible.
11:00 a.m.
Introduction
Lawrence H. Kushi, Kaiser Permanente, Oakland, CA
11:05 a.m.
Tumor data abstraction using electronic medical records in the DOD
Jennifer Cullen, Center for Prostate Disease Research, Rockville, MD
11:25 a.m.
Discussion
11:30 a.m.
Opportunities and limitations in precision cancer care research utilizing
electronic health records
Richard B. Schwab, UCSD Moores Cancer Center, La Jolla, CA
11:50 a.m.
Discussion
11:55 a.m.
Statistical challenges and opportunities in the analysis of data from electronic
medical records
Rebecca Hubbard, University of Washington, Seattle, WA
12:15 p.m.
Discussion
12:20 p.m.
EMR-based data resource development for collaborative cancer research:
The HMO Cancer Research Network experience
Lawrence H. Kushi, Kaiser Permanente, Oakland, CA
12:40 p.m.
Panel Discussion
608
CURRENT CONCEPTS IN
ORGAN SITE RESEARCH
Melanoma Therapeutic Targeting and
Drug Resistance
New Horizons in Sarcoma Research
Chairperson: Roger S. Lo, University of California, Los
Angeles, CA
Basic and translational research in melanoma has
ushered this cancer into the combinatorial therapeutic
era. About half of advanced melanomas are addicted to
mutant BRAF, and the advent of BRAF inhibitors in the
clinical arena has crystallized an intense effort to
understand therapeutic resistance. This session will
focus on the genetic and nongenetic mechanisms of
resistance to signaling/oncogene-targeted therapies in
melanoma and their implications for designing nextgeneration therapeutics.
11:00 a.m.
Melanoma evolution during MAPK
pathway-targeted therapy
Roger S. Lo, University of California,
Los Angeles, CA
11:20 a.m.
Discussion
11:25 a.m.
Intersection of PI3K-AKT pathway
signaling, cellular metabolism, and
therapeutic resistance in melanoma
Michael A. Davies, The University of Texas
MD Anderson Cancer Center, Houston, TX
11:45 a.m.
Discussion
11:50 a.m.
Basic biology and clinical implications of
NRAS and BRAF signaling in melanoma
Richard M. Marais, Paterson Institute for
Cancer Research, Manchester, United
Kingdom
12:10 p.m.
Discussion
12:15 p.m.
Resistance to anti-BRAF and anti-MEK
agents: Lost in translation?
Caroline Robert, Institut Gustave Roussy,
Villejuif Paris-Sud, France
12:35 p.m.
Discussion
12:40 p.m.
Panel Discussion
Chairperson: Lee J. Helman, National Cancer Institute,
Bethesda, MD
Sarcomas encompass a large number of distinct tumor
entities that can arise virtually in any area of the body
and encompasses both adult and pediatric populations.
Many of these tumors are driven by a disease-defining
translocation leading to mutant transcription factors that
have proven difficult to target. Furthermore, most
patients ultimately die of disseminated disease and little
progress has been made in developing effective
therapeutics for metastatic disease. During this session,
new research data will be presented discussing the role
of hypoxia in metastatic behavior of undifferentiated
pleomorphic sarcomas, the identification of novel drivers
of metastases in high-risk pediatric sarcomas,
development of targeted combination therapies for
pediatric sarcomas, and mechanistic studies on the role
of the t(x;18) translocation in synovial sarcomas.
11:00 a.m.
Development of novel combination
targeted therapies for pediatric
sarcomas
Lee J. Helman, National Cancer Institute,
Bethesda, MD
11:20 a.m.
Discussion
11:25 a.m.
Searching for novel drivers of metastatic
disease in high-risk childhood sarcomas
Poul H.B. Sorensen, University of British
Columbia, Vancouver, BC, Canada
11:45 a.m.
Discussion
11:50 a.m.
Hypoxia, metastasis, and
undifferentiated pleomorphic sarcoma
M. Celeste Simon, Abramson Family
Cancer Research Institute, Philadelphia, PA
12:10 p.m.
Discussion
12:15 p.m.
Chromatin regulation in synovial
sarcoma: Novel mechanisms and
therapeutic implications
Cigall Kadoch, UCSF Comprehensive
Cancer Center, San Francisco, CA
12:35 p.m.
Discussion
12:40 p.m.
Panel Discussion
609
MAJOR SYMPOSIA
Room 6CF, San Diego Convention Center
Chemical Genetics and Biology
Discovery and Clinical Application of
Germline Sequencing for Cancer Risk in
the GAME-ON Consortia
Chairperson: Nathanael Gray, Dana-Farber Cancer
Institute, Boston, MA
This session will describe recent work using the tools of
chemical biology to identify and validate new potential
anticancer targets and to develop “proof-of-concept”
inhibitors. Nathanael Gray will describe new approaches
to target “pseudo kinases” such as Her3 and how to
develop covalent inhibitors of the nucleotide pocket of
G12C K-RAS. John Tallarico will describe the use of
chemoproteomics to identify and validate new targets.
Ben Cravatt will describe how chemo proteomics can be
used to map signaling pathways in tumor cells and how
they respond to drug treatment. Kevan Shokat will
describe a novel allosteric binding pocket in KRAS that
can be targeted using covalent inhibitors.
11:00 a.m.
Introduction
11:10 a.m.
New approaches to old targets: HER3
and KRAS
Nathanael Gray, Dana-Farber Cancer
Institute, Boston, MA
11:30 a.m.
Discussion
11:35 a.m.
Chemical genetics on the frontline of
drug target discovery: Pathways,
targets, and technology
John Tallarico, Novartis Institutes For
BioMedical Research, Cambridge, MA
Chairperson: David J. Hunter, Harvard School of Public
Health, Boston, MA
Hundreds of inherited variants have been discovered
that are statistically significantly associated with risk of
specific cancer sites. What do they mean and what have
we learned through these discoveries? Speakers in this
session will address the methods for these studies, the
number of variants yet to be discovered, the implications
for mechanisms, risk prediction, and gene-environment
interactions. What are the next steps in finding more risk
variants, and explaining a higher proportion of estimated
inherited risk? What is the role of next-gen sequencing
versus large-scale SNP array analyses? Cancers
discussed include breast, prostate, ovary, and
colorectal cancer.
11:00 a.m.
Introduction
11:10 a.m.
Genetic variation and breast cancer risk
David J. Hunter, Harvard School of Public
Health, Boston, MA
11:30 a.m.
Discussion
11:35 a.m.
Genetic predisposition to prostate
cancer (PrCa) and its clinical application
Rosalind A. Eeles, Institute of Cancer
Research, Sutton, United Kingdom
11:55 a.m.
Discussion
11:55 a.m.
Discussion
12:00 p.m.
Chemo proteomic mapping of signaling
pathways and drug action in cancer
cells
Benjamin F. Cravatt, The Scripps Research
Institute, La Jolla, CA
12:00 p.m.
Consortium efforts to discover ovarian
cancer risk variants
Thomas A. Sellers, H. Lee Moffitt Cancer
Center and Research Institute, Tampa, FL
12:20 p.m.
Discussion
12:25 p.m.
Genetic risk factors for colorectal
cancer: Search for common and rare
variants, gene-environment interactions,
and translation towards risk prediction
Ulrike Peters, Fred Hutchinson Cancer
Research Center, Seattle, WA
12:45 p.m.
Discussion
12:50 p.m.
General Discussion
12:20 p.m.
Discussion
12:25 p.m.
Identification of a new druggable pocket
on K-Ras
Kevan M. Shokat, University of California,
San Francisco, CA
12:45 p.m.
Discussion
12:50 p.m.
General Discussion
610
Room 6A, San Diego Convention Center
Inflammation, Immunity, and Cancer
Oncogene Addiction: Signaling
Chairperson: Michael Karin, University of California
San Diego, La Jolla, CA
Chairperson: Frank McCormick, UCSF Helen Diller
Family Comprehensive Cancer Center, San Francisco, CA
This session will discuss the reciprocal interactions
between cancer cells and components of the innate and
adaptive immune systems. Chronic inflammation that
precedes tumor development greatly increases cancer
risk, but once tumors develop they can establish their
own inflammatory microenvironment. In addition to
stimulating tumor growth and malignant progression,
inflammation can interfere with immunosurveillance and
thus treatments that target tumor-associated
inflammation can potentiate the immune-rejection of
malignant tumors.
This session will focus on targeting signaling pathways
directly downstream from Ras, RTKs, and mTOR. These
pathways are intimately connected, and have been
targeted extensively in human cancer. Cancer cells often
appear addicted to abnormal signaling in these
pathways, suggesting that they are appropriate targets
for intervention. However, the effectiveness of targeted
agents is frequently compromised by feedback
mechanisms and adaptive resistance. To understand
how to shut down these pathways effectively and
selectively, we need to understand these pathways in
more depth and develop models that predict the results
of interfering with single or multiple targets. Deep
analysis of these critical pathways also reveals new
potential opportunities for effective treatment.
11:00 a.m.
Introduction
11:10 a.m.
Tumor-elicited inflammation and
malignant progression in colorectal
cancer
Michael Karin, University of California
San Diego, La Jolla, CA
11:30 a.m.
Discussion
11:35 a.m.
The role of immature myeloid cells in
gastrointestinal cancer
Timothy C. Wang, Columbia University
Medical Center, New York, NY
11:55 a.m.
Discussion
12:00 p.m.
Distinct responses of dynamic
macrophage and dendritic cell
subpopulations revealed by
intravital imaging
Zena Werb, UCSF Helen Diller Family
Comprehensive Cancer Center,
San Francisco, CA
12:20 p.m.
Discussion
12:25 p.m.
Immune control of spontaneous tumor
development
Ming Li, Memorial Sloan Kettering Cancer
Center, New York, NY
12:45 p.m.
Discussion
12:50 p.m.
General Discussion
11:00 a.m.
Introduction
11:10 a.m.
New targets in KRAS signaling pathways
Frank McCormick, UCSF Helen Diller
Family Comprehensive Cancer Center,
San Francisco, CA
11:30 a.m.
Discussion
11:35 a.m.
Title to be announced
Neal Rosen, Memorial Sloan-Kettering
Cancer Center, New York, NY
11:55 a.m.
Discussion
12:00 p.m.
Regulation of growth by the mTOR
pathway
David M. Sabatini, MIT Whitehead Institute
for Biomedical Research, Cambridge, MA
12:20 p.m.
Discussion
12:25 p.m.
Unique onocogenic drivers in pediatric
high-grade giloma
Suzanne J. Baker, St. Jude Children’s
Research Hospital, Memphis, TN
12:45 p.m.
Discussion
12:50 p.m.
General Discussion
611
MAJOR SYMPOSIA
Room 6B, San Diego Convention Center
Overcoming Radiation Resistance
Synthetic Lethality
Chairperson: Theodore S. Lawrence, University of
Michigan, Ann Arbor, MI
Chairperson: René Bernards, Netherlands Cancer
Institute, Amsterdam, The Netherlands
Radiation therapy alone or in combination with standard
chemotherapy is highly effective in the treatment of
locally advanced cancers, but further improvements in
outcome are limited by normal tissue toxicity. New
therapies are required that address radio-resistant cells
(including cancer stem cells). This symposium will focus
on new approaches to overcoming radiation resistance
that target cancer-specific pathways, with the goal of
improving cancer control without increasing normal tissue
injury. The speakers will focus both on the biology of
resistance and on preclinical studies motivating the
translation of new agents into clinical trials.
Treatment of cancer is hampered by a paucity of suitable
drug targets. Moreover, single-agent therapies are rarely
curative for advanced disease. Synthetic lethality holds
the promise to deliver both entirely new classes of
targets for cancer therapy and it allows for the
identification of very effective combination therapies.
This session will focus on the use of synthetic lethal
genetic screens to accomplish these two goals.
11:00 a.m.
Introduction
11:10 a.m.
Translational control and tumor stem
cell radio response
Philip J. Tofilon, National Cancer Institute,
Bethesda, MD
11:30 a.m.
Discussion
11:35 a.m.
Sensitization to chemoradiation by
inhibition of cell cycle checkpoints
Meredith Ann Morgan, University of
Michigan, Ann Arbor, MI
11:55 a.m.
Discussion
12:00 p.m.
Novel DNA repair inhibitors for
radiosensitization and cancer therapy
Peter M. Glazer, Yale University School of
Medicine, New Haven, CT
12:20 p.m.
Discussion
12:25 p.m.
Activation of anticancer immune
responses using radiation
William H. McBride, University of California,
Los Angeles, CA
12:45 p.m.
Discussion
12:50 p.m.
General Discussion
11:00 a.m.
Synthetic lethality as a tool to find
effective combination therapies
René Bernards, Netherlands Cancer
Institute, Amsterdam, The Netherlands
11:20 a.m.
Discussion
11:25 a.m.
Targeting the DNA damage response
Christopher Lord, Institute of Cancer
Research, London, United Kingdom
11:45 a.m.
Discussion
11:50 a.m.
Depletion of a putatively druggable class
of phosphatidylinositol kinases inhibits
growth of p53 null tumors
*Brooke M. Emerling, Weill Cornell Medical
College, New York-Presbyterian,
New York, NY
12:05 a.m.
Discussion
12:10 p.m.
Screening for triple-negative breast
cancer vulnerabilities
Judy Lieberman, Harvard Medical School,
Boston, MA
12:30 p.m.
Discussion
12:35 p.m.
Synthetic lethal approaches for the
treatment of lung cancer
Trever G. Bivona, University of California,
San Francisco, CA
12:55 p.m.
Discussion
*NextGen Star, selected to give a talk by the AACR President
and Annual Meeting Program Chairperson through a
competitive application process designed to bring more
visibility to early-career scientists. Abstract can be found in the
Invited Abstracts: NextGen Stars section of the Proceedings.
612
12:25 p.m.
Autophagy inhibition or induction for
cancer therapy
Guido Kroemer, INSERM U848 - Institut
Gustave-Roussy, Villejuif, France
12:45 p.m.
Discussion
12:50 p.m.
General Discussion
Targeting Protein Processing in Cancer
Chairperson: J. Alan Diehl, University of Pennsylvania,
Philadelphia, PA
The increased cell growth and proliferation that
accompanies neoplasia is highly dependent upon
increased protein synthesis. Elevated protein production
can rapidly exceed the capacity of the quality control
machinery that ensures proper protein maturation
resulting in the accumulation of misfolded/aggregated
proteins, which when unchecked triggers cell death.
However, upon the accumulation of misfolded proteins,
cells trigger an adaptive signaling pathway, the unfolded
protein response pathway, which is composed of three
signal transducers: the PERK and Ire1 protein kinases,
and the ATF6 transcription factor. UPR activation
facilitates cell adaptation by inhibiting cell division,
decreasing protein translation, increasing chaperone
production and engagement of protein catabolism
pathways such as autophagy. The capacity of the UPR
and autophagy to facilitate cell survival and tumor
progression suggests that the development of targeted
small-molecule inhibitors may provide significant
therapeutic potential. This session will provide novel
insights into the molecular function of the UPR and
autophagy and discuss the potential impact of emerging
therapeutic opportunities.
11:00 a.m.
Introduction
11:10 a.m.
Critical role of stress chaperone
GRP78/BiP in cancer
Amy S. Lee, University of Southern
California Keck School of Medicine, USC
Norris Comprehensive Cancer Center,
Los Angeles, CA
11:30 a.m.
Discussion
11:35 a.m.
Insights into prosurvival signaling by
PERK
J. Alan Diehl, University of Pennsylvania,
Philadelphia, PA
11:55 a.m.
Discussion
12:00 p.m.
Targeting the unfolded protein response
in cancer
Randal J. Kaufman, Sanford/Burnham
Medical Research Institute, La Jolla, CA
12:20 p.m.
Discussion
613

Detailed Schedule - Wednesday, April 9

Transcription

Similar documents

Universal Health Care and Interdisciplinar y Research in Asia

TUMORI UTERINI MESENCHIMALI

donor report - American-Italian Cancer Foundation

TUMOR LAMBUNG

Prostate Biopsy - Facoltà di Medicina e Chirurgia

biobanking for cancer research: rules and roles

DeFlora - Tumori_professionali

Donor Report - American-Italian Cancer Foundation

Immunotherapy meets Lung Cancer: New treatments for

Nuovi farmaci per terapia in uso clinico: Ra-223